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iAbstract
Dendritic cells (DC) are potent antigen presenting cells which have been implicated in a
number of autoimmune diseases. Tumour necrosis factor (TNF) is a key mediator of
inflammatory diseases such as rheumatoid arthritis (RA) and plays a central role in DC
biology. My aim was to identify the individual contributions of the two TNF receptors
(TNFR1 and TNFR2) in regulating the maturation and survival of human inflammatory
monocyte-derived (moDC) and steady-state myeloid DC. To address this, I have made
use of TNFR-selective ligands in order to dissect the individual contributions of the two
receptors.
In moDC, TNFR1-selective, but not TNFR2-selective stimulation resulted in increased
expression of DC maturation markers CD83 and CD86, and enhanced T cell
stimulatory capacity. A DNA binding assay was used to demonstrate that in moDC
TNFR1, but not TNFR2, activates the classical p65 NFB pathway whereas both
TNFR1 and TNFR2 activate the alternative p100/p52 NFB pathway, highlighting
differences in signalling downstream of the receptors. Furthermore, moDC survival was
prolonged by selective stimulation of either TNFR1 or TNFR2 as shown by reduced
intracellular levels of active caspase-3, indicating that innate signals can promote DC
survival in the absence of DC maturation. Accordingly, the p65 NFB pathway was
involved in the pro-survival effect of TNFR1 whereas the Bcl-2/Bcl-xL pathway
(identified by the use of small molecule inhibitors) was essential to survival mediated by
both TNFR.
In contrast, in myeloid DC, maturation was mainly mediated through TNFR1, whereas
TNFR2 was superior in protecting DC from cell death. Antagonistic TNFR1-specific
antibodies were used to confirm that cell death protection via TNFR2 was independent
of TNFR1-mediated signalling and vice versa confirming that the two receptors can act
independently of one another. Understanding the immunoregulatory properties of
signalling through these two TNF receptors is important for the design of more targeted
anti-TNF therapy.
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11. Introduction
1.1. Dendritic cells
The term ‘dendritic cell’ (DC) was first proposed by Steinman and Cohn in 1973
(Steinman & Cohn 1973) in reference to the morphological features of a novel stellate
cell population identified in mouse lymphoid organs. These cells had previously been
identified in the epidermis by Paul Langerhans in 1868 and were initially termed
Langerhans cells. DC have since been proven to function as potent antigen presenting
cells (APC) (Sunshine et al. 1980) which can initiate and regulate antigen specific
immune responses by activating naïve T cells thus providing a key link between innate
and adaptive immunity (reviewed in (Banchereau & Steinman 1998; Steinman 2007)).
Research into DC initially proved difficult until a method of culturing DC from mouse
bone marrow in the presence of GM-CSF was discovered in 1992 (Inaba et al. 1992).
This was followed by simultaneous studies showing that human DC could be cultured
from monocytes in the presence of IL-4 and GM-CSF (Sallusto & Lanzavecchia 1994;
Romani et al. 1994) therefore allowing large quantities to be generated for use in in
vitro studies.
DC initially play a sensory role in the immune system and are specialised for the
capture and processing of antigens. They reside in an immature state with high
endocytic activity in areas of the body which are vulnerable to infection such as the
skin, nasal passages, gastrointestinal tract and genitals, where they constantly sample
their environment in search of pathogens. In the event that a pathogen associated
molecular pattern (PAMP) or damage associated molecular pattern (DAMP) such as a
toll-like receptor (TLR) ligand e.g. lipopolysaccharide (LPS) (Matzinger 2002) is
identified, DC undergo a complex process of maturation into APC with a high capacity
to stimulate naive T cells. DC maturation is characterised by the upregulation of MHC
class II molecules, co-stimulatory molecules (such as CD80, CD83 and CD86), and
chemokine receptors (e.g. CCR7), which allow migration into the lymph nodes where
DC can interact with other immune cells. DC have also been shown to be 100 times
more powerful at activating T cells than other types of APC such as macrophages
(Steinman & Witmer 1978).
21.1.1. Origins and subsets
DC are heterogeneous and exist in several subsets varying in origin and function within
the immune system (mouse and human subsets have been reviewed extensively
(Geissmann et al. 2010; Haniffa et al. 2013; Merad et al. 2013)). The phenotype of
these subsets plays an important role in T cell activation, polarisation and the induction
of tolerance. All human DC subsets are capable of antigen uptake and presentation to
naive T cells, and are therefore capable of linking the innate and adaptive immune
systems. For example, DC can detect pathogens through pattern recognition receptors
(PRR) (see chapter 1.1.2) which provides an immediate defence against infection
(innate immunity) but they can also process antigens and activate naïve T cells leading
to long-lasting immunity (adaptive immunity). DC constitutively express MHC II
molecules (HLA-DR) and lack the lineage markers CD3 (T cells), CD19/CD20 (B cells)
and CD56 (NK cells). There is currently evidence for two DC developmental lineages;
DC can develop from lymphoid-committed progenitors which also give rise to T cells, or
myeloid-committed progenitors which are shared with phagocytes. The majority of DC
are derived from CD34+ haematopoietic stem cells and are continually produced in the
bone marrow (BM) (Figure 1). Studies have suggested that Flt3L is required for human
DC differentiation as administration of Flt3L has been shown to expand DC populations
(Maraskovsky et al. 2000). Different tissues contain multiple subsets of DC with
different functions and origins. However, more research is needed to determine
whether specific subsets are specialised for the induction of different forms of
tolerance.
DC can be divided into subsets based on location and surface phenotype (Figure 1) as
well as their cytokine profile. In humans two of the main subtypes of DC are
plasmacytoid (pDC) and conventional DC (cDC), each of which have specific functions
within the immune system. Human pDC express CD123 and are characterised as
CD303/BDCA-2+ and CD304/BDCA-4+ (Reizis et al. 2011), whereas human cDC are
CD11c+, although CD11c is also expressed on monocytes/macrophages. The pDC
population produces high amounts of type I interferons (IFN) and is specialised in
mediating anti-viral responses (reviewed in (Colonna et al. 2004)). Two cDC subsets
(often referred to as myeloid DC) are present in the blood; CD1c/BDCA-1+ DC are the
most common and CD141/BDCA-3+ DC form a small population (Dzionek et al. 2000;
Macdonald et al. 2002). Similar CD1c/BDCA-1+ and CD141/BDCA-3+ subsets are also
found in lymphoid tissues such as the spleen and tonsils and are referred to as lymph
node-resident cDC (Segura et al. 2012). Lymph nodes also include migratory
Langerhans cells (LC), migratory CD1a+ DC and CD14+ DC (Segura et al. 2012;
Haniffa et al. 2012). The skin contains epidermal langarin+ Langerhans cells (LC), two
3subsets of dermal DC (CD1a+/CD14- DC and CD1a-/CD14+ DC) (Nestle et al. 1993)
and a small subset of CD141/BDCA-3+ DC (Zaba et al. 2007; Haniffa et al. 2012).
Migratory DC sample their environment before migrating to draining lymph nodes in
order to present tissue-derived antigen to T cells whereas lymphoid tissue DC develop
within the tissue and reside there throughout their lifespan. LC are langarin+, CD1a+,
CD45+ and EpCAM+ and are found in skin and mucosa but are most prominent within
stratum spinosum layer of the epidermis (Merad et al. 2008).
In general, myeloid DC capture antigens in the periphery, migrate to lymphoid organs
where they can initiate an immune response, whereas lymphoid DC are found in the
lymph nodes and may be responsible for inducing tolerance. Plasmacytoid DC are
less efficient at antigen presentation but have the capacity to rapidly produce type I
interferon (IFN) for example, in response to viruses. Both pDC, whose immediate
precursor remains unknown, and preDC, the precursor of cDC, arise from a common
lymphoid or myeloid progenitor which can no longer form monocytes (Liu et al. 2009)
(Figure 1). Lymphoid tissue resident DC develop from the common DC progenitor
which responds to Fms-related tyrosine kinase (Flt3) ligand and expresses a receptor
for the stem cell factor c-Kit (Onai et al. 2007). Alternatively, the common macrophage
DC precursor can give rise to cDC and macrophages but not pDC in vitro (Fogg et al.
2006).
To date, the relationship between mouse and human DC remains unclear. This is
partially to do with the low frequencies of DC in human peripheral blood and also
involves a difference in surface marker expression. In mice, lymphoid organs e.g. the
spleen and lymph nodes contain cDC along with pDC which can be further divided into
CD8+ and CD8- pDC, whereas in non-lymphoid organs such as the skin, lung and
intestine DC can be further divided into migratory DC, Langerhans cells, interstitial DC
and dermal DC (Merad & Ginhoux 2007). In mice the common DC progenitor gives rise
to pDC in the spleen and lymph node but cannot develop into macrophages (Shortman
& Naik 2007). Unlike mouse DC, human DC do not express CD8 which has led to
difficulties in defining different subsets. However, recent studies have suggested that
human CD141+ DC may represent CD8+ cDC in mice and that human CD1c+ DC may
represent mouse CD11b+ DC (Villadangos & Shortman 2010). For example, one of the
hallmarks of CD141+ DC is their ability to cross-present (Bachem et al. 2010) and in
mice cross-presentation is exclusive to CD8+ DC (den Haan et al. 2000; Schulz & Reis
e Sousa 2002).
The phenotypical and functional overlap between DC subsets and also the overlap with
other myeloid cell types has made the DC lineage and its subsets difficult to
distinguish. It has been suggested that epigenetic systems such as chromatin
4regulation may be responsible for plasticity between DC subsets, as varying levels of
accessible chromatin may enable flexibility in gene expression depending on the
microenvironment (Paul & Amit 2014). Additionally, the presence of transcription
factors has been shown to have a direct effect on lineage plasticity between different
cell types including the reprogramming of committed T cell progenitors to a DC
phenotype (Laiosa et al. 2006; Graf & Enver 2009) as well as affecting plasticity
between DC subsets. Blood myeloid DC and blood pDC have been shown to have
distinct migratory capacities in response to chemokines. Myeloid DC have been shown
to migrate in response to MCP-1/CCL-2, RANTES/CCL-5 and CXCL-12 whereas pDC
only migrated in response to CXCL-12 (Penna et al. 2002). CD1c/BDCA-1+ DC are
specialised for the presentation of antigens to CD4+ T cells, have the capacity to
produce high levels of IL-12p70 following TLR activation (Nizzoli et al. 2013) and have
been shown to have a higher capacity to stimulate allogenic T cells than CD141/BDCA-
3+ DC and pDC (Macdonald et al. 2002). DC are essential for cross priming of CD8+ T
cells in vivo (Jung et al. 2002). The CD141/BDCA-3+ subset of DC have been shown to
have a higher ability to cross-present cell-associated antigens than CD1c/BDCA-1+ DC
and pDC (Bachem et al. 2010) and are found in tissues such as the skin, lung and liver
as well as peripheral blood (Haniffa et al. 2012). TLR9 (which detects unmethylated
CpG DNA) is mainly restricted to pDC in humans (which also express high levels of
TLR7 which detects ssRNA), suggesting that pDC may be more specialised in the
detection of intracellular viral/bacterial infections than other DC subsets (Crozat et al.
2009).
1.1.1.1. Monocyte-derived DC and inflammatory DC
Monocytes found in the blood can differentiate into monocyte-derived DC (moDC), and
have a high capacity to present antigen to T cells. MoDC are not normally found in
healthy tissues although low numbers can be found in draining lymph nodes during the
steady state and moDC numbers increase during inflammation (i.e. after stimulation
with TLR ligands such as LPS). The differentiation of moDC from monocytes and
subsequent recruitment into lymph nodes has been demonstrated in mice (Cheong et
al. 2010) although more work is needed in order to define this subset in humans. In
mice, monocytes which express GR-1 (a myeloid differentiation antigen; also known as
Ly6G) have been shown to infiltrate inflamed skin and differentiate into Langerhans
cells in vivo (i.e. under inflammatory conditions) (Ginhoux et al. 2006) and may also be
the precursor to inflammatory TNF and nitric oxide (iNOS)-producing (Tip)DC (Serbina
et al. 2003).
5In humans, inflammatory DC exist in different subsets and have been described in
synovial tissues and tumour ascites (Segura & Amigorena 2013). In addition,
inflammatory TipDC and slan DC (6-sulfo LacNAc expressing DC) (both of which are
CD14- CD1c-) have been identified in inflamed skin (Gunther et al. 2012), although slan
DC and CD16+ monocytes are difficult to distinguish from eachother (but are distinct to
blood DC) (Haniffa et al. 2012). Other populations of inflammatory DC have been
described in both inflamed synovial tissues and malignant ascites which express
CD206+/CD1a+/CD11b+/SIRP-+/FcR1+ but unlike TipDC/slanDC they are CD14+
CD1c+ (Segura & Amigorena 2013). Human inflammatory DC have also been shown to
drive Th17 polarisation (Segura, et al. 2013).
MoDC can be generated in vitro from human peripheral blood in large quantities
therefore they are the most extensively studied subset of DC in humans. Although
generated in vitro, MoDC are considered to resemble inflammatory DC i.e. DC derived
from monocytes under inflammatory conditions (as reviewed in mice (Shortman & Naik
2007) and humans (Segura & Amigorena 2013)). Inflammatory DC are thought to be
derived from monocytes during cases of chronic inflammation such as RA therefore
moDC may not represent all steady state (i.e. absence of inflammation) DC subsets in
vivo.
6Figure 1: Human DC subsets. DC originate from the bone marrow and can be divided
into different subsets based on their precursors, location and surface phenotype as
indicated. Two of the main human blood borne subtypes are plasmacytoid (pDC;
CD123+) and conventional DC (cDC; CD1c/BDCA-1+ or CD141/BDCA-3+). Similar cDC
subsets are found in lymphoid tissues and the lymph nodes include a number of
migratory subsets. The skin contains epidermal langarin+ Langerhans cells (LC) and
the dermis contains 3 subsets of dermal DC (CD1a+/CD14- DC, CD1a-/CD14+ DC and
CD141/BDCA-3+ DC). Monocytes may also differentiate into inflammatory DC at sites
of inflammation. See section 1.1.1 for further information.
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71.1.2. DC function and pattern recognition
DC initiate and regulate immune responses, are highly specialised for antigen
presentation and can polarise immune responses towards a Th1, Th2, Th17 or
regulatory T cell (Treg) phenotype. Subsets of pDC and monocyte-derived DC have a
tolerogenic phenotype and can induce Treg cells in the periphery (Kuwana 2002). It has
been shown in mouse models that constitutive depletion of DC or defects in DC
apoptosis induced autoimmunity (Ohnmacht et al. 2009; Chen et al. 2006).
Alternatively, the removal of DC in another mouse model was shown to abolish T cell
priming and therefore inhibit autoimmunity (Jung et al. 2002) showing that DC are
important at several stages of the immune response.
DC identify danger signals (PAMP or DAMP) through PRR on their surface. It was first
proposed that the immune system senses bacterial products in order to distinguish self
from non-self by Janeway in 1989 (Janeway 1989). This was further developed into the
‘danger hypothesis’ (Matzinger 2002) whereby immune cells also identify alarm signals
from cells undergoing injury or stress e.g. heat shock proteins (Breloer et al. 2001).
1.1.2.1. Toll-like receptors
PRR are a primitive part of the immune system which evolved prior to the adaptive
immune system however, they amount to the first line of defence for many types of
infection and can recognise products from bacteria (such as lipopolysaccharide (LPS)),
fungi (dectin-1 ligands) and viral particles (CpG). PRR include toll-like receptors (TLR)
which recognise conserved sequences found throughout many bacterial species which
are not usually found on self-cells. TLR were first discovered in Drosophila
melanogaster. There are 10 TLR genes in humans which recognise different PAMP
(Table 1), are highly evolutionarily conserved and are found in all vertebrates (Gay et
al. 2006). Although the specific TLR-10 ligand remains unknown it has recently been
shown the TLR-10 on macrophages and epithelial cells is activated and drives an
inflammatory response to Listeria monocytogenes (Regan et al. 2013). Upon activation,
all TLR except TLR-3 activate transcription factors (e.g. NFB) via the adapter protein
myeloid differentiation primary response gene 88 (MyD88).
The range of TLR expressed by each subset of DC can determine the cell’s response
to a particular pathogen and can also differentially regulate DC biology (for example,
the cytokine profile produced by the DC) (Zanoni & Granucci 2010). For example,
CD11c+ lamina propria cells in the intestinal lumen of mice express high levels of TLR-
5 and low levels of TLR-4 which allows a response to pathogens but maintains
tolerance to commensal gut flora (Uematsu et al. 2006). TLR-2 is highly expressed on
8tolDC but not mature DC (Harry et al. 2010). TLR-1-6, 8 and 10 are expressed by cDC
whereas pDC respond strongly to viral infection and release high amounts of IFN as
they express high levels of TLR-7 and TLR-9 which are stimulated by ssRNA and
ssDNA, respectively.
Although TLR serve to protect the body by recognising pathogens they may also play a
role in disease. It has been shown that the stimulation of multiple TLR pathways can
synergistically enhance the production of inflammatory mediators by DC and that TLR-
2 and TLR-4 mediated stimulation of moDC from RA patients resulted in higher
production of inflammatory cytokines than moDC from healthy controls (Roelofs et al.
2005). This suggests that DC TLR signalling can lead to a pro-inflammatory
environment and may play a role in the breakthrough of tolerance leading to RA. It has
also been shown that the human immunodeficiency virus type 1 (HIV-1) requires
signalling by TLR-8 and DC-SIGN (dendritic cell-specific intercellular adhesion
molecule-3-grabbing non-integrin) for replication in DC (Gringhuis et al. 2010).
Toll-like receptor Ligand Location of expression
TLR-1 dimer
TLR-2/TLR-6 dimer
Peptidoglycan
Extracellular
Lipoproteins
Lipoarabinomannan
GPI
Zymosan
TLR-3 dsDNA Intracellular
TLR-4 dimer (+CD14) LPS Extracellular
TLR-5 Flagellin Extracellular
TLR-7 ssRNA Intracellular
TLR-8
TLR-9 Unmethylated CpG (ssDNA) Intracellular
TLR-10 Unknown Extracellular
Table 1: Toll-like receptor recognition molecules. Humans express 10 different toll-like
receptors which recognise a range of different ligands as indicated. Adapted from
(Kanzler et al. 2007).
1.1.3. Antigen uptake and presentation by DC
Immature DC constantly sample and process antigens from their environment.
Antigens are processed into peptide fragments and are presented to T cells via the
MHC complex. MHC class I molecules are made of an  chain and a 2-microglobulin
chain, are found on almost all nucleated cells and present peptides from cytosolic
proteins (such as viral proteins) to CD8+ T cells. For the activation of T cells via the
9MHC I pathway cytosolic proteins are degraded by the proteosome into peptides which
are typically 7-9 residues long. Peptides are then transported into the endoplasmic
reticulum (ER) by a transporter associated with antigen processing (TAP) in an ATP
dependent manner (Chapman & Williams 2010).
Alternatively MHC class II molecules are made of an  and  chain, are found on APC
(such as DC) and present antigens from extracellular proteins to CD4+ T cells (Jensen
2007). For the activation of T cells via MHC II molecules antigens are first taken up by
endocytosis (including macropinocytosis and receptor-mediated endocytosis via the
mannose receptor) (Sallusto et al. 1995). Following this the endosome fuses with a
lysosome whose mildly acidic pH (4.5 to 5.5) allows optimal protease activity which
degrades the proteins. In the ER, three invariant chains (Ii) form a complex with three
MHC II molecules ( chains and  chains). Ii prevents inappropriate loading of the
MHC II molecule by occupying the peptide binding groove (Gautam et al. 1997). The
complex then leaves the ER and fuses with the peptide-containing endosomes. The Ii
chain is cut by cathespins to produce the class II associated Ii peptide (CLIP) which
then dissociates from the MHC II complex and is replaced by the peptide with the
assistance of the chaperone protein HLA-DM. MHC II-peptide complexes can then be
presented on the APC membrane.
Antigen cross presentation describes the ability of DC and other APC to present
extracellular antigens derived from the MHC II molecules of infected APC, on their own
MHC I molecules to CD8+ T cells without infection (reviewed in (Joffre et al. 2012)).
Some DC subsets such as CD8+ DC in the mouse (Hildner et al. 2008) or BDCA3+
(Cohn et al. 2013) and CD103+ DC (Bedoui et al. 2009) in humans are specialised in
cross presentation which is important in both viral and anti-tumour responses.
1.1.4. Maturation of DC
Under steady state conditions DC typically reside in an immature state where they
have little ability to activate an effector T cell response and instead induce tolerance.
The maturation state of DC is critical in determining their immunomodulatory role as
DC play a key role in instigating effective immunity and in maintaining self-tolerance.
Upon activation by PAMP or inflammatory cytokines, DC mature and express high
levels of MHC II-peptide complexes, co-stimulatory molecules (e.g. CD86) and
cytokines (such as IL-12). This drives the expansion of antigen specific T cells and can
polarise the response depending on the nature of the maturation stimulus (Diebold
2008). Inflammatory mediators (such as TNF) alone are not sufficient to fully mature
DC and induce effector T cell responses (Spörri & Reis E Sousa 2005) as full DC
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maturation requires the recognition of PAMP such as a TLR agonist. The effect of TNF
on DC maturation will be discussed in more detail later in this chapter (section 1.3.1).
In mouse models an increase in maturation signals through the overexpression of TLR-
7 has been shown to increase DC proliferation and also systemic autoimmunity (Deane
et al. 2007). It has been shown that NFB1 (p105) is crucial in maintaining DC in an
immature state and prevents the spontaneous production of TNF (Dissanayake et al.
2011). Another study has shown that dimethyl fumarate, a potential new treatment for
multiple sclerosis (MS), inhibits the maturation of murine DC by suppressing p65 NFB
signalling and therefore prevents Th1 and Th17 cell differentiation (Peng et al. 2012).
The maturation state of DC also determines their sensitivity to different death inducing
ligands. It has been shown that immature DC are sensitive to Fas (CD95) induced
apoptosis but not apoptosis via MHC class II cross-linking whereas mature DC are not
as sensitive to apoptosis via Fas but are sensitive to apoptosis induced by MHC class
II cross-linking (McLellan et al. 2000). Also, mature human DC were more resistant to
FasL (also known as Apo-1L or CD95L) and TRAIL mediated killing than immature DC
(Leverkus et al. 2000).
1.1.5. DC survival and lifespan
The regulation of DC survival is important in determining DC function including both
immunity and tolerance. Prolonging the lifespan of DC has been shown to break
tolerance and result in autoimmunity (Wang et al. 1999; Chen et al. 2006), whereas a
decrease in DC survival reduces immune protection from pathogens and inhibits
autoimmunity (Jung et al. 2002; Whartenby et al. 2005). Thus, the lifespan of DC is
extremely important in both health and disease. Impaired apoptosis is not only
associated with autoimmunity but is involved in cancer development. DC have been
studied in relation to cancer immunotherapy and the development of DC-based
vaccines (Palucka et al. 2007; Palucka et al. 2011). The effectiveness of these
vaccines would depend on the survival potential of the DC.
Previous research suggests that DC have a short lifespan which is dependent on both
the acquired immune system and on their environment (including pro-inflammatory
cytokines). They undergo apoptosis shortly after maturation to prevent excessive T cell
activation and subsequent autoimmunity ((McLellan et al. 2000) and reviewed in
(Zanoni & Granucci 2010)). DC co-cultured with peptide specific T cells in vitro undergo
rapid apoptosis through the ligation of Fas (on DC) with FasL (on T cells) (Matsue et al.
1999). However not all DC die upon T cell activation (Matsue et al. 1999) therefore
surviving cells may have a role in the regulation or termination of immune responses.
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Other groups have suggested that the upregulation of Bcl-xL by mature DC may be
responsible for the protection of DC from Fas-mediated killing (Lundqvist et al. 2002).
Bromodeoxyuridine (BrdU) staining has been used to show that the half-life of DC in
mice varies between different populations, for example the time taken to replace most
DC is approximately 3 days in the spleen, 4 days in the mesenteric lymph nodes and 9
days in the thymus and skin-draining lymph nodes (Kamath et al. 2002). DC with longer
half-lives due to an inherited mutation in caspase-10 have been identified in human
patients with autoimmune lymphoproliferative syndrome (ALPS) which can result in a
number of autoimmune effects (Wang et al. 1999). Other studies have shown that the
type of T cell that DC interact with may also determine DC fate as memory CD8+ T
cells can protect DC from apoptosis induced by cytotoxic CD8+ T cells (Watchmaker et
al. 2008). In addition, the location of DC also plays a role as it has been shown that DC
in proximity to stromal cells are long lived and have a regulatory phenotype (Zhang et
al. 2004). LPS (Franchi et al. 2003), prostaglandin E2 (PGE2) (Vassiliou et al. 2014),
and CD40 ligation (Haenssle et al. 2008; Caux et al. 1994) are known DC survival
factors. TNF also promotes DC survival (Ludewig et al. 1995; Lehner et al. 2012)
however the effect of TNF on DC survival will be discussed in more detail later in this
chapter (section 1.3.1).
The regulation and expression of B-cell lymphoma 2 (Bcl-2) family members can also
regulate DC survival (see chapter 1.4.2.1 for more detail on this pathway). DC
expression of Bcl-2 itself can inhibit pro-apoptotic molecules such as Bim, Bax and Bad
(Hou & Parijs 2004). Activation and maturation of DC through TLR-stimulation has
been shown to upregulate Bcl-xL and enhance survival (Chen et al. 2007).
1.1.6. Human DC deficiencies
DC are important in maintaining the balance between immunity and tolerance, however
defects in DC apoptosis or the enhancement of DC survival may break tolerance and
lead to autoimmunity. Several DC deficiencies have recently been described in humans
and illustrate the importance of DC in regulating the immune system. For example, DC,
monocyte, B and NK lymphoid deficiency (DCML) is caused by a heterozygous
mutation in GATA-binding factor 2 (GATA2) and is associated with a complete lack of
blood DC, pDC, tissue cDC, circulating monocytes, B cells and NK cells but does not
affect granulocytes or platelets (Bigley et al. 2011). It has been discovered that 1 in 4
patients with DCML develop autoimmunity (Collin et al. 2011). Furthermore, two
disease-causing mutations affecting the transcriptional activity of interferon regulatory
factor 8 (IRF8) have been identified which show that IRF8 is critical for the
development of DC and monocytes (Hambleton et al. 2011). The K108E variant was a
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severe autosomal recessive immunodeficiency and patients had a complete lack of
circulating DC and monocytes. The T80A variant had an autosomal dominant
immunodeficiency which was less severe and patients showed a selective depletion of
CD11c+/CD1c+ circulating DC (Hambleton et al. 2011). In addition, patients with
reticular dysgenesis (an inherited immunodeficiency) lack Langerhans cells, blood
monocytes, neutrophils and have low lymphocyte counts (Emile et al. 2000).
1.1.7. DC interaction with T cells
Upon pathogenic infection, relevant information is obtained from affected cells or other
immune cells e.g. NK or macrophages leading to DC activation and subsequent
activation of naïve T cells. Activation of T cells requires three signals, firstly the
recognition of peptide-MHC complexes via the T cell receptor (TCR), secondly an
interaction between the co-stimulatory molecules such as CD80 and CD86 on the APC
with CD28 on the T cell and thirdly pro-inflammatory cytokines. These signals can
convey information on the identity of the pathogen, the antigenic structure and its
pathogenicity as well as leading to T cell polarisation (see chapter 1.1.7.1), meaning
that T cells in lymph nodes can be primed without experiencing the pathogen directly. If
any of these signals are absent then the T cell is not activated and may undergo cell
death or become anergic.
Immature DC express the chemokine receptors CCR1, CCR2, CCR5 and CXCR1
which recognise inflammatory chemokines and therefore recruit DC to inflamed tissues.
Following DC maturation the expression of these chemokine receptors is reduced and
the expression of CCR7 is increased (Sallusto et al. 1998) allowing the homing of DC
to lymphoid organs. CCR7 deficient mice show impaired migration of DC to the lymph
nodes (Förster et al. 1999). DC then localise to the T cell areas of the lymph nodes
where they interact with naive T cells.
The formation of an immunological synapse allows cross-talk between DC and T cells.
This involves the interaction of DC-derived cytokines or DC surface molecules with the
corresponding receptor on the surface of naïve T cells and can influence T cell
proliferation and differentiation (Figure 2 (A)). Both CD28 and CTLA-4 can bind to
CD80 and CD86, however CD28 ligation stimulates the T cell whereas CTLA-4
transmits an inhibitory signal to the T cell and antagonises CD28 binding (Freeman et
al. 1993). CD83 is also upregulated on DC during maturation and although its direct
ligand is unknown, it is thought to dimerise and enhance T cell activation as prevention
of dimerisation in an EAE model decreased T cell activation (Zinser et al. 2004). The
ligation of cell surface molecule ICAM-1 (on DC) or the cytokine IL-12 (released by DC)
to their respective receptors on naïve T cells results in Th1 polarisation, whereas
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OX40-L ligation to OX40 (on T cells) results in Th2 polarisation. In addition, IL-23/IL-
23R ligation results in Th17 polarisation and IL-10/IL-10R ligation results in Treg
polarisation. CD80 and CD86 are co-stimulatory molecules which can bind to either
CD28 and induce T cell activation or CTLA-4 which downregulates T cell responses.
PD-L1/PD-1 ligation reduces T cell proliferation (Figure 2 (A)). Although mature DC can
mediate antigen-specific T cell expansion and direct effector T cell responses, these
interactions are not unidirectional. In addition, T cells can activate DC via CD40/CD40L
interactions which induce DC to prime CD8+ cytotoxic T cells, thus explaining the
mechanism by which T helper cells are also involved in the cytotoxic T cell response
(Schoenberger et al. 1998).
1.1.7.1. T cell polarisation
DC can adopt different Th1- or Th2-promoting effector functions (i.e. via the production
of cytokines) depending on the context of their activation, thereby polarising the T cell
response to a variety of pathogens. This is often referred to as the ‘third signal’
resulting in the antigen-specific activation of T cells (Kaliński et al. 1999). Immature DC 
are influenced by the presence of different factors such as inflammatory cytokines,
whereas as they mature DC become less susceptible thereby the acquisition of
polarizing signals is restricted to the site of pathogen entry. T cell lineages are shown in
Figure 2 (B) and described below.
T helper 1 (Th1) cells are critical for the clearance of intracellular pathogens such as
bacteria, parasites, yeast and viruses and is characterised by high IFN production
(Zhu & Paul 2008). The presence of IFN during DC maturation increases their ability
to produce IL-12. NK cells, cytotoxic T cells and complement fixing IgG2A antibodies act
alongside the Th1 response in order to efficiently clear pathogens (O’Garra & Arai
2000). Th1 responses are induced by the cytokines IFN, IL-12 and IL-18, which
activate transcription factors such as STAT4 and T box expressed in T cells (T-bet).
The release of IL-12 by DC following PRR ligation is important in promoting Th1
lineage commitment from naive CD4+ T cells. Binding of DC-derived IL-12 to its
receptor (IL-12Rβ2 on T-cells) leads to the activation of STAT4 which affects 
transcriptional regulation and can upregulate expression of IL-18R. IL-18 and IL-12
then function to enhance IFN production and perpetuate the Th1 phenotype
(Tominaga et al. 2000). T-bet is an essential regulator of the Th1 phenotype which is
induced independently of STAT4, via IFN-mediated activation of STAT1 and induces
IFN production and represses IL-4 expression (Afkarian et al. 2002).
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The signature cytokine of Th1 cells is the pro-inflammatory cytokine IFN, but Th1
cells also produce IL-2, IL-3 and GM-CSF (Mosmann & Coffman 1989). Alternatively,
Th1 cells also produce anti-inflammatory IL-10 in order to minimise tissue damage
(O’Garra & Vieira 2007). IL-10 inhibits the ability of DC to produce IL-12 and reduces
DC stimulatory capacity thereby inducing a tolerogenic phenotype. The balance
between IL-10 and IFN production are important in determining whether an infection is
cleared efficiently. The production of IFN from Th1 cells upregulates the IL-12 receptor
on DC which in turn increases the production of IL-12 and amplifies the Th1 response
and inhibits the development of Th2 cells (Gajewski & Fitch 1988). Th1 cells also
produce IL-10 to limit the immune response and prevent excessive tissue damage
(Gazzinelli et al. 1996). However IL-10 must be tightly regulated otherwise its
production may lead to chronic infection (Ejrnaes et al. 2006; Brooks et al. 2006). In
addition, the induction of T-bet in Th2 cells induces a Th1 cell phenotype showing
plasticity between Th subsets (Szabo et al. 2000).
Th2 responses cells are required for the clearance of extracellular pathogens (including
helminths) and are induced by the cytokines IL-4, IL-5, IL-9, and IL-13 (Paul & Zhu
2010), which activate the transcription factors STAT6 and GATA3. Th2 cells can
activate mast cells and eosinophils and also provide B cell help resulting in the
generation of IgG1 and IgE antibodies which are important in immunity to parasites but
are also the cause of type I hypersensitivity (allergic) reactions. IL-4/IL-4R mediated
signalling can induce STAT6 activation and increases expression of the transcription
factor GATA3 and c-Maf (O’Garra & Arai 2000) which may further increase the
expression of IL-4R on the T cell surface. In addition, Th2 cells produce high levels of
IL-4 which further induced GATA3 expression and provides a positive feedback loop
(Ho et al. 2009). GATA3 inhibits Th1 differentiation via suppression of the IL-12R2
thereby preventing STAT4 activation and subsequent Th1 cell responses (Ouyang et
al. 1998). Also, GATA3 expression in Th1 cells can induce Th2 response genes (Zheng
& Flavell 1997). PGE2 is an inflammatory mediator produced by stromal fibroblasts.
When present during DC maturation it reduces DC production of IL-12 thereby
promoting the Th2 lineage (Kaliński et al. 1997) and is another example of a 
modulatory factor which can influence DC-mediated T cell polarisation.
Th17 cells produce large amounts of IL-17 and lead to a pro-inflammatory response as
well as inducing neutrophil recruitment and providing immunity against extracellular
bacteria and fungi. In humans, IL-6, IL-1, TGF, and IL-23 regulate Th17 development
(Acosta-Rodriguez et al. 2007; Manel et al. 2008; Volpe et al. 2008; Wilson et al. 2007;
Segura, Touzot, et al. 2013). Th17 differentiation also requires activation of the
transcription factor RAR-related orphan receptor (ROR)t (Zhang et al. 2008). The
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strength of T cell stimulation also plays a role in the Th17 response as low-strength but
not high-strength T cell activation promoted Th17 responses (Purvis et al. 2010). The
Th17 response has been shown to be important in the clearance of infections. For
example, B. Pertussis can activate TLR4 on DC and induce the secretion of IL-1, TNF
and IL-23, thus enhancing T cell expression of IL-17 (Higgins et al. 2006). Th17 cells
have also been widely implicated in the development of inflammatory diseases such as
RA. For example, blocking IL-17 in a mouse experimental arthritis model decreased the
severity of antigen-induced arthritis (Koenders et al. 2005). Also human inflammatory
DC can induce the differentiation of Th17 cell from naive CD4+ T cells (Segura, Touzot,
et al. 2013). In addition, when TGF is absent and IL-12 is present, Th17 cells have
been shown to switch to a Th1 cell phenotype which is again dependent on the Th1
transcription factors STAT4 and T-bet (Lee et al. 2009).
Treg cells have the ability to suppress the immune response to self and non-self
antigens. Naturally occurring Treg cells are produced in the thymus during development
(Ng 2001) and are CD4+FoxP3+CD25+. FoxP3 is a transcriptional repressor of IL-12
(which is involved in T cell proliferation and B cell, NK cell, monocyte and macrophage
growth). The expression of FoxP3 is essential for the suppressive function of naturally
occurring Treg cells (Walker et al. 2003) and mutations in FoxP3 lead to severe
autoimmune disease in both mice (‘scurfy’ mutant) and humans (Immunodysregulation
polyendocrinopathy enteropathy X-linked (IPEX) syndrome) (Gambineri et al. 2003;
Kim et al. 2007). Alternatively Treg cells can be induced in the periphery by cytokines
such as IL-10 or TGF (Buckner & Ziegler 2004). Treg cells induced by IL-10 are FoxP3-
CD4+CD25- (CD25 is the  chain of the IL-2R), whereas Treg cells induced by DC-
derived TGF are FoxP3+CD4+CD25+ (Marguti et al. 2009; Dumitriu et al. 2009). It has
been shown that the regulation of Th17 and Treg cells is linked showing plasticity
between T cell phenotypes. In the absence of IL-6, TGF induces FoxP3 expression
which negatively effects Th17 differentiation. Alternatively, the presence of IL-6
prevents TGF-induced FoxP3 expression thus allowing Th17 induction (Zhang et al.
2008; Ichiyama et al. 2008).
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Figure 2: Surface molecules, cytokines and transcription factors involved in T
cell activation and polarisation by DC. DC can activate and polarise T cell
responses. (A) Transmembrane surface molecules and cytokines (circles) involved in
cross talk between DC and T cells. ICAM-1 or IL-12 ligation to their respective
receptors results in Th1 polarisation, OX40-L ligation results in Th2 polarisation, IL-23
results in Th17 polarisation and IL-10 results in Treg polarisation. CD80 and CD86 are
co-stimulatory molecules which can bind to either CD28 (T cell activation) or CTLA-4
(downregulates T cell responses). PD-L1/PD-1 ligation reduces T cell proliferation. (B)
Upon activation by DC, naïve T cells differentiate into Th1, Th2 and Th17 lineages
which result in immunity or DC may induce the production of Treg cells which induce
tolerance. The transcription factors involved in each lineage are shown in red and the
effector cytokines produced by the differentiated T cells are shown in green.
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1.1.8. The balance between immunity and tolerance
DC play a central role in inducing and maintaining both central and peripheral T cell
tolerance. Central tolerance involves the presentation of self-antigens by thymic DC
which have been shown to mediate the negative selection of developing thymocytes in
vivo (Brocker et al. 1997). Peripheral tolerance develops upon antigen encounter in the
absence of co-stimulatory signals, for example self-antigens generally do not induce
DC activation therefore their presentation leads to T cell tolerance (Hawiger et al.
2001).
The balance between immunity and tolerance is determined by the maturation and
activation status of DC. Immature DC are often described as having a tolerogenic
phenotype as they express low levels of co-stimulatory molecules (CD80/CD86) and
produce high levels of IL-10 and can induce tolerance in the periphery (reviewed in
(Mahnke et al. 2002)). Alternatively mature DC express high levels of co-stimulatory
molecules and produce cytokines such as IL-4, IL-12, IL-23 or IL-17 which can skew T
cell responses towards a Th1, Th2 or Th17 phenotype. Autoreactive T cells are
generally deleted within the thymus during development, however some T cells escape
and can be found in the periphery (Walker & Abbas 2002) requiring a further level of
regulation to ensure self-tolerance is maintained. This is achieved by the induction of T
cell deletion (through an unknown mechanism), T cell anergy or through differentiation
into Treg cells.
In the steady state immature DC constantly endocytose antigen (Sallusto et al. 1995).
In the absence of co-stimulatory molecules DC do not become activated and
recognition of the peptide-MHC complex leads to T cell anergy leaving the T cell
unresponsive to any further activation, even by APC which do express the correct co-
stimulatory molecules (Janeway & Bottomly 1994). DC endocytosis can be used to
target antigens to DC and induce T cell anergy in vivo (Hawiger et al. 2001). In mouse
models immature BM-DC generated in vitro and injected intravenously can also induce
CD4+ T cell anergy which has been shown to prolong the acceptance of allogeneic
heart transplants (Fu et al. 1996; Lutz et al. 2000). However, it is not only immature DC
which can induce tolerance as under certain circumstances, mature DC can also
induce regulatory CD4+ T cells and produce IL-10 in vivo (Akbari et al. 2001; McGuirk
et al. 2002). Recent theories suggest that as only full maturation is enough to initiate an
immune response whereas tolerance is seen when partial maturation of DC occurs
(Frick et al. 2010; Lutz & Schuler 2002).
Silencing of RelB has been shown to prevent full maturation of DC and the resulting
semi-mature DC inhibited the immune response, allowed the expansion of Treg cells
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and prevented allograft rejection (Li et al. 2007). Blockade of TNF has also been shown
to prevent the maturation of DC which prevents the initiation of a T cells response and
could also prevent allograft rejection in half of the recipients (Wang et al. 2012). It has
been suggested that DC may be used as a novel tolerance-inducing cellular
therapeutic. The potential use of different subsets has been described (Lebre & Tak
2009) and it has been shown that clinical grade tolDC can be generated from RA
patients (Harry et al. 2010). Two Phase I clinical trials using tolDC in type I diabetes or
RA have been conducted recently and results showed that DC treatment was well
tolerated with no major adverse effects (Giannoukakis et al. 2011; Thomas et al. 2011).
Another Phase I tolDC trial studying autologous tolDC for the treatment of RA
(AUTODECRA) is currently nearing completion (Hilkens & Isaacs 2013) and has also
found that tolDC treatment is safe (C. Hilkens, personal communication). The potential
for tolDC treatment in the prevention of transplant graft rejection has also been widely
investigated (Ezzelarab & Thomson 2012; Svajger & Rozman 2014).
1.2. Rheumatoid arthritis
The name rheumatoid arthritis (RA) was first coined in 1859 by Dr Alfred Baring
Garrod, a British rheumatologist, although the disease had previously been described
in 1800 by the French physician Dr Augustin Jacob Landré-Beauvais (Fraser 1982).
RA is a chronic autoimmune disease which, along with many other autoimmune
diseases, is the product of a breakdown in self-tolerance the outcome of which is the
development of chronic inflammation and tissue destruction. RA is characterised by
synovial inflammation of peripheral joints as well as cartilage loss and bone destruction
(Firestein 2003), however its precise aetiology remains unknown. The pattern of joint
involvement is often symmetrical and frequently affects the shoulders, wrists, knuckles,
middle finger joints, knees, ankles, balls of feet and middle toe joints. Subtypes of RA
and the assessment of disease progress are described by (Scott & Steer 2007).
1.2.1. An overview of RA epidemiology, aetiology and pathology
RA affects around 0.5 – 1% of the population (Silman & Pearson 2002) in total and
over 400,000 people in the UK with onset most commonly between the ages of 40 and
50. RA affects pre-menopausal women 2 to 3 times more than men and its incidence
increases with age. RA patients have an increased risk of comorbidity for example
cardiovascular, infectious, haematologic, gastrointestinal and respiratory diseases
(Gabriel & Michaud 2009). Overall life expectancy is lower in RA patients compared to
the rest of the population and research suggests that this difference may be increasing
(Gonzalez et al. 2007).
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The disease can lead to severe disability therefore has a great impact on both the
National Health Service as well as the economy, with around 30% of patients losing
their jobs within 5 years due to disease severity (Sokka et al. 2010). The direct cost
(medicines and care) of RA estimated by the UK National Audit Office is around £560
million and the total costs (including indirect costs such as unemployment) can be up to
£4.8 billion a year (National Audit Office 2009). The development and manufacture of
new therapeutics is expensive and prices can be over £10,000 per patient per year.
Over time the benefit of such treatments may balance their cost (Schoels et al. 2010)
although this is difficult to determine until treatments have been in use for several
years.
Autoantibodies such as rheumatoid factor (RF) and anti-citrullinated peptide antibody
(ACPA) are associated with RA diagnosis (Goëb et al. 2008) and can appear in the
blood 10-15 years before the clinical onset suggesting that the process leading to RA
starts long before symptoms occur. ACPA recognise citrullinated epitopes such as
citrullinated fibrin, fibrinogen, collagen and vimentin whereas RF is an autoantibody
specific for the Fc portion of IgG. IgM RF is present in up to 75% of RA patients and is
associated with a more severe disease pathology although IgG and IgA RF are also
been implicated in disease. It is important to also consider that RF is not RA specific
may also be found in other autoimmune diseases, infections and malignancies. IgM RF
and ACPA are highly associated with each other and with more aggressive RA. Other
putative autoantigens include type II collagen (Kim et al. 1999), cartilage glycoprotein
39 (van Bilsen et al. 2004), aggrecan (Zou et al. 2003) and BiP (Bodman-Smith et al.
2004) to which reactivity has been shown in RA patients.
The synovial membrane lines non-weight bearing parts of the synovial cavity and
contains two major cell types; type A synoviocytes (macrophage-like) and type B
synoviocytes (fibroblast-like) (Iwanaga et al. 2000). During RA the synovial membrane
becomes hyperplastic; neovascularisation occurs, the number of type A and type B
synoviocytes increases and the sublining becomes infiltrated with immune cells. As the
disease progresses synoviocytes migrate onto the articular cartilage forming the
pannus and immune cells infiltrate the synovium. Articular cartilage is made up of
chondrocytes within a matrix of collagen and proteoglycans. The breakdown of
cartilage is mediated by metalloproteinases which are regulated by tissue inhibitors of
metalloprotinases (TIMP) (Firestein 2003). Growth factors such as transforming growth
factor  (TGF) and insulin-like growth factor-1 (IGF-1) stimulate cartilage growth
however, in RA the increase in inflammatory cytokines (IL-1 and TNF) reduces
synthesis and increases the breakdown of cartilage.
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Pro-inflammatory cytokines are abundant in RA joints mainly including TNF, IL-1, and
IL-6 but others are also present including IL-12, IL-15, IL-17 and IL-18. The RA joint
also includes anti-inflammatory cytokines including IL-10, IL-13 and TGF as well as
neutralising factors such as soluble TNFR and IL-1 receptor antagonist. Other
inflammatory mediators such as vascular endothelial growth factor (VEGF) and
vascular cell adhesion molecule-1 (VCAM-1) which stimulate endothelial cell growth
may also be involved in RA. An imbalance between pro- and anti-inflammatory cytokine
is known to play a role in autoimmunity and inflammation and is therefore an important
pathogenic mechanism in RA (reviewed in (McInnes & Schett 2007)). In addition, the
accumulation of reactive oxygen species (ROS) is attributed to reperfusion injury within
the chronically inflamed joint. Consequent hypoxia contributes to the promotion of
neovascularisation in rheumatoid synovitis.
Infectious triggers have been implicated in RA and a transient infection could trigger
chronic inflammation. Epstein Barr virus (EBV) has been shown to enhance antibody
production of CD25+ B cells in RA patients which may contribute to inflammation
(Brisslert et al. 2013). Mycobacterium tuberculosis and heat shock proteins have also
been identified as possible triggers and Parovirus B19 is known to cause an illness in
humans with similarities to RA (Colmegna & Alberts-Grill 2009). As RA is more
common in women but improves during pregnancy, this suggests that sex hormones
may be involved. Also, certain foods may trigger episodes of arthritis or may be
protective (Di Giuseppe et al. 2013) and, although it seems to vary between patients,
caffeine consumption and high protein diets have both been implicated. A flow diagram
of the pathology of RA is shown in Figure 3.
1.2.2. Genetic involvement in the aetiology of RA
Studies have shown that there is a genetic susceptibility to RA as disease concordance
in monozygotic (identical) twins was around 15% and dizygotic (non-identical) twins
was 3.6% (Silman et al. 1993). This shows that RA does have a genetic factor,
however, other influences may also be involved in its aetiology.
The MHC genetic region has been linked to RA. This region includes both class I (HLA-
A, HLA-B and HLA-C) and class II (HLA-DR, HLA-DQ and HLA-DP) genes. A degree
of genetic association with the HLA-DR haplotypes can be seen as over 90% of RA
patients possess a HLA-DRB1*04 subtype (DRB1*0401, *0404, *0405, *0408) whereas
the frequency of these alleles in the average population is around 35% (Ebringer &
Wilson 2000). The HLA-DRB1 allele includes a 5 amino acid sequence (position 67-74)
in the third hypervariable region known as the ‘shared epitope’ which is strongly
associated with RA pathogenesis (Gregersen et al. 1987). Although the autoantigen in
21
RA has not been definitively identified, it is possible that the shared epitope may bind
an autoantigen-derived peptide with high affinity leading to an increased risk of RA. It is
also possible that the shared epitope may be homologous to microbial antigens and
bacterial heat shock proteins therefore T cells generated during an infection may cross
react with autoantigens leading to disease.
Other genes associated with RA include protein tyrosine phosphatase-22 (PTPN22)
which regulates lymphocyte activation by reducing TCR signalling (Fousteri et al. 2013;
Begovich et al. 2004), cytotoxic T lymphocyte-associated protein 4 (CTLA-4) which
downregulates T cell activation and STAT4 which is a signalling molecule downstream
of the IL-12/IL-23 receptor. An interaction between the HLA-DRB1 shared epitope and
the A allele of PTPN22 polymorphism R620W are associated with ACPA positive RA
(Kallberg et al. 2007).
A relationship between smoking and the shared epitope has been identified as
important in RA aetiology. It has been shown that smoking is linked to RA in patients
which carry a predisposing genotype (such as HLA-DRB1) and is potentially due to
citrullination of proteins in the lung (Klareskog et al. 2006; Mahdi et al. 2009). This
along with other genetic factors such as single nucleotide polymorphisms (Hussein et
al. 2011) and non-genetic risk factors, suggest that the epidemiology of RA cannot be
attributed to a single distinct cause (Silman & Pearson 2002).
1.2.3. The contribution of immune cells to RA pathogenesis
During RA, immune cells such as CD4+ T cells, B cells, macrophages and DC infiltrate
the synovium where they can form highly organised structures (e.g. germinal centres)
and interact with synoviocytes. Type B (fibroblast-like) synoviocytes are major effectors
of cartilage destruction. They also secrete growth factors which inhibit apoptosis of
lymphocytes such as BAFF which maintains B cell survival and IFN which prevents T
cell apoptosis (Bartok & Firestein 2010). Receptor activator of nuclear factor B ligand
(RANKL) is induced on type B synoviocytes and osteoblasts by pro-inflammatory
cytokines and a soluble form is secreted by activated T cells. It interacts with RANK on
osteoclast precursors resulting in their differentiation and activation leading to bone
destruction (Zhang et al. 2001). Macrophage colony stimulating factor (M-CSF) is also
required for osteoclast formation.
The vascular endothelium in rheumatoid synovium expresses a number of adhesion
molecules (including E-selectin) and intercellular adhesion molecules (such as ICAM),
the expression of which is stimulated by pro-inflammatory cytokines and results in the
recruitment of inflammatory cells. Chemokines including monocyte chemotactic protein-
1 (MCP-1), IL-8, RANTES, monocyte chemoattractant protein 4 (MCP-4) and CCL20
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also recruit inflammatory cells (Szekanecz et al. 2003). Therefore although pro-
inflammatory cytokines play a role in the pathology of RA (McInnes & Schett 2007), it is
unlikely that they are the primary cause.
The role of B cells in RA (reviewed in (Marston et al. 2010)) involves the production of
autoantibodies (RF and ACPA) and the secretion of pro-inflammatory cytokines (TNF
and IL-6). B cells may contribute to RA through a number of different mechanisms
including antigen presentation, T cell activation and DC modulation via the production
of cytokines. B cells produce a wide range of cytokines (Pistoia 1997) and the cytokine
profile produced is dependent on a range of different signals. For example B cells have
been shown to produce pro-inflammatory cytokines (TNF, LT and IL-6) in response to
B cell receptor (BCR) and CD40 stimulation but produce anti-inflammatory cytokines
(IL-10) in response to CD40 stimulation alone (Duddy et al. 2004). Also it has been
shown that RF specific B cells can be activated by immune complexes via synergistic
activation of the B cell receptor and TLR (Leadbetter et al. 2002). B cell depletion (e.g.
using Rituximab) has proved to be an effective therapy for RA and is usually used
following the failure of at least one TNF antagonist (Edwards et al. 2004; Lee et al.
2011)(Lee et al. 2011).
Macrophages have also been implicated in RA pathogenesis, although they are
unlikely to be the primary cause, as they are found in high numbers in synovial fluid
and can produce pro-inflammatory cytokines. Macrophages produce a number of pro-
inflammatory cytokines including TNF, IL-1, IL-6 and macrophage migration inhibitory
factor (MIF) which is a potent pro-inflammatory cytokine (Morand et al. 2006) which can
contribute to and amplify inflammation.
1.2.3.1. DC involvement in RA pathogenesis
DC have been suggested as the driving force behind RA and contribute to its
pathogenesis in a variety of ways (Lutzky et al. 2007; Pettit & Thomas 1999). DC
production of pro-inflammatory cytokines such as TNF may directly contribute to the
pathogenesis of RA (Leung et al. 2002). In the rheumatoid joint the DC population
increases in response to the inflammatory environment and may drive the development
of CD34+ progenitors to form CD14-derived DC (Santiago-schwarz et al. 2001). TNF in
the joint may also induce differentiation of inflammatory DC from monocytes as data
has shown that monocytes can differentiate into CD70+ DC which induce Th1 and Th17
responses in the presence of TNF (Iwamoto et al. 2007). Inflammatory DC have been
shown to act as effectors in cartilage destruction (characteristic of arthritis) via an
indirect mechanism involving the production of TNF (Lakey et al. 2009).
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Differentiated DC which are positive for nuclear RelB and have a high capacity to
stimulate T cells are enriched in the synovial tissues of RA patients (Thomas et al.
1994; Pettit et al. 2000). DC are often found in close association with T cells and have
the capacity to present autoantigens and activate T cells therefore may perpetuate the
inflammatory response (Lutzky et al. 2007). It has therefore been suggested that in
disease, peripheral DC may prime the immune system to respond to self-antigens as
opposed to inducing tolerance.
Both myeloid and pDC are present within RA synovial tissues (Jongbloed et al. 2006).
Myeloid DC having a more mature phenotype and express CD80, CD83, CD86 and
DC-LAMP (Thomas & Quinn 1996; Thomas et al. 1994) whereas pDC appear more
immature and have low or no expression of CD83, CD86 or DC-LAMP (which promotes
Th1 responses) (Van Krinks et al. 2004). However, myeloid DC can respond to further
stimulation ex vivo suggesting that they may not be fully mature within the synovial
tissues (Jongbloed et al. 2006). Both myeloid DC and pDC have been shown to
express IL-15, IL-18 and IFN/ were mainly expressed by pDC and IL-12p70 and IL-
23p19 were mainly expressed by myeloid DC (Lebre et al. 2008).
DC may also affect the initiation and propagation of RA by presenting arithrogenic
antigens to T cells. It has also been shown that myeloid DC expressing high levels of
heat shock protein (hsp)70 can be found in synovial fluid of RA patients and indicates
that hsp70 may chaperone autologous antigens onto the surface of DC (Martin et al.
2014). This suggests that DC found in synovial fluid may be capable of presenting
autoantigens within the joint. Synovial DC can induce Th1 responses ex vivo and
therefore potentially also promote a Th1 response in vivo (Santiago-schwarz et al.
2001). It has been shown in a mouse model of arthritis that the expression of tenascin-
C by DC is important in the DC-mediated polarisation of T cells to Th17 cells during
inflammation (Ruhmann et al. 2012).
1.2.3.2. T cell involvement in RA pathogenesis
T cells play an important role in the immune system, are present in rheumatoid
synovium (Bankhurst et al. 1976) and have been implicated in the pathogenesis of RA
(Lundy et al. 2007). T cells develop in the thymus and can recognise a wide range of
antigens due to gene rearrangement of the T cell antigen receptor (TCR). Any T cell
which recognise self-antigens are usually clonally deleted before they can leave the
thymus (von Boehmer et al. 1989), but a number of auto-reactive T cells escape
negative selection and are released from the thymus. The effects of T cells in RA
pathogenesis are reviewed by (Cope 2008).
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It has been shown that CD4+ T cells (also known as T helper cells) are essential for the
transfer of collagen-induced arthritis (CIA) to severe combined immunodeficient (SCID)
mice which have no B or T cells (Kadowaki et al. 1994). The K/BxN mouse model
(100% of which develop spontaneous arthritis) shows that arthritis may result from a
breakdown in the mechanism of self-tolerance as opposed to recognition of a specific
autoantigen (Kouskoff et al. 1996). In this model arthritis is caused by an autoimmune
systemic T cell-mediated response to the cytosolic enzyme glucose-6-phosphate
isomerise (GPI) (Kamradt & Schubert 2005).
Regulatory T (Treg) cells maintain tolerance to self-antigens in the periphery by
suppressing the immune system. CD4+CD25+ Treg cells isolated from the peripheral
blood of RA patients have been shown to be ineffective in the suppression of
CD4+CD25- effector T cells suggesting that their function is impaired. Treatment with
anti-TNF resulted in an expansion of natural Treg cells and an increase in their
suppressive activity (Ehrenstein et al. 2004). Also the success of CTLA4Ig treatment
such as Abatacept which inhibits T cell co-stimulation and down regulates their
activation shows that T cells are important in RA pathogenesis (Teng et al. 2005).
Abatacept is composed of the Fc region of IgG1 and the extracellular domain of CTLA4
which blocks co-stimulation between CD28 and CD80/CD86 (B7 molecules) and
therefore blocks the co-stimulation of T cells (Buch et al. 2008). Effector T cell and Treg
function can also be restored by anti-TNF therapy in RA patients (Maurice et al. 1999;
Bryl et al. 2005).
RA is often considered a Th1-mediated disease however recent data also implicate
Th17 cells in the pathogenesis of inflammatory diseases. IL-17 is highly produced in
the RA synovium (Chabaud et al. 1999). Th17 cells have been shown to play a role in
enhancing collagen induced arthritis (CIA) in mice (Murphy et al. 2003). Other mouse
models have shown that inhibition of IL-17 in the joints suppresses inflammation and
damage whereas overexpression increases joint damage (Lubberts et al. 2005). IL-17
activates endothelial cells and induces pro-inflammatory cytokines (TNF, IL-1, IL-6 and
IL-8) and RANKL on chondrocytes and osteoblasts leading to osteoclast activation
(Van bezooijen et al. 1999; Lubberts et al. 2005). These contribute to synovial
inflammation and bone damage.
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Figure 3: Factors contributing to the development of RA. The primary trigger for
RA remains unknown but may involve an infectious trigger, citrullination of proteins, a
genetic predisposition or a combination of these factors. The infiltration of immune cells
into the synovium leads to the initiation of an immune response and recruitment of
immune cells. B cells may produce autoantibodies and T cells release pro-inflammatory
cytokines. The following production of pro-inflammatory mediators and the release of
enzymes leads to the destruction of bone and cartilage resulting in arthritis.
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1.3. Tumour necrosis factor
Tumour necrosis factor (TNF) is a ubiquitously expressed cytokine with a diverse
biological role and is a key mediator of inflammatory diseases such as RA. It was first
described and named by Carswell et al. in 1975 (Carswell et al. 1975) and was later
cloned and biochemicaly characterised (Pennica et al. 1985). The TNF superfamily
contains 19 members, which signal through 29 membrane receptors. TNF is produced
as a 26 kDa type II membrane protein (mTNF) (Kriegler et al. 1988) by many different
cell types including activated immune cells such as DC. The transmembrane TNF
protein forms stable homotrimers and can be cleaved by the metalloprotease TNF
converting enzyme (TACE) to release a soluble form (sTNF) (Black et al. 1997; Wajant
et al. 2003). Both mTNF and sTNF exist as homotrimeric bioactive forms and exert
differential, but also overlapping functions. Transgenic mouse models have been used
to show that sTNF is required for the development of chronic inflammation whereas
mTNF can protect against chronic inflammation and autoimmunity (Apostolaki &
Victoratos 2010).
1.3.1. TNF in DC survival and maturation
TNF also plays an important role in DC survival and function. It promotes both DC
survival (Ludewig et al. 1995) and maturation and has been shown to increase the
expression of MHCII and co-stimulatory molecules such as CD40 (Sallusto &
Lanzavecchia 1994). Mice deficient in TNF fail to induce full DC maturation in vivo in
response to viral challenge (Trevejo et al. 2001) and ex vivo generation and maturation
of DC is also impaired but can be restored by the addition of exogenous TNF (Ritter et
al. 2003; Brunner et al. 2014). Immature DC can induce T cell tolerance whereas
mature DC activate T cells, therefore dysregulation of TNF in DC maturation may be
linked to autoimmunity (Chen et al. 2006).
Neutralisation of autocrine TNF during DC maturation impaired the survival of DC and
enhanced co-stimulatory molecule expression and T cell stimulatory capacity (Baldwin
et al. 2010; van Lieshout et al. 2005; Lehner et al. 2012). The effect of blocking TNF
during the maturation of monocyte-derived DC isolated from RA patients and healthy
controls has also been studied. Results showed that although cell surface maturation
markers such as CD86, CD83 and HLA-DR were not altered in either RA or control
cells, the TNF blockade resulted in a semi-mature DC phenotype with reduced
chemokine receptor expression and decreased IL-1 and IL-6 secretion (van Lieshout
et al. 2005). In addition, DC from RA patients receiving anti-TNF therapy display
impaired upregulation of CD80 and CD86 after ex vivo LPS stimulation (Baldwin et al.
2010).
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Autocrine TNF is essential for moDC survival and induces anti-apoptotic members of
the Bcl-2 family (Lehner et al. 2012). Overexpression of Bcl-2 specifically in DC can
prolong their survival in transgenic mice (Nopora & Brocker 2002) and upregulation of
Bcl-xL is associated with a reduction in Fas-mediated apoptosis induced by DC
activation (Lundqvist et al. 2002), thereby indicating the importance of Bcl-2/Bcl-xL in
DC survival which will be discussed in more detail in chapter 1.4.2.1.
1.3.2. TNF receptors
TNF exerts its bioactivity via two transmembrane receptors; TNF receptor (TNFR) 1
and TNFR2, however the individual functions of these receptors is not yet fully
understood. TNFR1 is expressed ubiquitously at low levels whereas TNFR2 expression
is highly regulated and restricted to subpopulations of immune cells (including DC),
neuronal tissues and endothelial cells (Wajant et al. 2003) (Table 2). Both receptors
are capable of binding mTNF and sTNF with high affinity. However, only sTNF leads to
efficient activation of TNFR1, whereas mTNF is capable of activating both TNFR1 and
TNFR2 (Grell et al. 1995). Although the molecular basis of this difference is not yet fully
understood, it could be demonstrated that the difference in response of TNFR1 and
TNFR2 to sTNF is instead controlled by the TNFR stalk region, which links the
transmembrane region with the extracellular four cystein-rich regions of the TNFR
(Richter et al. 2012), thereby affecting the cell surface distribution, pre-clustering and
localisation of the TNFR and thus its responsiveness towards sTNF. The half-life of the
TNF/TNFR complex seems to have less impact on sTNF responsiveness than
originally thought (Krippner-Heidenreich et al. 2002; Richter et al. 2012).
TNFR1 TNFR2
Ubiquitously expressed Immune cell and neuron restricted
Responds strongly to both sTNF and
mTNF
Responds strongly to mTNF but not
sTNF
Mainly pro-inflammatory Pro- and anti-inflammatory
Direct activator of cell death Cooperates or counteracts TNFR1signalling
Table 2: A comparison of TNFR1 and TNFR2. Differences in expression, TNF
responsiveness and signalling between TNFR1 and TNFR2 are shown.
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Members of the TNFR superfamily are divided into two groups according to their
intracellular domains; death domain containing receptors (e.g. TNFR1) and non-death
domain containing receptors (e.g. TNFR2) which contain one or more TNF receptor
associated factor (TRAF) binding sites. Receptor activation results in the recruitment of
the adaptor molecule TRAF 2 via a consensus motif (Ye et al. 1999) and leads to the
activation of the JNK and NFB pathways (as described in chapter 1.4 and 1.4.1). As
well as a death domain, TNFR1 also contains a TNFR1 internalisation domain (TRID)
which includes an YXXW motif essential for receptor internalisation. A single amino
acid substitution in this motif prevents internalisation and therefore prevents the
formation of the death-inducing signalling complex (DISC) and TNF-induced apoptosis
(Schneider-Brachert et al. 2004) indicating that TNFR1 internalisation is essential for
the induction of apoptosis.
The extracellular domains of both TNFR contain four cystein rich domains (CRD)
connected to a transmembrane domain by a stalk region. Each CRD contains two out
of five structural molecules (A1, A2, B1, B2 and C2) as described by Naismith and
Sprang (Naismith & Sprang 1998). The intracellular domain of TNFR1 includes a death
domain whereas TNFR2 contains two TNF associated factor 2 (TRAF2) binding
domains. Crystal structure analysis of the LT/TNFR and the TNFR/TNF complex
revealed that receptor subunits bind the grooves between TNF or LT homotrimer
subunits (Rodseth et al. 1994). The membrane distal CRD (CRD1) at the N-terminus of
each receptor includes a conserved pre-ligand binding assembly domain (PLAD) which
is distinct from the ligand binding domain and is involved in the formation of TNFR
homodimers/homotrimers prior to ligand binding. Efficient binding of the TNF ligand by
the TNFR has been shown to depend on receptor self-assembly and is abolished by
the deletion of CRD1 (F. K.-M. Chan 2000), although this could also be caused by
potential destabilization of the ligand binding domain of CRD2 (Branschädel et al.
2010). TNFR homodimerisation/pre-assembly does not in itself induce signalling but
may function to enhance the efficiency and specificity of TNFR-signalling by avoiding
heterodimerisation with other TNFR (i.e. TNF may otherwise recruit TNFR2 to a
TNFR1 complex which would inhibit TNFR1-mediated signalling). Alternatively, this
may not be the case as TRAIL receptors have been shown to form PLAD-mediated
ligand-independent heterodimers (Neumann et al. 2014) and TNFR heterodimers may
be prevented by different areas of receptor localisation.
1.4. Initiation of TNFR1- and TNFR2-mediated signalling
Efficient signalling requires the formation of TNF-TNFR clusters. Binding of TNF is the
prerequisite for receptor clustering, the formation of the signalling complex and finally
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for signal initiation (Banner et al. 1993). The minimal cluster size required for efficient
signalling is not known to date, however, in the case of the Fas/FADD complex
biochemical and structural analyses reveal that higher order ligand/receptor clusters
optimally position the FADD death effector domain (DED) to interact with the caspase-8
DED (Scott et al. 2009), thus suggesting 5-7 receptors complexed to two ligands as the
minimal signalling competent ligand/receptor complex (Wang et al. 2010). As Fas and
TNFR1 are both members of the TNFR superfamily which can recruit FADD and lead
to DISC formatting, it is possible that TNF/TNFR complexes may follow a similar
pattern.
TNFR exist as pre-formed complexes on the cell surface (involving the PLAD domain
within CRD1), which is thought to be essential for ligand binding (Chan 2000;
Branschädel et al. 2010). Interestingly, soluble PLAD proteins can block the effects of
TNFR1 and TNFR2 mediated signalling in vitro and in a collagen induced arthritis (CIA)
mouse model (Deng et al. 2005) indicating the importance of PLAD in ligand binding
and/or higher molecular TNF/TNFR complexes. Upon TNF binding the PLAD
interaction is replaced by a more stable receptor-ligand interaction and therefore free to
associate with other TNF/TNFR trimers. This could be the link to higher order
molecular TNF/TNFR complexes such as a dimer- (Figure 4) or trimer-based model.
However, it currently remains unclear whether this is indeed the case.
Figure 4: Dimer model of a ligand-bound receptor complex. It is possible that three
pre-assembled receptor dimers may bind one TNF homotrimer therefore aggregation of
dimers is required to maintain the threefold symmetry of the ligand-bound receptor
complex (Krippner-Heidenreich et al. 2002; Schneider-Brachert et al. 2004; Chan
2007).
TNF
homotrimer
TNFR
homodimer
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TNFR-mediated signalling can activate a number of different signalling pathways for
example; the NFB pathway (chapter 1.4.1), the mitogen-activated protein kinase-
dependent (MAPK) pathway and the PI3K pathway. The MAPK/extracellular signal-
regulated kinases (ERK) pathway (also known as the Ras-Raf-MEK-ERK pathway) is
pro-apoptotic and involves a chain reaction of protein phosphorylation which acts as an
on/off switch to downstream proteins. After membrane receptor activation the GTPase
Ras activates Raf (MAP3K) which activates MEK1 and MEK2 turn activate a MAPK
which can then activate various transcription factors such as AP-1. The PI3K pathway
(summarized in (Cantley 2002)) is important in the inhibition of apoptosis. PI3K
activation leads to the activation and phosphorylation of Akt (a serine/threonine protein
kinase), which can activate proteins involved in protein synthesis, cell proliferation, cell
cycle entry and apoptosis.
Intracellular signalling mechanisms of TNFR1 and TNFR2 are summarised in Figure 5.
Briefly, TNFR1 activates the anti-apoptotic classical NFB pathway and the pro-
apoptotic caspase and MAPK pathways. Unlike the NFB and MAPK pathways which
occur after TNFR1 complex formation at the cell surface, apoptosis induction is
dependent on TNFR1 endocytosis (Schneider-Brachert et al. 2004). Notably, TNFR1
can also be involved in superoxide production, lipid metabolism and activation of JNK,
p38 and Akt pathways although these are not the focus of my work. TNFR2 can
provide cell protective functions through the activation of NFB and can also mediate
MAPK activation (Zhao et al. 2007) as well as influencing apoptosis in T cells (Lin et al.
1997). Although TNFR2 does not contain a death domain and is therefore not capable
of directly activating caspases, it may indirectly provide apoptosis inducing functions,
but this is dependent on the cell type and its environment. For example, using blood
from type I diabetes patients, TNFR2 agonism resulted in the selective death of insulin-
autoreactive T cells but not other activated or memory T cells (Ban et al. 2008). TNFR2
can also induce activation induced cell death (AICD) in CD8+ T cells as activated
TNFR2-/- CD8+ T cells were resistant to AICD (Twu et al. 2011). In contrast, TNFR1
showed enhanced classical NFB activation and subsequent pro-survival signals which
limited TNFR2-dependent AICD (Twu et al. 2011).
TRAF2 interacts directly with TNFR2 whereas it is recruited to TNFR1 via the adapter
protein TRADD. TRADD also recruits the protein kinase RIP (receptor interacting
protein) to TNFR1 which associates with TRAF2 and is essential for the activation of
p65 NFB. The poly-ubiquitination of RIP1 is mediated by cellular inhibitor of apoptosis
proteins (cIAP) 1 and 2 which are constitutively bound to TRAF2. This induces the
assembly of IKK complexes (Varfolomeev & Vucic 2008) which are essential for the
phosphorylation and degradation of the inhibitory IkB protein (described in more detail
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in chapter 1.4.1). The TRAF2-cIAP1/2 complex promotes NFB activation and
caspase-8 inhibition. It therefore leads to TNF stimulated expression of pro-survival
genes e.g. transcription factors which inhibit the activation of JNK and anti-apoptotic
factors such as c-FLIP, cIAP1/2 and Bcl-xL.
The efficacy of TNF-mediated signalling may also depend on the concentration of
soluble TNFR (both receptors can be cleaved from the cell surface as observed in
chronic inflammation where high amounts of particularly soluble TNFR2 is found in the
serum). Soluble TNFR1 and soluble TNFR2 can inhibit the effects of TNF by reducing
its availability to bind with signalling competent receptors. Also, TNFR2 activation can
lead to TRAF depletion thereby limiting its availability for recruitment to TNFR1,
reducing the activation of the classical NFB pathway and leading to apoptosis (Fotin-
Mleczek et al. 2002; Rauert et al. 2011).
1.4.1. The NFB pathway
Nuclear factor (NF)B is a transcription factor which controls cell proliferation and
survival and is widely implicated in both pro- and anti-inflammatory processes (Bonizzi
& Karin 2004). Defects in the NFB pathway contribute to inflammatory disease
pathology and NFB is constitutively active in many autoimmune diseases therefore
targeting the NFB pathway is considered a promising potential target for RA
therapeutics.
In mammalian cells the NFB family contains five members; p65 (RelA), RelB, c-Rel,
p50/p105 (NFB1) and p52/p100 (NFB2) which can form homo- and heterodimers
with each combination exerting a different function in gene regulation. The inhibitor of
B (IB) family are characterised by 6 or 7 ankyrin repeats in the C-terminus and
include IB, IB, IB and Bcl-3 which interact with (and inhibit) NFB proteins.
NFB family members all contain a Rel homology domain (RHD) in their N-terminus
which allows dimerisation, nuclear translocation and IB interaction (Perkins 2007). In
the cytoplasm of unstimulated cells NFB dimers are held in an inactive state by IB
proteins which mask the NFB nuclear localization sequence located within the RHD.
IB is only partially effective as when dimerised with NFB the complex may still enter
the nucleus. However, the IB/NFB complex is quickly exported due to a nuclear
export sequence in IB (Hayden & Ghosh 2004).
NFB signalling involves 2 major pathways; the classical (cannonical) pathway and the
alternative (non-canonical) pathway (Figure 5). The classical pathway is induced by
inflammatory stimuli and can be activated by both TNFR1 and TNFR2 (Wajant &
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Scheurich 2011; Lawrence 2009). It involves the activation of the IKK complex leading
to rapid phosphorylation of IB at Ser32 and Ser36 causing its degradation by the
26S proteosome. This most commonly results in the activation of the p50/p65
heterodimer and its translocation into the nucleus. Classical NFB activation results in
the transcription of cytokines, chemokines and adhesion molecule receptors
(Vallabhapurapu & Karin 2009) and is therefore a key component in the pro-
inflammatory effects of TNF. The alternative pathway can be activated by non-
inflammatory stimuli and can result in the inhibition of pro-inflammatory cytokines and
the induction of T cell tolerance (Zhu & Fu 2010). It can be initiated by TNFR2 but not
TNFR1 (Rauert et al. 2010) and involves the activation of IKK (but not IKK or NEMO)
by NFB inducing kinase (NIK). It is characterised by the induction of p100 processing
and the formation of p52. Heterodimers of p52 and RelB then enter the nucleus where
they bind specific B elements and induce genes involved in proliferation and the
adaptive immune response (Perkins 2007). Defects in the alternative NFB pathway
have been shown to result in defects in immune development (Caamaño et al. 1998;
Franzoso et al. 1998) and lead to autoimmunity (Cheema et al. 2001).
The classical (p65) NFB pathway NFB pathway can be activated by both TNFR1 and
TNFR2 (Lawrence 2009; Wajant & Scheurich 2011) and has been shown to be
essential for DC survival (Sánchez-Sánchez et al. 2004; Kim & Joo 2009). TNF-
induced phosphorylation of p65 at serine-276 is required for p65/RelB complex
formation and in the absence of ser-276 phosphorylation, TNF stimulation leads to a
strong increase in RelB controlled genes such as pro-survival Bcl-xL (Jacque et al.
2005). Some research indicates that TNF may activate the classical but not the
alternative NFB pathway (Derudder et al. 2003), however this result appears to
depend on both the cell type and the type of stimulation used as the alternative
(p100/p52) pathway has been shown to be activated by TNFR2 but not TNFR1 in
primary T cells (Rauert et al. 2010).
Although there has been a lot of research into the signalling mechanisms of TNFR1,
much less is known about TNFR2. TNFR2 was described to activate both the classical
and non-classical NFB pathways (Krippner-Heidenreich et al. 2002; Rauert et al.
2010), although the classical NFB pathway was activated to a lesser extent
(McFarlane et al. 2002). Upon TNFR2 stimulation TRAF2 recruitment to the receptor is
required for the activation of JNK and NFB. Activation of TNFR2 can lead to the
production of sTNF which results in the activation of TNFR1 in an autocrine/paracrine
fashion resulting in a feedback loop. It has been shown that blocking TNFR2 on
activated T cells inhibited TNF production which suggested that mTNF on the surface
of monocytes may mediate signalling (Rossol et al. 2007). TNFR2 was also shown to
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activate NFB via the activation of PI3K and Akt in mouse neurons (Fontaine et al.
2002). However, more research is needed to determine whether these mechanisms
are also activated on DC. Also, DC expression of NIK (involved in the alternative NFB
pathway) is required to promote Th1 and Th17 responses (Hofmann et al. 2011)
whereas NIK is not required for the activation of the classical NFB pathway by TNF
(Yin et al. 2001). During alternative NFB signalling RelB complexes with p52 and
translocates to the nucleus. RelB deficient mice have defects in DC cross-priming
(Castiglioni et al. 2002) indicating its importance in the immune response.
1.4.2. Caspases and apoptotic cell death
Caspases are a family of cysteine proteases that play an essential role in cell death
(both apoptosis and necrosis). To date, 14 caspases have been identified in mammals,
11 or 12 of which are found in humans; caspase-1 to caspase-10, caspase-14 and
caspase-12 (depending on hereditary polymorphisms) (Saleh et al. 2004). Caspases
exist in the cell as inactive pro-enzymes (pro-caspases) which are found in all
nucleated mammalian cells and are regulated at a post-translational level ensuring that
they can be rapidly activated. Cleavage activates the caspase molecule which contains
an N-terminal pro-domain, a large subunit containing the active site and a small C-
terminal subunit. There are two types of apoptotic caspases; initiator caspases e.g.
caspase-2, -8, -9 and -10 which activate effector caspases e.g. caspase-3, -6 and -7
thus leading to apoptosis. Other caspases such as caspase-4 and -5 are inflammatory
enzymes (reviewed in (Venero et al. 2013).
The initiation of apoptosis can occur via a cell intrinsic or extrinsic pathway. The
intrinsic pathway requires the release of cytochrome c from mitochondria (Figure 6)
and involves members of the Bcl-2 family (as described in more detail in chapter
1.4.2.1). The extrinsic pathway involves the binding of an external ligand to a ‘death
receptor’ (e.g. TNFR1 or Fas) on the plasma membrane. This allows the recruitment of
proteins (such as FADD) to the intracellular portion of the receptor and promotes the
activation of initiator caspases and subsequent effector caspases resulting in apoptosis
(Parrish et al. 2013). When pro-caspase-8 is cleaved to its active form (caspase-8), it
can lead to the activation of the extrinsic (type I) or intrinsic (type II) signalling pathway
(Figure 5). High levels of activated caspase-8 initiate the type I pathway by mediating
the activation of procaspase-3 to caspase-3 resulting in apoptosis (Schütze et al.
2008). Alternatively, low amounts of caspase-8 result in the type II pathway where the
low signal is amplified via mitochondria resulting in the activation of caspase-3 via
caspase-9.
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Figure 5: TNFR1 and TNFR2 signalling pathways. TNFR-mediated signalling can
activate caspases leading to cellular apoptosis (via either the intrinsic/mitochondrial
pathway or the extrinsic/death receptor-mediated pathway) or can activate NFB
thereby inducing the expression of anti-apoptotic molecules and preventing apoptosis.
TNFR1 and TNFR2-signalling can activate the classical NFB pathway (including the
phosphorylation and translocation of p65) which usually exerts anti-apoptotic signals.
Whereas TNFR1 generally only activates the classical NFB pathway, TNFR2-
mediated signalling can activate both the classical and the non-classical NFB
pathways. The non-classical NFB involves the processing of p100 to p52 and its
translocation to the nucleus. Signalling pathways described in detail in section 1.4.
Adapted from (Schütze et al. 2008; Perkins 2007).
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1.4.2.1. The Bcl-2 family
The mitochondrial pathway of apoptosis (type II pathway) is shown in Figure 6 and
involves members of the B cell lymphoma (Bcl-2) family. The Bcl-2 family play a major
role in both positively and negatively regulating mitochondria-dependent apoptosis.
Pro-apoptotic family members such as Bax and Bak can indirectly activate pro-
caspases by inducing the release of cytochrome c whereas anti-apoptotic members
including Bcl-2 itself and Bcl-xL inhibit cytochrome c release, therefore preventing
apoptosis. Both p65 NFB and p52 NFB can bind to the Bcl-xL promoter therefore
both the classical and alternative NFB pathways may play a role in the regulation of
its expression (Marinari et al. 2004; Tamatani 1999).
Other members of the Bcl-2 family include BH3-domain only proteins such as tBid, Bad
and Bik, which consist only of the BH3 death domain. These proteins can initiate
apoptosis by activating pro-apoptotic members or inactivating anti-apoptotic members.
For example, the activation of pro-apoptotic members can be mediated by an apoptotic
stimulus which can then lead to the cleavage of Bid to tBID which translocates into the
mitochondria. The translocation of tBID to the mitochondria causes Bax and/or Bak
(pro-apoptotic members of the Bcl-2 family) to oligomerise and form a pore in the outer
mitochondrial membrane (Ow et al. 2008). Oligomerisation of Bax and/or Bak may be
inhibited by Bcl-2 itself which is an anti-apoptotic family member. This pore formation
allows the release of cytochrome c which binds the adapter protein apoptotic protease-
activating factor-1 (Apaf-1) and along with the co-factor ATP, catalyzes its
oligomerisation forming a complex called the apoptosome (Solary et al. 2008). A
caspase recruitment domain (CARD) motif in Apaf-1 recruits procaspase-9 via a CARD
motif in its prodomain (Chen & Wang 2002) resulting in auto-processing to caspase-9,
which activates caspase-3. Unlike executioner caspases, caspase-9 is an initiator
caspase and must be bound to Apaf1 as well as being cleaved to allow its activation
(Zanoni & Granucci 2010).
1.4.2.2. TNFR-mediated caspase activation
TNFR1 mediates both pro- and anti-apoptotic actions. Following classical NFB
pathway activation through TNFR1 there is an increase in expression of anti-apoptotic
genes, resulting in enhanced cell survival. Alternatively, when the classical NFB
pathway is not fully activated, TNFR1 can mediate a pro-apoptotic signal via activation
of the caspase cascade (Festjens et al. 2007). Upon TNF binding, TNFR-associated
death domain (TRADD) is recruited to the TNFR1 death domain. This leads to
recruitment of Fas-associating protein including death domain (FADD) and
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procaspase-8 which form the death-inducing signalling complex (DISC) required for
apoptosis (Fesik 2000). Death receptor mediated apoptosis can be directly inhibited by
cFLIP which modulates caspase-8 activation (Schütze et al. 2008) (Figure 5).
TNFR1 may mediate pro- and anti-apoptotic responses by the formation of two
separate protein complexes after TNF binding and caspase-8 activation (Micheau &
Tschopp 2003). Complex I forms within minutes at the plasma membrane and may
lead to NFB activation without affecting apoptosis, whereas complex II is formed in
the cytoplasm after around 2 hours. Caspase-8 and FADD are recruited to complex II
and initiates apoptosis unless NFB signalling has induced the appropriate anti-
apoptotic proteins. TNFR2 can also activate the caspase cascade for example
caspase-3 is activated during the selective death of autoreactive T cells following
TNFR2 agonism in blood from type I diabetes patients (Ban et al. 2008).
Figure 6: The intrinsic (mitochondrial) pathway of apoptosis. A proposed
mechanism by which Bcl-2 protein family members contribute to cytochrome c release
and apoptosis. Cytochrome c is sequestered in cristae junctions in the inner
mitochondrial membrane (IMM). The cleavage and subsequent activation of Bid occurs
via stress signals or the extrinsic pathway of apoptosis and induces pore formation by
Bax/Bak oligomerisation in the outer mitochondrial membrane (OMM). Bax/Bak
oligomerisation can be inhibited by anti-apoptotic proteins such as Bcl-2 thereby
preventing apoptosis. Once released, cytochrome c associates with Apaf1 and
activates the caspase cascade resulting in apoptosis. Adapted from (Fraser 1982;
Lutzky et al. 2007).
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1.5. Differential functions of TNFR1 and TNFR2 in disease models
TNFR1 can mediate inflammatory actions (Chen & Goeddel 2002) but has also been
shown to be involved in the negative regulation of pro-inflammatory IL-12p70 and IL-23
(Zakharova & Ziegler 2005). A number of studies have utilised TNFR-deficient mouse
models to elucidate the role of TNFR1 and TNFR2 in disease. The data from a wide
range of disease models indicate that the two TNFR can mediate opposing effects and
point to a pro-inflammatory, destructive role for TNFR1 and a protective, anti-
inflammatory role for TNFR2 (Masli & Turpie 2009).
In the murine antigen-induced experimental autoimmune encephalomyelitis (EAE)
model TNFR1-/- deficient mice showed disease suppression whereas TNFR1-/-/TNFR2-/-
double-deficient mice showed an increase in symptoms (Kollias 2005). Another group
showed that EAE was enhanced in TNFR2 deficient mice whereas TNFR1 deficient
mice were resistant to EAE (Suvannavejh et al. 2000). Also in EAE, it has been shown
that TNF1 is required for the detrimental effects of TNF during the acute phase of
disease but is not required for TNF-mediated immunosuppression and subsequent
disease remission (Kassiotis & Kollias 2001). In addition, the absence of TNFR1 has
been shown to reduce the severity of induced arthritis whereas the absence of TNFR2
increased arthritis development (Blüml et al. 2010) and TNFR2 has been shown to play
a protective role in bone resorbtion in mouse models (Nagano et al. 2011). These
studies suggest a role for TNFR2 in suppressing inflammatory responses. Furthermore,
TNFR1 has been shown to mediate cardiac dysfunction whereas TNFR2 plays a
cardioprotective role in TNF-induced myocardial infarction (Higuchi et al. 2004; Monden
et al. 2007) and pulmonary inflammation following bacterial challenge is increased in
TNFR2 deficient mice but attenuated in TNFR1 deficient mice (Peschon et al. 2014).
Also, in a murine model of CIA, a TNFR1-selective antagonist showed anti-
inflammatory effects in established disease and did not result in the reactivation of viral
infections unlike Etanercept (Shibata et al. 2009) suggesting that TNFR1 mediates pro-
inflammatory effects.
A lack of TNFR2 has been shown to enhance neurodegeneration in a retinal ischemia
mouse model whereas a lack of TNFR1 reduced the neurodegeneration (Fontaine et
al. 2002). In addition, in vitro culture of mouse microglia have shown that TNFR2
promotes anti-inflammatory pathways (Veroni et al. 2010). In a mouse model of
polymicrobial sepsis, mice lacking TNFR1 had enhanced survival whereas mice lacking
TNFR2 had shortened survival and enhanced symptoms (Ebach et al. 2005). In mice
with traumatic brain injury, a TNFR2 agonist reduced the inflammatory response after
trauma by inhibiting the activation of the NFB and p38MAPK pathways (Wang et al.
2013). Moreover, in human autoimmune diseases such as type 1 diabetes it has been
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shown that TNFR2 agonists can selectively target and destroy autoreactive T cells from
isolated human blood (Chen et al. 2010), further suggesting a protective role for
TNFR2. In addition, TNFR2 has been shown to be preferentially expressed by Treg cells
and promotes their survival and expansion (Chen & Oppenheim 2011).
This array of previous research shows opposing roles for TNFR1 and TNFR2 in
different diseases, including both mouse and human models. Of particular interest is
the anti-inflammatory function of TNFR2 as although TNF is primarily thought of as a
pro-inflammatory cytokine, it has also long been known for its puzzling anti-
inflammatory functions. For example inflammatory IL-12 production is reduced in TNF-
treated murine macrophages and DC (Zakharova & Ziegler 2005) and although anti-
TNF treatment can improve the disease state of RA patients, in MS anti-TNF
exacerbated the disease (Robinson et al. 2001) and it may also result in demyelination
and lupus (Mohan et al. 2001). The actions of TNFR2 may therefore be disease-
protective and provide a potential avenue for the development of more targeted
therapies i.e. involving the specific blockade of TNFR1 or specific activation of TNFR2.
1.6. The role of TNF in RA and the rational for anti-TNF therapies
TNF has been associated with a range of autoimmune diseases such as RA, diabetes,
multiple sclerosis (MS) and Crohn’s (inflammatory bowel) disease (Feldmann et al.
2005). Synovial fluid (SF) from RA patients contains detectable levels of TNF (Saxne et
al. 1988). Also, TNF has been shown to induce collagenase production by synovial
cells (Dayer et al. 1985) as well as stimulating bone resorption in vitro (Bertolini et al.
1986) suggesting that TNF is intricately involved in the pathogenesis of RA.
Furthermore, a direct involvement of TNF in arthritis was shown using a mouse model
expressing human TNF (Keffer et al. 1991). Blocking TNF in the collagen induced
arthritis (CIA) mouse model, which is the most commonly studied autoimmune model of
RA, showed a reduction in disease severity whether administered before or after the
onset of clinical arthritis (Williams et al. 1992). As in other autoimmune diseases the
role of TNFR1 and TNFR2 in arthritis was originally investigated using mouse models.
TNFR1 is generally considered as the driving force in arthritis development. The
absence of TNFR1 has been shown to suppress induced arthritis whereas the absence
of TNFR2 increased arthritis development (Blüml et al. 2010). Another group has also
shown that TNFR1 is essential for the development of arthritis in mice transgenic for
human TNF (Armaka et al. 2008). Furthermore, reintroduction of TNFR1 in
mesenchymal cells in this model was sufficient for the development of arthritis (Armaka
et al. 2008). As in other disease models, this data suggests a mainly pro-inflammatory,
destructive role for TNFR1 and a protective, anti-inflammatory role for TNFR2 however,
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there are also studies which show opposing data. For example, the role of TNFR1 in
collagen induced arthritis (CIA), which is often used as a model for RA, appears to be
more complicated. One study has shown that a lack of TNFR1 on haematopoietic cells
increased the severity of CIA suggesting that TNFR1 may mediate an anti-
inflammatory response in these cells. Alternatively, in another study, TNFR1 deficient
mice were used to show that TNFR1 was essential for the proinflammatory signal in
CIA whereas TNFR2 was found to be involved during CIA onset even in the absence
of TNFR1 (Tada et al. 2001). These studies suggest that the roles of TNFR1 and
TNFR2 are not as simple as ‘disease-enhancing’ and ‘disease-protective’, but vary
according to cell type and environment therefore it is important to take into account the
two TNFR when studying different cell types and also different diseases.
Therapeutic blockade of TNF is a very successful treatment for RA with five TNF
antagonists currently approved for use in the UK; infliximab (a mouse-human chimera
monoclonal antibody), adalimumab (a fully humanised monoclonal antibody)
golimumab (human monoclonal antibody), certolizumab (PEGylated Fab’ fragment a
humanised monoclonal antibody) and etanercept (a soluble TNFR Fc-fusion protein)
(Tracey et al. 2008). These have been shown, from phase III clinical trials onwards, to
provide significant benefits even in patients who do not respond to other disease-
modifying anti-rheumatic drugs (DMARD) (Maini et al. 1999; Feldmann et al. 2005).
However, 30-40% of patients still do not respond to anti-TNF treatment and a
significant number who do respond later relapse. Also, these TNF antagonists are
associated with a number of side effects such as reactivation of latent infections e.g.
tuberculosis or an increased risk of serious infections and malignancies e.g. lymphoma
(Bongartz et al. 2006). This shows both the importance of TNF in RA and the need for
improved and more targeted therapies.
Another member of the TNF superfamily is lymphotoxin (LT) which is a close
homologue to TNF and can bind both TNF receptors (TNFR1 and TNFR2) (Medvedev
et al. 1996) along with its own receptor herpesvirus entry mediator (HVEM) (reviewed
in (Remouchamps et al. 2011)). LT can be detected in the joints of RA patients. In
addition, LT was shown to be preferentially expressed on Th1 and Th17 cells in a
murine model of RA, and its removal inhibited arthritis (Chiang et al. 2009). LT was as
effective as TNF at activating type B (fibroblast-like) synoviocytes and, therefore, could
contribute to RA pathogenesis (Calmon-Hamaty et al. 2010). Etanercept (a TNFR2-Fc
fusion protein) also blocks LT and was shown in one patient to induce clinical
remission after failure of anti-TNF infliximab therapy (Buch et al. 2004), which may
have been due to the different ligand specificities of infliximab and etanercept.
Therefore, the role of LT in arthritis is still unclear (Calmon-Hamaty et al. 2011).
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1.7. Hypothesis
TNF is known to play an important role in the maturation and survival of DC, but the
individual roles of the two TNFR remain unknown. The majority of previous research
has focussed on mouse models where either TNFR1 and/or TNFR2 have been
knocked out, thus allowing the effects mediated by the two TNFR to be studied
individually. While the human TNFR system is relatively understudied, the use of
mouse models indicates that the two TNFR can mediate opposing effects in disease
models. I hypothesise that TNFR1- and TNFR2-mediated signalling will exert different
effects on human DC maturation and survival, and that these effects may differ
between inflammatory and steady-state DC subsets.
1.8. Aims
1) To utilise previously defined TNFR-selective ligands in order to dissect the roles
of TNFR1 and TNFR2 in DC.
2) Identify the expression of TNFR1 and TNFR2 on human DC subsets (moDC,
pDC and blood myeloid CD1c+ DC).
3) Determine the competency of each TNFR for the activation of downstream
NFB signalling in moDC.
4) Investigate the involvement of TNFR1 and TNFR2 in the maturation of moDC
and blood myeloid CD1c+ DC.
5) Determine the individual roles of TNFR1 and TNFR2 in moDC and blood
myeloid CD1c+ DC survival and identify the pathways involved in the regulation
of DC lifespan.
6) Determine the effect of TNFR1 and TNFR2 on the maturation and survival of
myeloid CD1c+ DC isolated from synovial fluid in order to compare steady state
DC and DC from an inflammatory environment.
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2. Materials and Methods
2.1. Cell isolation and culture
The use of leukocyte reduction system (LRS) cones from platelet donations from
healthy volunteers was approved by the Newcastle and North Tyneside Research
Ethics Committee 2.
2.1.1. PBMC isolation
LRS cones were diluted 1:2 (or peripheral blood 1:1) with room temperature Hanks
balanced salt solution (HBSS; Ca2+ and Mg2+ free; Sigma-Aldrich, St Louis, USA,
H9394) + 2mM EDTA. Peripheral blood mononuclear cells (PBMC) were isolated from
LRS cones by density gradient centrifugation on Lymphoprep (Axis-Shield Diagnostics;
Oslo, Norway). 20ml blood was layered onto 15ml Lymphoprep and centrifuged for 30
min at room temperature (895 g). PBMC were recovered from the interface and
washed in cold Hanks + 1% FBS (Gibco; Paisley, UK), 600 g, 7 min, 4C to remove
any lymphoprep. Cells were then washed again in cold Hanks 1% FCS (250 g, 7 min,
4C) to remove any platelets which may activate monocytes. Cells were filtered through
a 70m nylon filter to remove any debris and counted using a Burker counting
chamber.
2.1.2. Monocyte-derived DC
To generate immature monocyte-derived DC (moDC) as previously described
(Anderson et al. 2008), CD14+ monocytes were isolated from PBMC by positive
magnetic selection using anti-CD14 magnetic microbeads (Miltenyi Biotec; Cologne,
Germany). PBMC were resuspended in ice-cold MACS buffer (PBS, 2mM EDTA +
0.5% FCS) at 800l per 100 x 106 PBMC and microbeads (coupled to anti-CD14
monoclonal antibodies) at 100l per 100 x 106 PBMC and incubated on ice for 20 min.
PBMC were then washed in MACS buffer (400g, 7 min, 4C) to remove any unbound
microbeads and the pellet was resuspended in 3ml MACS buffer. PBMC were added to
an LS MACS column pre-rinsed with MACS buffer where CD14+ cells are attracted to
the magnetic beads within the column and are therefore retained in the column
whereas CD14ˉ cells flow through into the waste tube. The column was washed 3 
times with 3ml MACS buffer, then it was removed from the magnet and the CD14+ cells
were flushed out with 3ml MACS buffer. The PBMC population generally contained 15-
30% CD14+ monocytes.
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Cells were then washed in Hanks 1% FBS, plated at 0.5 x 106/ml in RPMI-1640
(Sigma-Aldrich) supplemented with 10% (v/v) fetal bovine serum (FBS; Gibco BRL),
100 U/ml penicillin, 100 μg/ml streptomycin and 2 mM L-glutamine (all Sigma-Aldrich) 
in a 24 well plate and cultured for 6 days in the presence of IL-4 and GM-CSF (50
ng/ml each, Immunotools, Friesoythe, Germany) at 37°C, 5% CO2 to generate
immature monocyte-derived (mo)DC. On day 3 media was refreshed by removing
480l media and adding 500l warm RF10 containing 50ng/ml IL-4 and GM-CSF. All
further moDC cultures were carried out at 37°C, 5% CO2, in RPMI-1640 supplemented
with 10% (v/v) fetal bovine serum, 100 U/ml penicillin, 100 μg/ml streptomycin and 2 
mM L-glutamine.
2.1.3. Myeloid blood DC
Blood myeloid DC were separated from PBMC using an immunomagnetic negative
selection kit (EasySep human myeloid DC enrichment kit; StemCell Technologies;
Vancouver, Canada). Up to a maximum of 4 x 108 PBMC were placed in a 14 ml (17 x
100 mm) polystyrene tube (BD Biosciences; Oxford, UK) at a concentration of 5 x 107
cells/ml in PBS, 2% FBS, 1 mM EDTA (Ca2+ and Mg2+ free). The anti-human CD32
(Fcγ RII) Blocker was added at 15 l per 1 ml, the EasySep™ Human Myeloid DC
Enrichment Cocktail was added at 50 l per 1 ml of cells and cells were incubated at
room temperature for 30 min.
EasySep™ D Magnetic Particles were vortexed for 30 seconds to ensure that the
particles are in a uniform suspension with no visible aggregates prior to use. The
EasySep™ D Magnetic Particles were added to the cells at 100 l per 1 ml of cells and
were incubated at room temperature for 10 minutes. The cell suspension was brought
to a total volume of 10 ml with PBS, 2% FBS, 1 mM EDTA (Ca2+ and Mg2+ free) and
were mixed gently by pipetting up and down. Then the tube was placed into the Silver
EasySep™ Magnet (without the tube cap) and incubated at room temperature for 5
min. Then the EasySep™ Magnet (and tube) was picked up and inverted in one
continuous motion, pouring off the desired fraction into a new 14 ml polystyrene tube.
The magnet and tube were left inverted for 2 - 3 seconds, then return to upright
position being careful not to shake or blot off any drops that may remain hanging from
the mouth of the tube. The magnetically labelled unwanted cells remained bound inside
the original tube, held by the magnetic field of the EasySep™ Magnet. The original
tube was removed from the EasySep™ Magnet and replaced with the new tube,
incubated for another 5 min before pouring off the desired fraction as previously (for a
total of 2 separations). 10 ml PBS, 2% FBS, 1 mM EDTA (Ca2+ and Mg2+ free) was
added to the original tube and mixed gently, then the 5 min incubation and pouring off
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of the desired fraction was repeated (another total of 2 separations). The negatively
selected, enriched cells in the final tube (20 ml) were washed once (400g, 7 min) and
then cultured in a 96-well plate at 6.5 x 104 cells/200 μl. 
2.1.4. T cells
CD4+ T-cells were isolated from LRS cones using a human CD4+ T-cell enrichment
cocktail (RosetteSep; StemCell Technologies). RosetteSep Human CD4+ T Cell
Enrichment Cocktail was added at 75 l per ml whole blood, mixed well and incubated
for 20 min at room temperature. The sample was diluted 1:2 with PBS + 2% FBS,
mixed gently and enriched cells were separated by density gradient centrifugation on
Lymphoprep (Axis-Shield Diagnostics) (895 g, 30 min, room temperature). Cells were
recovered from the interface and washed in PBS + 2% FBS (600g, 7 min, room
temperature) and counted using a Burker counting chamber.
2.2. Cell lines
The MF TNFR1-Fas and MF TNFR2-Fas cells are chimaeric constructs of TNFR-Fas
stably expressed in immortalized fibroblasts derived from double-receptor knock-out
mice (Krippner-Heidenreich et al. 2002). The CD40L (J558L) cells (Lane et al. 1995)
are mouse B cell myeloma cells which have been transfected so they express mouse
CD40L (which cross reacts with human CD40) and were a kind gift from Peter Lane
(Birmingham).
2.3. TNF ligands, antibodies and inhibitors
The TNF ligands used were recombinant sTNF (50 ng/ml; 2 x 107 units/mg; provided by
Knoll AG, Ludwigshaven, Germany), recombinant CysTNFwt and mutants derived
thereof (TNFR1-selective CysTNF32W/86T, CysTNFR1; TNFR2-selective
CysTNF143N/145R, CysTNFR2; all at 50 ng/ml) (Krippner-Heidenreich et al. 2002;
Bryde et al. 2005). The mutations that provide selectivity for the two TNFR were
originally selected by a mutagenesis screen and were analysed for selective binding to
either TNFR1 or TNFR2 in competition with wild type sTNF (Loetscher et al. 1993). It
was found that a combination of the mutations Arg32 to Trp and Ser86 to Thr showed
high affinity binding to TNFR1 comparable to sTNF, but over 6000-fold lower affinity to
TNFR2. Whereas the mutation Asp143 to Asn combined with Ala145 to Arg showed low
affinity to TNFR1 (over 2500-fold lower than sTNF), however, binding to TNFR2 was
reduced by 5-10-fold (Loetscher et al. 1993). The cloning, expression and purification
of the CysTNF variants were described previously (Krippner-Heidenreich et al. 2002;
Bryde et al. 2005). CysTNFwt, CysTNFR1 and CysTNFR2 contain a free Cys residue at
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their N-terminus which leads to oligomerisation of the TNF monomers, primarily to
hexamers. Additionally, each of the CysTNF variants contain an N-terminal His-tag
thereby facilitating their purification. It has been demonstrated that sTNF and the TNF
variants possess similar bioactivities when used at saturating concentrations of 50
ng/ml (which is at least 50-fold in excess of their ED50). The ED50 of sTNF and
CysTNFR1 = 0.1-0.3 ng/ml and the ED50 of CysTNFwt and CysTNFR2 plus MAb 80M2 =
0.3-1 ng/ml as determined by a cellular in vitro system (see method 2.4, Figure 8 and
(Krippner-Heidenreich et al. 2002)).
Ligand TNFR activation
sTNF TNFR1
CysTNFwt TNFR1 and TNFR2
CysTNFR1 TNFR1
CysTNFR2 TNFR2
The antibodies used include MAb 80M2; a mouse anti-human TNFR2-specific
monoclonal antibody which was a kind gift from Peter Scheurich, IZI Stuttgart,
Germany; (Grell et al. 1995). The antagonistic TNFR-specific antibodies are TNFR1-
specific H398 (Hbt Hycult) and TNFR2-specific MR2-1; (Hbt Hycult for moDC) or clone
22221; (R&D Systems, for blood DC). The small molecule inhibitors used were BAY
11-7082 (Cell Signalling), Abt-737 (Selleck Chemicals), LY294002 (Cell Signaling
#9903), U0126 (MEK1/2, Cell Signaling #9901).
2.3.1. Antibodies for flow cytometry
Antibody Fluorophore Clone Company
Active Caspase-3 PE C92-605 BD Biosciences
CD1c PE-Cy7 L161 Biolegend
CD3 FITC UCHT1 BD Biosciences
CD11c FITC Lot 5130228177 Miltenyi
CD11c V450 B-ly6 BD Biosciences
CD14 APC-H7 MΦPg BD Biosciences 
CD16 APC B73.1 BD Biosciences
CD19 FITC HIB19 BD Biosciences
CD20 FITC 2H7 BD Biosciences
CD45 V500 H130 BD Biosciences
CD54 (ICAM-1) APC Lot 74900 BD Biosciences
CD56 FITC B159 BD Biosciences
CD83 APC HB15e BD Biosciences
CD86 FITC 2331 BD Biosciences
CD123 PerCP-Cy5.5 6H6 eBiosciences
CD274 (PD-L1) FITC MIH1 BD Biosciences
HLA-DR AF700 G46-6 BD Biosciences
HLA-DR Per-CP L203 R&D Systems
Anti-mouse IgG2A Biotin R19-15 BD Biosciences
Mouse IgG2A Isotype PE Lot LHC0809031 R&D Systems
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2.4. Cytotoxicity assay (activity test for TNF and TNF variants)
Cells were seeded at 2 x 104 (MF TNFR1-Fas or MF TNFR2-Fas) per well of a 96 well
plate in RPMI 1640 + 10% FCS + 2mM L-Glutamine and incubated overnight at 37C.
The next day MF TNFR-Fas cells were left untreated or treated in triplicates with
increasing concentrations of TNF, CysTNF or variants thereof with subsequent 3 fold
dilutions (0.0153 - 100 ng/ml) for 6 hours at 37C.
Supernatants were discarded and cells were washed with PBS. Any residual PBS was
removed by tapping the plate upside down on a dry paper towel. Cells were then
incubated for 15 min with 50 l/well crystal violet solution (0.5% w/v crystal violet
powder, 20% v/v methanol in 1000 ml dH2O). The residual stain was washed away with
running water (whilst being careful not to splash water directly onto the cells). Plates
were allowed to dry overnight then 100 l methanol was added to each well and results
were read on a TECAN microplate reader at λ=550nm. 
2.5. Stimulation of DC with TNF
Immature moDC were harvested on ice, washed three times in HBSS (Sigma-Aldrich)
containing 1% FBS then re-plated in a 24 well plate at either 2.5 x 105 cells/ml (for flow
cytometric analyses) or 5 x 105 cells/ml (for all other assays). MoDC or myeloid blood
DC were left untreated or were stimulated with recombinant sTNF or with recombinant
CysTNFwt and mutants derived thereof (TNFR1-selective CysTNFR1; TNFR2-selective
CysTNFR2), all at 50 ng/ml. As a positive control, DC were treated with standard-grade
E. coli LPS (100 ng/ml; Sigma-Aldrich). For TNFR2-selective stimulation, DC were pre-
treated with 80M2 MAb (2 μg/ml) for 5 min prior to the addition of CysTNFR2.
Where indicated, DC were incubated for 30 min with or without TNFR1- and/or TNFR2-
specific antagonistic antibodies H398 (Hbt Hycult) and 22221 (R&D Systems),
respectively; 10 μg/ml each, prior to the addition of TNF ligands. Alternatively,  DC 
were incubated for 30 min with or without  10 μM of signaling pathway small molecule 
inhibitors BAY 11-7082 (Cell Signalling), Abt-737 (Selleck Chemicals), LY294002 (Cell
Signaling #9903) or U0126 (MEK1/2, Cell Signaling #9901) (all resuspended in
DMSO), prior to the addition of TNF ligands.
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2.6. Flow Cytometry
All flow cytometry experiments were analysed using FlowJo (TreeStar) software.
2.6.1. Cell surface protein expression
DC were harvested 24 h after stimulation and re-suspended in fluorescence-activated
cell sorting (FACS) buffer (phosphate-buffered saline (PBS) containing 3% FBS, 0.1%
sodium azide and 2 mM EDTA). Cells were incubated for 30 mins on ice with human
IgG (a kind gift of Sophie Hambleton, UK) and selected MAbs. For moDC the following
MAbs were used as indicated; HLA-DR-PerCP, CD83-APC, CD86-FITC, ICAM-1-APC
and PD-L1-FITC. For blood myeloid DC, purity was checked with CD11c-FITC and
CD1c-PE-Cy7. Cells were then washed twice and resuspended in a final volume of 200
l FACS buffer and data were acquired on a FACSCanto II flow cytometer (Becton
Dickinson). Alternatively, PBMC were incubated with CD3-FITC, CD19-FITC, CD20-
FITC, CD56-FITC, CD123-PerCP-Cy5.5, CD1c-PE-Cy7, CD16-APC, HLA-DR-AF700,
CD14-APC-H7,CD11c-V450 and CD45-V500 and acquired on a Fortessa X20.
2.6.2. TNFR expression
For the detection of cell surface TNFR1 and TNFR2 a 3-step amplification system was
used. First, DC were re-suspended in 100l PBA (PBS containing 0.5% w/v bovine
serum albumin (BSA) and 0.01% w/v sodium azide) and incubated with anti-TNFR1
MAb (H398, 100-150 μg/ml) or anti-TNFR2 MAb (MR2-1; 50 μg/ml; Hbt Hycult for 
moDC; clone 22221; 150 μg/ml for blood DC) in the presence of 2% human IgG (to 
block non-specific binding to Fc receptors) and incubated for 1 h on ice in the dark.
Surface protein MAb (as described previously) may also be added at this point for
multiple surface staining of PBMC. Cells were then washed twice in PBA and blocked
in 2% rat serum (Sigma) in PBA for 10 min on ice prior to incubation with biotinylated
rat anti-mouse IgG2A antibodies (eBioscience, final dilution 1/50) for 20 min. Cells were
then washed twice in PBA and incubated with APC- (moDC; eBioscience) or PE-
(blood DC; Beckton Dickinson) coupled streptavidin (BD Biosciences, final dilution
1/10) for another 20 min on ice. Cells were then washed twice in PBA and then
resuspended in a final volume of 200l PBA and acquired on a FACSCanto II flow
cytometer.
2.6.3. Annexin V/ViaProbe
For Annexin V/ViaProbe detection DC were washed twice with cold PBS and
resuspended in 100l 1x Binding Buffer (0.01M Hepes (pH7.4), 0.14M NaCl, 2.5mM
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CaCl2). Then 5 l of AnnexinV and/or 5 l ViaProbe (BD Biosciences) was added to the
cells and incubated for 15 min at room temperature in the dark before 1x binding buffer
was added to a final volume of 200l.
2.6.4. Intracellular active caspase-3
For caspase-3 staining moDC or myeloid blood DC were harvested after 48 or 24 h of
stimulation, respectively, fixed with 100 l Cytofix/Cytoperm buffer for 20 min on ice
then washed twice in 2x Perm/Wash buffer (both from BD Biosciences). Cells were
incubated with 2% (v/v) rabbit serum (Sigma) for 15 min at 4°C prior to the addition of
MAb specific for active caspase-3-PE (C92-605; BD Biosciences) for 20 min at room
temperature in the dark. Cells were then washed twice in Perm/Wash buffer and
resuspended in a final volume of 200l FACS buffer. Data were acquired on a
FACSCanto II flow cytometer.
2.6.5. PhosFlow
Freshly isolated blood myeloid DC were resuspended at 250,000 cells/ml in ‘v’
bottomed eppendorf tubes and stimulated with sTNF or the TNFR-selective ligands for
5, 15 or 30 min in a pre-heated 37°C water bath. Cells were centrifuged (400 g, 5 min),
the cell pellet was resuspended in 100l PBS (containing Ca2+ and Mg2+) + 0.2% BSA +
0.01% azide (PBA) and 1 ml BD PhosFlow Fix Buffer I was added. Tubes were
incubated in a water bath for 12 min at 37°C before centrifugation (600 g, 8 min, room
temperature). Supernatants were aspirated, tubes were vortexed and cells were
washed in 1 ml PBA (including Ca2+ and Mg2+) (600 g, 8 min, room temperature). Cells
were then resuspended in 1 ml pre-chilled (-20°C) Perm Buffer III and stored overnight
at -80°C. Once cells had thawed they were transferred into FACS tubes and washed
twice in 3 ml PBA. To block the cells 50l 4% mouse serum was added and tubes were
incubated for 15 min at room temperature (final volume will be 100l with 2% block).
50l Ab solution was added (phosho-p65 PEcy7, 1:50), tubes were vortexed and
incubated at room temperature for 1 hour (protected from the light). Cells were then
washed (3 ml PBA, 600 g, 6 min at room temperature), resuspended in 200 l and data
were acquired on a FACSCanto II flow cytometer.
2.7. Cell death analysis (colorimetric assay)
MoDC were harvested, washed once and collected by centrifugation at 250 x g for 10
minutes. The supernatant was gently removed and discarded while the cell pellet was
lysed by the addition of 25 l of cold Lysis Buffer (R&D Systems) per 1 x 106 cells. The
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cell lysate is incubated on ice for 10 minutes and then centrifuged at 10,000 x g for 3
minutes and the supernatant was transferred to a new tube and kept on ice. The
protein content of the lysates was measured using a Bradford assay and the caspase-3
colorimetric assay was performed on 100 μg total protein from lysed moDC in a flat 
bottomed 96 well plate. Prior to use, 10 μl of fresh DTT stock was added per 1 ml of 2X 
Reaction Buffer 3, which was then added to the lysates to a final volume of 50 l. Next,
5 l of the p-nitroaniline-coupled Caspase-3-specific tetrapeptides (Asp-Val-Glu-
Asp(DVED)-pNA) substrate (R&D Systems) was added and the plate was incubated at
37°C for 2 hours. Absorbance was measured at 405 nm on a microplate reader
(Sunrise; Tecan Ltd.).
2.8. Bradford assay
The Bradford assay was used to determine protein concentrations. When coomassie
dye is bound to protein it results in a colour change (red to blue) and an absorbance
shift from 470 to 590 nm. The change in fluorescence is proportional to the amount of
protein present. A standard dilution of BSA was prepared; 2000 g/ml, 750 g/ml, 1000
g/ml, 500 g/ml, 250 g/ml, 125 g/ml and 0g/ml (H20) in order to give a standard
curve. 10 l/well of each standard was added to a well of a flat bottomed 96 well plate
in duplicate along with 10l for the blank (e.g. of lysis buffer). Samples were diluted in
dH2O as required (e.g. 5l sample + 5l dH2O). 150 l/well of room temperature
Bradford reagent was added to each well and samples were read at  = 595nm on a
microplate reader (Sunrise; Tecan Ltd.).
2.9. NFB activation
Reagents were prepared according to manufacturer’s instructions (Active Motif) as
follows (volume for 1 well, multiplied according to the number of wells required):
Complete Lysis buffer DTT 0.11 l
Protease inhibitor cocktail 0.23l
Lysis buffer AM2 22.2 l
Complete Binding buffer DTT 0.07l
Herring sperm DNA 0.34l
Binding buffer AM3 33.4l
1x Wash buffer dH2O 2.025l
10x Wash buffer AM2 225l
1x Ab binding buffer dH2O 202.5l
10x Ab Binding buffer AM2 22.5l
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2.9.1. Preparation of nuclear extracts
Nuclear extracts were prepared from moDC which had been stimulated with TNF,
variants thereof or LPS for 15 min (for p65) or 24 h (for p52) using an Active Motif
Nuclear Extract Kit. DC were harvested and washed in ice-cold PBS then re-
suspended in ice-cold 500 l 1x hypotonic buffer and incubated on ice for 15 min. 25 l
detergent was added and the cells were vortexed for 10 seconds before centrifugation
at 4°C, 14,000 g for 1 min. The supernatant (cytoplasmic fraction) was removed and
stored at -80°C. The nuclear pellet was re-suspended in 50l complete lysis buffer (10
mM DTT, lysis buffer AM1, protease inhibitor cocktail), vortexed for 10 sec and
incubated for 30 min on ice on a rocking platform set at 150 rpm. Extracts were
vortexed for 30 sec, centrifuged at 4°C, 14,000 g for 10 min and supernatants (nuclear
fraction) were stored at -80°C.
2.9.2. Oligonucleotide binding assay
The oligonucleotide binding capability of p65 and p52 NFB was assessed using
TransAM transcription factor kits specific for p65 or p52 (Active Motif). 5 μg of total 
nuclear protein per DC sample was used (except in titration experiments), as
determined by Bradford assay.
First 30 l of complete binding buffer was added to each well, then 5 g of each
sample of nuclear extract was diluted to a volume of 20 l and added to the wells
before the plate was sealed with an adhesive cover and incubated at 100 rpm on a
rocking table for 1 h at room temperature. Wells were washed 3 times with 200l 1x
Wash Buffer, 100 l of the NFB antibody (p65 or p52) diluted in 1x antibody binding
buffer (1;1000) was added per well and the plate was incubated for one hour at room
temperature without agitation. Wells were washed 3 times as previously, 100 l of
HRP-conjugated antibody diluted in 1x antibody binding buffer (1:1000) was added per
well and the plate was incubated at room temperature for 1 h. wells were then washed
4 times as previously, 100 μl room temperature developing solution was added and 
wells were incubated for 5 min at room temperature protected from direct light. 100 μl 
Stop Solution was added to each well and the NFB-binding to the oligonucleotide-
coated 96-well plates was determined at 450 nm on a microplate reader (Sunrise;
Tecan Ltd.).
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2.10. Mixed lymphocyte reaction
The principle of an MLR is that the T cell receptor on allogeneic T cells will react to the
mismatched MHC molecules present on the DC resulting in an alloresponse. MoDC
were stimulated with TNF, variants thereof or LPS for 24 h, harvested and washed
thoroughly in HBSS containing 1% FBS. 1 x 104 DC were co-cultured in triplicate with 1
x 105 allogeneic CD4+ T-cells (isolated from LRS cones using a human CD4+ T-cell
enrichment cocktail (RosetteSep; StemCell Technologies)) in a 96-well plate (total
volume 200 μl/well,). After 3 days supernatants (100 μl/well) were harvested and IL-10 
and IFN-γ levels were determined using a specific sandwich ELISA (BD Biosciences). 
To measure T-cell proliferation 10 kBq 3H-thymidine (Perkin-Elmer, Shelton, CT) was
added to each well for 8 h and radioactivity was quantified using a beta-scintillation
counter (Perkin-Elmer Microbeta Trilux).
2.11. ELISA
ELISA CaptureAntibody
Top
Standard
Detection
Antibody Develop Read
IL-6 1g/ml 2000 pg/ml 1g/ml 30 min 490 nm
IL-10 2g/ml 2000 pg/ml 1g/ml 40 min 490 nm
IL-12 4g/ml 4000 pg/ml 1g/ml 30 min 490 nm
IFN 1g/ml 2000 pg/ml 1g/ml 30 min 490 nm
TNF 2g/ml 2000 pg/ml 0.5g/ml 30 min 490 nm
IL-23 1/250 2000 pg/ml 1/250 15 min 450 nm
The capture antibody was diluted to the required concentration (see table above) in
coating buffer (0.06 M Na2HPO4 (4.35g), 0.08 M NaH2PO4.H2O (5.37g)) and 50 l was
added to each well, the plate was covered with adhesive plate sealer and incubated in
a moist box at 4°C overnight. The next day the capture antibody was discarded, the
plate was washed once with wash buffer (PBS, 0.1% Tween-20), and 100 l block
(PBS, 1% BSA) was added to each well. The plate was sealed and incubated at room
temperature for 1-2 hours. The plate was washed 3 times as previously and 50l
standards or samples diluted in diluent (PBS, 1% BSA, 0.1% Tween-20) was added to
each well. The plate was sealed and incubated overnight at 4°C. The plate was
washed 4 times as previously, 50 l biotinylated detection antibody (diluted in diluent)
was added per well, the plate was sealed and incubated at room temperature for 1 h.
Next the plate was washed 4 times as previously, the streptavidin-horseradish
peroxidase conjugate was diluted 1/1000 in diluent, 50 l was added per well, the plate
was sealed and incubated at room temperature for 30 min. The plate was washed 5
times as previously and the substrate; one OPD tablet, 13ml citrate phosphate buffer
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(0.03 M citric acid (2.55g), 0.05 M Na2HPO4 (3.66g), 0.03 M Na2HPO4.2H2O (4.58g))
and H2O2 (6 l 30% stock, added immediately prior to use) for the appropriate
development time. The reaction was stopped by the addition of 50 l 3M H2SO4 and
the absorbance was read at the appropriate wavelength on a microplate reader
(Sunrise; Tecan Ltd.).
2.12. Stimulation of DC and preparation of cell lysates
DC were harvested, washed in HBBS 1 % FCS and 2 x 106 cells per condition were
added to 250 l RF10. For MAb 80M2 treatment cells were pre-incubated with MAb
80M2 (2 g/ml) for 30 minutes, then stimulated with the appropriate ligand (sTNF,
CysTNFwt, CysTNFR1, CysTNFR2 100ng/ml) and incubated at 37ºC for specific time
points. Stimulation of DC was stopped by the addition of ice-cold DPBS and
centrifuging for 30 s at 400 g, 4˚C then DPBS was aspirated leaving the cell pellet. 
MoDC lysed on ice in high salt buffer (250 mM Tris HCl, pH 7.5, 375 mM NaCl, 2.5%
(w/v) Deoxycholate (SOC), 1% (v/v) Triton X-100) supplemented with protease
inhibitors (Roche Applied Science) and 0.5 mM PMSF. Cell lysates were sonicated and
centrifuged at 14,500g for 10 min. Protein concentrations of supernatants were
determined by Bradford assay.
2.13. Western blotting
Prior to use, 80 μg of total protein was denatured at 96°C for 3 min in Laemmli buffer 
(62.5 mM Tris HCl pH 6.8, 10 % (v/v) glycerol, 4% (w/v) sodiumdodecylsufate (SDS),
0.1% w/v bromophenol blue, 5% (v/v) β-mercaptoethanol). Proteins were separated 
along with a pre-stained protein standard (NEB broad range 15-175 kDa) by SDS-
PAGE (12% Acrylamide). Proteins were then transferred onto hydrophobic
polyvinylidene fluoride (PVDF) membrane (pre-soaked in methanol prior to use) in
transfer buffer (0.025 M Tris base, 0.2 M glycine diluted with 20% v/v methanol and
H2O) at 100 V for 80 min at 1.4 mA/cm2. After the transfer, the membrane was blocked
with 5% non fat milk powder in PBS-T (PBS plus 0.05% Tween-20) for 1 hour. The
membrane was washed 4 times for 7 min in PBS-T before adding the primary
antibodies; with Bcl-xl (2762, Cell Signaling) and GAPDH (6C5, abcam) MAbs
overnight at 4ºC. The membrane was then washed again in PBS-T and incubated at
room temperature in the appropriate HRP-coupled secondary antibody; either goat
anti-rabbit IgG-HRP (Santa Cruz) or anti-mouse IgG-HRP (Dianova) antibodies for 2
hours. Chemiluminescence substrate SuperSignal West (Thermo Scientific/Pierce) was
used, and chemiluminescence was captured on Kodak autoradiography film.
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2.14. siRNA
DC were harvested, washed and re-plated at 0.5 x 106 in a 24 well plate at a final
volume of 1 ml antibiotic-free media plus IL-4 and GM-CSF (50 ng/ml each,
Immunotools, Friesoythe, Germany). The transfection reagent DharmaFECT 4 (0.5 - 5
l; Thermo Scientific) was added to TNFR1- or TNFR2-specific siRNA (ON-
TARGETplus SMARTpool siRNA, Dharmacon) or non-sense siRNA (all 5 - 50 nM) and
incubated for 20 min (room temperature) while keeping light exposure to a minimum,
then the solution was added to the moDC and incubated at 37°C, 5% CO2 for 24 h.
2.15. Statistics
Statistics were performed using Prism 5.0 (GraphPad Software) and a general linear
model was performed using SPSS (Version 19) software. Differences between the
treatment groups were tested after adjusting for subject-to-subject variability and the
assumptions underlying the model confirmed by residual analysis. An F-test was
performed to test for differences between the treatment groups and contrasts formed to
compare the groups stimulated with TNFR-selective ligands with and without inhibitors.
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3. TNF-induced maturation of monocyte-derived DC
3.1. Introduction
Dendritic cells (DC) are professional antigen presenting cells (APC) which play a key
role in initiating and regulating immune responses and can be divided into several
subsets, the main two in humans being conventional/myeloid DC (CD1c+ or CD141+)
and plasmacytoid (p)DC (CD123+). Under steady state conditions DC typically reside in
an immature state where they have little ability to activate an effector T cell response
and may instead induce T cell tolerance (Banchereau & Steinman 1998). Upon
activation by PAMP or inflammatory cytokines DC mature and express high levels of
MHC II-peptide complexes, co-stimulatory molecules and cytokines (Matzinger 2002;
Breloer et al. 2001). This drives the expansion of antigen specific T cells and can
control T cell polarisation depending on the nature of the maturation stimulus (Diebold
2008; Kaliński et al. 1999). The maturation state of DC is critical in determining their 
immunomodulatory role and in maintaining the balance between immunity and
tolerance, whereas dysregulation of DC function can lead to autoimmunity.
TNF is a cytokine predominantly known for its pro-inflammatory actions and can
promote DC maturation (Sallusto & Lanzavecchia 1994). Previous studies have shown
that mice deficient in TNF fail to induce full DC maturation in response to viral
challenge in vivo (Trevejo et al. 2001) and that maturation of BM-derived DC from
these mice is impaired (Ritter et al. 2003). More specifically, murine knock-out models
have shown that without TNFR1, DC maturation is impaired in response to pathogens
(Ding et al. 2011; Sundquist & Wick 2005). In human cells the importance of TNF in DC
activity can be demonstrated by the effect of TNF neutralisation which has been shown
to reduce the T cell stimulatory capacity of DC (van Lieshout et al. 2005; Baldwin et al.
2010). Furthermore patients on anti-TNF therapy display impaired co-stimulatory
molecule upregulation after LPS stimulation (Baldwin et al. 2010).
As TNF plays such an important role in DC, dissecting the role of its two receptors
(TNFR1 and TNFR2) is vital in the development of new DC modulating drugs. For
example, TNFR2 polymorphisms or upregulation of TNFR2 have been associated with
several autoimmune diseases (Barton et al. 2001; Holtmann et al. 2002; Komata et al.
1999) and in a transgenic mouse model, high levels of either TNFR resulted in severe
inflammatory diseases regardless of the level of TNF (Douni & Kollias 1998). However,
it has been shown that in type I diabetes a TNFR2 agonist selectively killed
autoreactive T cells in isolated human blood (Ban et al. 2008). Furthermore, TNFR-
deficient mouse models have shown that TNFR2 plays a protective role and TNFR1
plays a destructive role in EAE (Suvannavejh et al. 2000), neurodegeneration
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(Fontaine et al. 2002) and cardiac dysfunction (Higuchi et al. 2004; Monden et al.
2007), thus illustrating the need for the development of specific therapies which could
selectively target individual TNFR.
To date the contributions of the two TNF receptors to human DC survival and
immunostimulatory function are not fully understood. The majority of studies
investigating the individual roles of TNFR1 and TNFR2 have been conducted in mouse
models whereas the human TNFR system is relatively understudied. There is no
known natural TNFR2 ligand which does not bind to TNFR1 making human cell studies
difficult as any effects of TNFR2 may be masked or counteracted by TNFR1. For this
reason, much of the previous work has made use of mouse models where either
TNFR1 and/or TNFR2 has been knocked out thus allowing the effects mediated by the
two TNFR to be studied individually. To counteract this problem, I have made use of
previously described TNFR-selective ligands and a TNF mutein mimicking mTNF
bioactivity (Krippner-Heidenreich et al. 2002; Bryde et al. 2005) in order to dissect the
roles of TNFR1 and TNFR2.
3.2. Specific aims
1) Determine the expression of TNFR1 and TNFR2 on human moDC.
2) Determine the competency of each TNFR for the activation of downstream
NFB signalling in moDC.
3) Determine the involvement of TNFR1 and TNFR2 in the maturation and
subsequent T cell stimulatory capacity of moDC.
3.3. Experimental Approach
To address these aims I used monocyte-derived (mo)DC which are differentiated in
vitro and can be used as a model for inflammatory DC. MoDC are not normally found in
healthy tissue but are thought to differentiate from monocytes during cases of chronic
inflammation such as RA (as reviewed in (Shortman & Naik 2007; Segura, Durand, et
al. 2013)). MoDC were treated with sTNF, CysTNFwt and TNFR-selective variants
CysTNFR1 and CysTNFR2. As CysTNFR2 was used in combination with the TNFR2-
specific MAb 80M2, which facilitates efficient stimulation through pre-clustering of
TNFR2, 80M2 alone was used as a control in all experiments. MoDC were washed
extensively after harvesting prior to stimulation with TNF in order to remove any
cytokines (i.e. IL-4 and GM-CSF) from the culture medium following their differentiation
from monocytes. This is necessary because GM-CSF may enhance DC survival (Wan
et al. 2013) and IL-4 can reduce the expression of TNFR2 in DC (Lutz et al. 2002)
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which could affect my studies. An oligonucleotide binding assay was used to determine
NFB activation as this method detects phosphorylation at multiple sites compared to
antibodies used in Western blotting or flow cytometry. A small number of experiments
were only conducted once in order to optimise the experimental system and maximise
the amount of TNFR-specific data, for example, the time course and amount of nuclear
extract used in the NFB activation assays. All key experiments were repeated three to
six times.
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3.4. Results
3.4.1. Characterisation of moDC
The characterisation of moDC is outlined in Figure 7. CD14 is a myeloid cell-specific
glycoprotein expressed highly on the surface of monocytes and can be used as a
control for the positive selection of monocytes from peripheral whole blood. Results
show that human PBMC contain a small population of these CD14+ cells (10-20%)
whereas cells separated by positive selection are 99.9% CD14+ and no CD14+ cells
can be found in the flow through (which includes all cells that were not bound to the
anti-CD14 magnetic microbeads (Miltenyi Biotec)). Once the monocytes differentiate
into moDC (via the addition of IL-4 and GM-CSF) the expression of CD14 is abolished.
Resulting immature moDC expressed the appropriate surface markers; high CD1a (a
transmembrane glycoprotein which can present lipid/glycolipid antigens to T cells and
is commonly used as a marker for moDC cultures), low CD83 (involved in regulating
antigen presentation and T cell co-stimulation), low CD86 (a T cell co-stimulatory
molecule) and high HLA-DR (an MHC class II molecule involved in antigen
presentation). Upon stimulation with LPS (100 ng/ml) for 24 h, the expression of CD83,
CD86 and HLA-DR increase indicating phenotypical moDC maturation. This confirms
that the standard method of in vitro moDC generation used previously by our group
(Anderson et al. 2009; Baldwin et al. 2010) and by others (Delirezh & Shojaeefar 2012)
is appropriate for use in further experiments.
3.4.2. The bioactivity of TNF and TNFR receptor-selective ligands
TNF ligands had been generated prior to this project with specific mutations providing
specificity for one receptor or the other (CysTNFR1 or CysTNFR2) (Krippner-Heidenreich
et al. 2002). CysTNFwt has membrane-bound TNF-like activity due to its oligomerised
form generated by a free Cys residue at the N-terminus which leads to oligomerisation,
primarily to hexamers. The monoclonal antibody (MAb) 80M2 facilitates the clustering
of TNFR2 without causing its activation (Grell et al. 1995). To determine the bioactivity
of the various ligands (sTNF, CysTNFwt, CysTNFR1, CysTNFR2) a cytotoxicity assay
was performed using murine fibroblast (MF) TNFR1-Fas and MF TNFR2-Fas cell lines
as generated previously (Krippner-Heidenreich et al. 2002). Murine fibroblasts were
originally derived from TNFR1/TNFR2 double knock-out mice and were stably
transfected with hybrid constructs consisting of the N-terminal, extracellular and
transmembrane part of TNFR1 or TNFR2 fused to the cytoplasmic death domain
containing region of Fas, the prototype of apoptosis inducing receptors of the TNFR
57
superfamily. This allowed me to determine the ED50 (effective dose which produces a
response in 50% of the cells) of each ligand.
Figure 8 shows that the various TNF ligands are all highly bioactive. The cytotoxic
effects of both CysTNFwt and CysTNFR1 are comparable to that of sTNF in MF TNFR1-
Fas cells (Figure 8 (A) and Figure 8 (B), respectively). The ED50 of these ligands is
around 1 ng/ml. As expected due to the established inability of sTNF to activate
TNFR2, Figure 8 (C) shows no cytotoxic response of MF TNFR2-Fas to sTNF,
whereas the ED50 after treatment with CysTNFwt is 1 ng/ml (similar to that seen in MF-
TNFR1-Fas cells). Figure 8 (D and F) shows that MF TNFR2-Fas cells do not respond
to CysTNFR2 alone apart from a minimal effect at very high concentrations of 100
ng/ml. However, in combination with MAb 80M2 CysTNFR2 gains full bioactivity with an
ED50 = 1ng/ml which is comparable to that of CysTNFwt (Figure 8 (D)). Importantly,
80M2 alone does not have any effect on cell viability (purple unfilled diamond, one
point). This shows that the CysTNFR2 ligand is potent to initiate signalling, however, it is
only efficient when used in combination with 80M2. Notably, the activity of CysTNFwt
cannot be increased by co-treatment with 80M2 (Figure 8 (E)) suggesting that the low
bioactivity of CysTNFR2 is due to the two point mutations introduced to give its receptor
selectivity. In addition, CysTNFR1 has no effect on MF TNFR2-Fas cells (Figure 8 (F))
confirming that this ligand is not cross-reactive with TNFR2. Alternatively, recent data
from another member of the lab confirms these results and also shows that 100ng/ml
CysTNFR2 plus 80M2 has no effect on MF TNFR1-Fas cells (Etherington 2014).
Results confirm that the TNF ligands have comparable bioactivities and can therefore
be used in further experiments.
3.4.3. TNFR1 and TNFR2 are expressed on immature moDC
Prior to performing experiments examining the role of individual TNF receptor
stimulation in moDC it was necessary to confirm the expression of TNFR1 and TNFR2
on moDC. Flow cytometry was used to detect TNFR expression on the surface of
moDC (Figure 9). Results show that immature moDC do express both TNFR1 and
TNFR2 and that expression is reduced when cells are matured with LPS. As DC are
important in the induction of immune tolerance I also analysed the expression of each
TNFR on tolerogenic moDC (differentiated using Vitamin D3 and Dexamethasone)
(Anderson et al. 2008; Anderson et al. 2009). Results showed that both TNFR1 and
TNFR2 are expressed at higher levels on tolerogenic moDC than on immature DC
although donor to donor variability was also greater. TNFR1 and TNFR2 were detected
using H398 (an IgG2A antibody) and MR2-1 (an IgG1 antibody) respectively, and the
same biotin and streptavidin conjugated antibodies. As different subtypes of primary
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antibodies are used, it is difficult to accurately compare the relative amounts of each
TNFR. However, as saturating concentrations of the antibodies are used results
generally suggest that moDC express higher levels of TNFR2 as compared to TNFR1.
My data confirm that both TNFR1 and TNFR2 are present on the surface of moDC and
leads on to the question, ‘are the two TNFR signalling competent?’ which will be
addressed in the following section.
3.4.4. TNFR1- but not TNFR2-mediated signalling activates the classical p65
NFB pathway in moDC
As described previously both TNFR1 and TNFR2 are capable of activating the classical
NFB pathway (Wajant & Scheurich 2011; Lawrence 2009). It has been shown that
TNFR1 can activate the classical p65 NFB pathway in DC (Peng et al. 2012) but to
my knowledge there are no studies published demonstrating TNFR2-mediated p65
activation in DC. In order to determine if the two TNFR expressed on the surface of
moDC were capable of initiating downstream signalling pathways I investigated the
potential activation of classical and alternative NFB pathways. To investigate the
capability of TNFR1 and TNFR2 to induce classical NFB (p65) signalling a preliminary
Western blot was conducted using moDC lysates and a phospho-specific p65 antibody.
Figure 10 shows that p65 phosphorylation is induced by stimulation with sTNF and
CysTNFR1 after 30 min when compared to unstimulated cells. However it was difficult to
determine if any signalling was induced by TNFR2-stimulation.
The phospho-p65 antibody used in the Western blot only recognises p65 when it is
phosphorylated at Ser536, whereas it may alternatively be phosphorylated at other
sites including Ser276 and Ser468. The population of modified subunits is not uniform
and different stimuli may activate different pools therefore in order to allow for the
different phosphorylation sites and to increase accuracy an oligonucleotide binding
assay was used. The TransAM NFB assay kit recommends using between 2 and 20
g nuclear extract per well. Due to the limited amount of reagents and the use of
primary cells it was not possible to attain 20 g of nuclear extract per condition
therefore the assay was optimised by using varying amounts of nuclear extract (Figure
11 (A)). As the difference in p65 activation between immature moDC and TNFR1-
stimulated moDC was greater when using 5 g nuclear extract per well, this amount
was chosen and used for all future experiments. Furthermore, in all p65 assays moDC
were stimulated with TNF and its variants for 30 min as according to the Western blot
(Figure 10) 15 min was not enough time to allow phosphorylation and nuclear
translocation but after 60 min the signal was slightly decreased (Figure 10 and
confirmed in Figure 11 (B)).
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Results in Figure 12 (A and B) show that all of the TNFR1-stimulating ligands (sTNF,
CysTNFwt and CysTNFR1) activate the classical p65-mediated NFB pathway whereas
no activation was detected via TNFR2. Figure 12 (A) includes the controls CysTNFR2
and 80M2 alone which have no effect on p65 activation. Figure 12 (B) includes an
increased number of donors and shows that CysTNFR1 but not CysTNFR2 plus 80M2
significantly activates the p65 NFB pathway. The activation of p65 by TNFR1 and not
TNFR2 was also confirmed using flow cytometry (Figure 13). This technique only
requires p65 phosphorylation at Ser529 and not nuclear translocation therefore I
performed a time course of moDC stimulation between 5 and 30 min (Figure 13 (A)).
This experiment showed that the optimum time point for p65 phosphorylation was 5
min not 30 min as in the previous assays (Figure 10 and Figure 11). My results confirm
that TNFR1 on moDC is signalling-competent, however no TNFR2-mediated p65
activation was detected. The potential activation of other pathways is therefore
addressed in the following section.
3.4.5. TNFR1- and TNFR2-mediated signalling activates the alternative p52 NFB
signalling pathway
In contrast to TNFR1, TNFR2 was described to activate the alternative NFB signalling
pathway in primary T cells (Rauert et al. 2010). To assess whether this is also the case
in moDC I used a TransAM p52 oligonucleotide binding assay as the processing of
p100 to p52 is characteristic of the alternative NFB pathway activation. Longer time
points were predicted as cleavage of p100 is a slower process than that of p65-
phosphorylation (Naude et al. 2011), therefore, I stimulated moDC for 12, 24 and 48
hours (Figure 14). Results show that after 12 hours there is low activation of p52 by
CysTNFR1 but no activation by CysTNFR2 plus MAb 80M2, after 24 hours there is
activation through both receptors, however, activation via TNFR2 was diminished by 48
hours suggesting that signalling through TNFR2 may be more transient than signalling
via TNFR1. For all further experiments 24 hours was chosen as the optimum time
point.
Figure 15 (A) includes the controls CysTNFR2 and 80M2 alone which have no effect on
p52 activation. Figure 15 (B) shows that activation of the alternative NFB signalling
pathway is significantly induced by both TNFR1 and TNFR2 stimulation. To confirm
that the effect of TNFR1-stimulation is in fact occurring via TNFR1 I used the TNFR1-
specific antagonistic antibody H398 (Figure 16). Results show that blocking TNFR1
partially decreased the activation of p52 when used in combination with all of the
TNFR1-stimulating ligands. In order to account for a possible increase in cell death in
unstimulated moDC at the 24 hour time point GM-CSF was added to enhance cell
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survival (Wan et al. 2013). Figure 17 shows that the addition of GM-CSF did not alter
the activation of p52 compared to unstimulated cells and activation was still increased
by TNFR-selective stimulation. Also, as TNF is not necessarily a full maturation factor
for DC, I stimulated moDC with CD40L expressing J558L cells (mouse B cell myeloma
cells transfected to express CD40L), which resulted in a 2-fold increase in p52
activation compared to moDC stimulated with TNF (Figure 17).
Previous data suggest that high levels of the adapter kinase RIP1 may mediate the
activity of the classical NFB pathway and that RIP1 can suppress TNFR1-mediated
activation of the alternative NFB pathway (Kim et al. 2011; Gentle et al. 2011). As
TNFR1-selective stimulation activates both the classical and alternative NFB
pathways it is possible that RIP is not essential for activation of the classical pathway in
my system and that it may be absent, therefore allowing activation of the alternative
pathway. However, preliminary results suggest that this is not the case as RIP is
expressed in moDC and its expression is not reduced or absent during stimulation with
sTNF (Figure 18) therefore it remains unclear under which conditions TNFR1 induces
alternative NFB signalling (this will be discussed further in chapter 3.5.2). In summary,
my data show that both TNFR1 and TNFR2 are signalling competent in moDC and that
they differentially activate the classical and alternative NFB pathways.
3.4.6. TNFR1- but not TNFR2-mediated signalling enhances the expression of
surface molecules associated with moDC maturation
Maturation of DC can be characterised by an increase in the expression of surface
molecules such as CD83 (a regulator of antigen presentation), the co-stimulatory
molecule CD86 and the MHC class II molecule HLA-DR. MoDC were stimulated with
increasing concentrations of sTNF from 0.1 to 100 ng/ml and the expression of these
maturation-associated markers was assessed by flow cytometry. Results (Figure 19)
confirm that sTNF is capable of inducing phenotypical maturation of moDC and that 50
ng/ml is a suitable concentration for use in future experiments as this maximally
induced maturation marker expression. However, as the increase in marker expression
induced by sTNF is much lower than that of LPS I also investigated the addition of
cytokines which may potentially amplify the sTNF-mediated signal and allow a more
clear dissection of the roles of each TNFR.
Figure 20 shows the expression of maturation-associated markers following a titration
of both IL-1 and sTNF (0.4 to 50 ng/ml of each). Without the addition of IL-1, there is
an increase in expression of CD83, CD86 and HLA-DR after treating the cells with 10
or 50 ng/ml of sTNF (as shown previously in Figure 19). However, there is also an
increase in the expression of these molecules when IL-1 alone is added even at low
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concentrations of 0.4 ng/ml. Also, IL-1 concentrations higher than 2 ng/ml may mask
the effect of sTNF. Although 0.4 ng/ml of IL-1 alone resulted in increased marker
expression this expression was further increased in combination with 10 or 50 ng/ml of
sTNF when compared to sTNF alone. I also investigated the addition of TNFR1- and
TNFR2-selective ligands (Figure 21). However, the effect of TNFR1- or TNFR2-
selective stimulation was not affected by the addition of IL-1 therefore there was no
advantage to the addition of IL-1 in any future experiments.
Alternatively, another group has described synergy between IL-4 and TNF in murine
bone marrow derived DC (Lutz et al. 2002). Figure 22 shows that in moDC IL-4 alone
has no effect but can enhance the effect of sTNF by 38% (CD83), 30% (CD86) and
16% (HLA-DR). In order to dissect the roles of each individual TNFR, I then repeated
this experiment with the TNFR-selective ligands both in the absence (Figure 23 (A)) or
presence (Figure 23 (B)) of IL-4. Results show that all TNFR1-stimulating ligands
(sTNF, CysTNFwt and CysTNFR1) but not the TNFR2-selective ligands (CysTNFR2 plus
MAb 80M2) increased the surface expression of CD83, CD86 and HLA-DR. The
increase in CD83 and CD86 expression levels could be further enhanced by co-
treatment of sTNF, CysTNFwt or CysTNFR1 with the cytokine IL-4, which by itself did not
affect DC maturation. However, even in presence of IL-4, TNFR2-selective stimulation
did not significantly enhance expression of CD83, CD86 or HLA-DR. Similar results
were also seen with the expression of the surface markers PD-L1 and ICAM-1 where
expression was increased by LPS and TNFR1- but not TNFR2-selective stimulation
(Figure 24). PD-L1 plays a role in suppressing the immune system and is essential for
peripheral T cell tolerance (Keir et al. 2006; Latchman et al. 2001), whereas ICAM-1 is
an adhesion molecule which facilitates leukocyte endothelial transmigration and pro-
inflammatory effects (Yang et al. 2005). Results therefore indicate that TNFR1 may
affect both suppression and enhancement of immune responses thereby highlighting
the importance of TNFR-mediated responses.
Another indicator of DC maturation is immune cell-modulatory cytokine production. In a
preliminary experiment I looked at TNF production by moDC in response to LPS.
Figure 25 (A) shows that immature (unstimulated) moDC cultured for 24 h produce very
low levels of TNF which is comparable to that of moDC cultured with MAb 80M2 alone
indicating that the MAb 80M2 alone does not induce endogenous TNF production. As
no effect on maturation was seen upon TNFR2-selective stimulation, levels of TNF in
supernatants from CysTNFR2 (50 ng/ml) plus MAb 80M2 cultures was also measured.
The high amounts of TNF in these supernatants confirmed that the TNFR2-selective
ligand was indeed added to each of the cultures. Supernatants from the same cell
cultures were also analysed for the production of IL-6, IL-10, IL-12 and IL-23 (Figure 25
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(B)) and results show that neither TNFR1- or TNFR2-mediated signalling induces
detectable levels of these cytokines within 24 h of TNF treatment.
Data therefore show that TNFR1 but not TNFR2 induces moDC maturation in terms of
enhanced surface marker expression and leads to the question, ‘does an increase in
surface marker expression also translate to a functional effect?’ which will be
addressed in the following section.
3.4.7. MoDC matured in the presence of TNFR1-stimulating TNF ligands have
enhanced T cell stimulatory capacity
In order to assess whether the enhancement of maturation-associated surface marker
expression correlated with a functional effect, it is important to determine if moDC can
activate a T cell response. To investigate this, a mixed lymphocyte reaction was
performed in which moDC were stimulated with LPS, sTNF, CysTNFwt, CysTNFR1 or
CysTNFR2 + 80M2 for 24 h. MoDC were then washed thoroughly to remove any
remaining stimulus (e.g. TNF) before they were cultured with allogeneic T cells and the
incorporation of 3H-thymidine was detected. Immature moDC cultured with sTNF or
CysTNFwt (both of which can act via TNFR1) displayed a significantly increased ability
to induce T cell proliferation (Figure 26 (A-D)) but not IFN- production at either 3 or 6
days of co-culture (Figure 26 (E-F)). However, the TNFR1-selective ligand CysTNFR1
did not induce a significant T cell response (Figure 26 (A-F)). In addition, TNFR2-
stimulated DC did not enhance T cell stimulatory capacity as there was no significant
increase in T cell proliferation (Figure 26 (A-D)) and no IFN- cytokine production
(Figure 26 (E-F)) at either day 3 or day 6. This is in keeping with the lack of a
significant increase in maturation marker expression by CysTNFR2 + 80M2 stimulated
moDC. Figure 26 (A and B) also shows that T cells cultured alone (without moDC)
have very low levels of proliferation. As there was not a significant increase in T cell
proliferation at day 6 following LPS stimulation of the moDC (Figure 26 (B)), a time
course was performed showing that T cell proliferation peaked at 5 day after which
proliferation declined (Figure 26). Results suggest that TNFR1 but not TNFR2 induce
moDC maturation in terms of phenotype (enhanced maturation marker expression) and
function (enhanced T cell stimulatory capacity).
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Figure 7: Characterisation of moDC surface marker expression. PBMC were
isolated from peripheral whole blood and CD14+ monocytes were separated by positive
selection. Immature moDC differentiated using IL-4/GM-CSF were harvested at day 6
or matured by the addition of LPS for 24 h. Cells at each stage of isolation and
differentiation were analysed by flow cytometry. The first column shows side scatter (y
axis representing granularity) versus forward scatter (x axis indicating size). The other
columns show analysis of monocyte specific CD14, DC specific glycoprotein CD1a,
regulatory molecule CD83, co-stimulatory molecule CD86 and APC marker HLA-DR
(black lines) and are shown in relation to unstained cells (grey shaded). These data are
representative of at least three independent experiments.
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Figure 8: Determination of the bioactivity of TNF variants using MF-TNFR1-Fas
and MF-TNFR2-Fas cell lines. MF stably transfected with expression constructs
encoding TNFR1-Fas (A and B) or TNFR2-Fas (C-F) chimeras remained untreated or
were stimulated with increasing concentrations (0.015-100 ng/ml) of sTNF, CysTNFwt,
CysTNFR1 or CysTNFR2 +/- 80M2 (2 g/ml) as indicated, in triplicate for 6 hours.
Adherent cells were stained using crystal violet. Corresponding absorbances at 550 nm
were determined for quantitative analysis of cell viability. (A and B) represent four
independent experiments (C-E) represent two independent experiments (F) is
reproduced with permission from (Maney 2010) and represents one experiment.
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ined using a colorimetric oligonucleotide binding assay. The mean and SEM
(A) or 6 (B) independent donors are shown. Significance is shown in relation to
re (unstimulated) moDC and is determined using a student’s t test; *P≤0.05 
1 ***P≤0.001.  
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Figure 16: The activation of p52 by TNFR1 can be prevented by the addition of a
TNFR1-specific antagonistic antibody. Immature moDC were left untreated or
treated with the TNFR1-specific antagonistic antibody H398 (shaded bars) for 30 min
prior to stimulation with 50 ng/ml TNF-selective ligands +/- MAb 80M2 for 24 hours.
Nuclear proteins were extracted and 5 g was used to determine the translocation and
DNA-binding capability of p52 using a colorimetric oligonucleotide binding assay.
Results represent one individual experiment.
Figure 17: GM-CSF does not increase the basal level of p52 activation in moDC
and TNF is less efficient at activating p52 in moDC than CD40L cells. Immature
moDC (white) were left untreated, treated with GM-CSF (50 ng/ml, shaded bar) or
stimulated with 50 ng/ml TNF-selective ligands +/- MAb 80M2 or CD40L cells (grey) for
24 h. Nuclear proteins were extracted and 5 g was used to determine the
translocation and DNA-binding capability of p52 using a colorimetric oligonucleotide
binding assay. Results represent one individual experiment.
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Figure 18: MoDC express RIP both with and without stimulation with sTNF.
Immature moDC were left untreated or were stimulated as indicated with 50 ng/ml
sTNF for 9, 20 or 48 h. Cell extracts were analysed for the expression of RIP (60 kDa)
by Western blot analysis. Results represent one individual experiment.
CD83
0 0.1 1 10 50 10
0
0
200
400
600
800
1800
sTNF (ng/ml)
M
FI
CD86
0 0.1 1 10 50 10
0
0
500
1000
1500
2000
5500
sTNF (ng/ml)
M
FI
HLA-DR
0 0.1 1 10 50 10
0
0
1000
2000
3000
4000
5000
6000
sTNF (ng/ml)
M
FI
Figure 19: Stimulation of moDC with sTNF enhances the expression of surface
proteins associated with moDC maturation in a dose dependent manner.
Immature moDC were treated as indicated with increasing concentrations of sTNF (0.1
- 100 ng/ml) or with 100 ng/ml LPS (open square) for 24 h. The expression of CD83,
CD86 and HLA-DR was determined by flow cytometry. Data represent one
independent experiment.
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20: IL-1 induces an increase in moDC maturation marker expression
independent to the addition of sTNF. Immature moDC were treated as
with increasing concentrations of sTNF (0.1 - 100 ng/ml) and also increasing
ations of IL-1 (0.1 - 100 ng/ml) for 24 h. The expression of CD83 (A), CD86 (B)
-DR (C) was determined by flow cytometry and the median fluorescence
(MFI) is shown. Data represent one independent experiment.
HLA-DR
50 10 2 0.4 0 50 10 2 0.4 0 50 10 2 0.4 0 50 10 2 0.4 0 50 10 2 0.4 0
0
1000
2000
3000
4000
IL-1 50ng/ml
IL-1 10ng/ml
IL-1 2ng/ml
IL-1 0.4ng/ml
No IL-1
sTNF ng/ml
M
FI
C
75
R1
R2
R1
R2
Figure 21: IL-1 does not enhance moDC maturation marker expression mediated
by TNFR2. Immature moDC were treated as indicated with 50 ng/ml of CysTNFR1 or
CysTNFR2 plus MAb 80M2, with (grey) or without (white) 0.4 ng/ml IL-1 for 24 h. The
expression of CD83, CD86, HLA-DR, PD-L1 and ICAM-1 was determined by flow
cytometry. MFI indicates the median fluorescence intensity, error bars show the mean
of the MFI +/- SEM. Data represent 4 independent experiments. Statistical differences
were determined in relation to un-stimulated (immature) moDC using a student’s t test;
*P≤0.05 **P≤0.01 ***P≤0.001. 
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Figure 22: IL-4 enhances sTNF-induced expression of moDC maturation markers.
Immature moDC were treated as indicated with sTNF (50 ng/ml) in the presence or
absence of IL-4 (5 or 10 ng/ml) for 24 h. The expression of CD83, CD86 and HLA-DR
was determined by flow cytometry. Data represent one independent experiment.
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Figure 23: TNFR1- but not TNFR2-mediated signalling results in enhanced
expression of moDC surface proteins associated with moDC maturation.
Immature moDC were treated as indicated with LPS (100 ng/ml), TNF ligands (50
ng/ml) +/- MAb 80M2 (2 g/ml) for 24 h in the absence (A) or presence (B) of IL-4 (10
ng/ml). The expression of CD83, CD86 and HLA-DR was determined by flow
cytometry. (A and B) MFI indicates the median fluorescence intensity, error bars show
the mean of the MFI +/- SEM. Statistical differences were determined in relation to un-
stimulated (immature) moDC using a student’s t test; *P≤0.05 **P≤0.01 ***P≤0.001. (C) 
CD83 expression by ligand-treated moDC (black line) is shown in relation to expression
by immature moDC (grey shaded). Data are representative of 3 independent
experiments with moDC from different donors.
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Figure 24: TNFR1- but not TNFR2-mediated signalling results in enhanced
expression of additional surface proteins associated with moDC maturation.
Immature moDC were treated as indicated with LPS (100 ng/ml), TNF ligands (50
ng/ml) +/- MAb 80M2 (2 g/ml) for 24 h. The expression of PD-L1 and ICAM-1 was
determined by flow cytometry. (A and B) MFI indicates the median fluorescence
intensity; error bars show the mean of the MFI +/- SEM. Statistical differences were
determined in relation to un-stimulated (immature) moDC using a student’s t test;
*P≤0.05 **P≤0.01 ***P≤0.001. Data are representative of 3 independent experiments 
with moDC from different donors.
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Figure 27: T cell proliferation after co-culture with LPS-stimulated moDC is
highest after 5 days. Immature moDC were left untreated or were treated with LPS
(100 ng/ml) for 24 h, washed thoroughly and co-cultured with allogeneic CD4+ T cells at
a ratio of 2 x 104 moDC to 1 x 105 T cells for 3 to 6 days. T cell proliferation after
incubation with an excess of 3H-thymidine for 8 h was determined by quantification of
incorporated 3H-thymidine. Results represent one independent experiment.
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3.5. Discussion
This study is the first to use TNFR-selective ligands to investigate the roles of TNFR1
and TNFR2 in regulating human moDC maturation. I have made use of previously
developed and well defined TNFR-selective ligands to exclude knock-out induced side
effects and to directly investigate each receptor in human cells. I have also used
CysTNFwt which mimics the activity of mTNF as using sTNF alone will only efficiently
activate TNFR1 (but not TNFR2), whereas mTNF activates both TNFR and thus
resembles cell-to-cell interaction induced signalling.
The aims of this chapter were to investigate the expression and signalling competence
of TNFR1 and TNFR2 on human moDC, to explore the effect of TNFR signalling on
moDC maturation and to determine their ability to stimulate T cell proliferation. I have
shown that moDC do express signalling competent TNFR1 and TNFR2 and that the
downstream signalling of each receptor is different but overlapping. I have also shown
that TNFR1- but not TNFR2-mediated signalling results in moDC maturation as defined
by enhanced expression of maturation markers. However TNF-induced signalling alone
(when compared to the TLR ligand LPS) is not sufficient to induce full maturation as
shown by a lack of cytokine production by the moDC and by subsequently activated T
cells.
3.5.1. MoDC expression of TNFR and TNFR2
I have shown that both TNFR1 and TNFR2 are expressed on human immature moDC
and that their expression is reduced following moDC maturation (Figure 9). Although a
similar reduction in TNFR expression is seen in all samples, the variability in
expression on immature moDC between each donor is high (almost 3-fold in some
samples). This difference in receptor expression may account for donor to donor
variability in other assays i.e. some donors appear to have a greater response to TNF
than others.
3.5.2. NFB pathway activation and DC maturation
NFB transcription factors regulate a range of genes involved in the inflammatory
response and NFB signalling is widely implicated in inflammatory diseases, both in
pro- and anti-inflammatory processes (Bonizzi & Karin 2004). The regulation of the
classical and alternative NFB pathways is crucial in the balance between inflammation
and tolerance. My findings that the classical (p65) and alternative (p52) NFB
signalling pathways in moDC are differentially activated by TNFR1 and TNFR2 may
partially explain the opposing functions of TNF in disease (see chapter 1.5). The lack of
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activation of p65 via TNFR2 observed in my data is most likely to be moDC-specific as
others have shown that the classical NFB pathway is activated by TNFR2, albeit to a
lower extent compared to TNFR1 for example in cell lines (McFarlane et al. 2002) and
in mouse neurones which lack TNFR1 (Marchetti et al. 2004).
In contrast to my data, other groups have shown that TNFR2 can activate the classical
NFB pathway. In a mouse model with neurones lacking TNFR1, TNFR2-mediated
signalling activated the PI3K pathway leading to IB phosphorylation, degradation
and subsequent classical p65 NFB pathway activation (Marchetti et al. 2004).
Additionally, human KYM-1 rhabdomyosarcoma cells which express TNFR1 and high
levels of endogenously expressed TNFR2 or HeLa cells generated to over-express
exogenous TNFR2, can both activate the classical NFB pathway via TNFR1 and
TNFR2 as measured by IB degradation and NFB gene activity, although the effect
of TNFR2 was much weaker than TNFR1 (McFarlane et al. 2002). This suggests that
although TNFR1 is not responsible for all TNF-mediated classical NFB activation, it is
predominantly responsible, as even when over-expressed TNFR2 is not efficient in the
activation of p65 NFB. Therefore it is possible that TNFR2 may mediate some
activation of the classical NFB pathway in moDC but may still be too weak to be
detected by the DNA-binding ELISA used in this study.
The classical p65 NFB pathway is essential for DC maturation as suppression of p65
NFB signalling inhibits DC maturation in a mouse model (Peng et al. 2012).
Depending on the cell type and environment TNFR1 and TNFR2 can both
independently activate the classical NFB pathway, however they may differ in the
kinetics of this activation; in primary cortical neurones from TNFR knock-out mice,
TNFR1 induced transient p65 NFB activation with an optimum activation after 1 hour
of TNF treatment, whereas TNFR2 induced weaker but more long term p65 NFB
signalling for up to 4 hours (Marchetti et al. 2004). This partially fits with my data as
although no p65 activation could be detected via TNFR2-stimulation, the
oligonucleotide binding assay (Figure 11) showed that TNFR1-mediated signalling
activated the p65 NFB pathway optimally around 30 min with activity decreasing
slightly by 60 minutes.
Although not studied here, the NFB protein RelB has also been shown to be essential
for DC maturation (Zanetti et al. 2003). RelB is generally known as an effector of the
alternative NFB pathway (through a direct interaction with p52), but it has also been
shown to act as an effector of the classical NFB pathway through the formation of a
RelB-p50 dimer (Shih et al. 2012). Unlike the RelB-p52 dimer, the formation of the
RelB-p50 dimer is affected by the presence of IB molecules allowing rapid activation
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of the classical NFB pathway leading to DC maturation in response to pathogens
(Shih et al. 2012). Therefore the dimerisation partner of RelB may be the crucial switch
in determining the cellular response to TNFR-mediated signalling. It would be
interesting to investigate whether TNFR1-stimulation leads to DC maturation via RelB-
p50-supported p65 actiavtion, thereby contributing to the lower activation of the
alternative NFB pathway by TNFR1 than TNFR2.
My data also show that the alternative NFB pathway is activated by both TNFR1 and
TNFR2. TNFR1- and TNFR2-mediated p52 activation was increased at 24 h and the
TNFR1-mediated response remained the same after 48 h, whereas TNFR2-mediated
activation was transient and reduced after 24 h (Figure 14). It is not clear whether this
is a clear difference between TNFR1- and TNFR2-mediated p52 activation as this may
also be due to the effect of point mutations in the TNFR1- and TNFR2-selective ligands
which may alter the stability of TNF/TNFR complexes and therefore may affect their
signalling capabilities. CD40L (J558L) cells are mouse B cell myeloma cells which have
been transfected to express CD40L and were used as a positive control for p52
activation in moDC (Figure 17). Generally, this classical p52 activator showed only
around 2 fold higher activation of p52 compared to mTNF suggesting that mTNF is
quite efficient at activating p52. However, it was not possible to fully remove all the
CD40L cells from the moDC cultures before lysis therefore it cannot be excluded that
these cells also contribute to the p52 activation detected in my assay. Also, the
inclusion of some CD40L cells may decrease the amount of moDC nuclear protein
included in the assay leading to an underrepresentation of CD40L cell-mediated p52
activation.
In addition, the blocking effect of H398 (a TNFR1-specific antagonistic antibody) was
not complete for any of the TNFR1-stimulating ligands. This may be due to sub-optimal
conditions as H398 was not titrated or sTNF may have bound TNFR1 before the
antagonistic antibody had bound to all the TNFR1 molecules, although this is unlikely
as cells were incubated with H398 for 30 min prior to the addition of TNF and also a
high amount of H398 was used (10 g/ml). Alternatively, H398 has weak agonistic
activity and although the use of H398 alone has no effect (suggesting that this is not
the case), the agonistic effect may only occur in combination with sTNF or when the
ligands are used in combination. An alternate method for blocking individual TNFR
would be to use the monovalent Fab fragment of the antibodies which bind to TNFR1
or TNFR2 but are not able to crosslink and rearrange TNFR on the cell surface
preventing TNFR pre-clustering. These antagonists would also have the advantage
that they have no Fc portion and therefore cannot bind non-specifically to Fc receptors
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on the DC which may affect DC maturation, but have the disadvantage that due to the
low affinity of these Fab fragments, high amounts would be needed.
The strong activation of p52 by sTNF in moDC (Figure 15 (B)) is of particular interest
as this has not been reported to date, although more work is needed to identify the full
process as whether the increase in p52 upon sTNF stimulation is the result of active
p100 processing or due to a strong induction of p100 expression is not clear. However,
sTNF seems to act through TNFR1 as its activation of p52 can be partially blocked by
antagonising TNFR1 (Figure 16). The reason that the effect is not fully abolished may
be due to the weak agonistic activity of the H398 antagonisitc antibody.
3.5.3. TNFR signalling and DC maturation
The majority of previous work on the maturation of human DC has been performed
using sTNF giving no answer to the question of which TNFR is involved in DC
maturation. The use of murine knock-out models however, has shed some light on the
requirement of TNFR-signalling for DC maturation. Whereas mice deficient in TNFR1
show impaired DC maturation in response to attenuated mouse hepatitis virus, the lack
of TNFR2 does not affect DC maturation (Ding et al. 2011). Another study also shows
that in TNFR1 knockout mice DC maturation is impaired in response to pathogens, but
did not investigate the effect of TNFR2 (Sundquist & Wick 2005). Furthermore, TNFR1-
stimulation can also activate DC in an autoimmune context. For example, in a rat
model a retinal autoantigen (S-antigen) activated and induced the maturation of DC via
TNFR1 and these DC could then activate an antigen-specific B cell response in vivo
(Liversidge et al. 2000). Again, TNFR2 was not investigated in this study. In addition,
these studies do not address whether the TNFR1-mediated response is due to an
inability of TNFR2 to induce maturation or whether the pathogenic stimuli used do not
result in the availability of a TNFR2 ligand (e.g. mTNF).
My data show that TNFR1-mediated signalling increased the expression of surface
markers involved in the co-stimulation and activation of T cells. DC stimulated with
sTNF (which acts via TNFR1) also enhanced CD4+ T cell proliferation, however the
resulting T cells failed to produce an IFN response (Figure 26 (E and F)). The effect of
TNF-stimulated DC on T cell proliferation was much lower than that of LPS-stimulated
DC, which consequently were capable of inducing T cell IFN production. This supports
previous work which shows that inflammatory mediators (such as TNF) are not
sufficient to fully mature DC and induce effector T cell responses (Spörri & Reis E
Sousa 2005). Full DC maturation requires a PAMP (e.g. a TLR agonist) which can
induce the production of inflammatory cytokines (Roelofs et al. 2005) as well as
enhancing maturation marker expression.
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The role of TNF-induced phenotypical maturation of DC is uncertain. It is possible that
TNF may serve to sensitise cells of the immune system in order to enhance the release
of pro-inflammatory molecules. However, in vivo it is unlikely that DC would be
exposed to TNF alone as during infection or inflammation the cytokine milieu is broad
and can induce multiple overlapping signalling pathways. Furthermore, inhibition of
TNF during LPS maturation reduces stimulatory capacity (Baldwin et al. 2010), thus,
although TNF in itself is not enough for DC maturation, it may cooperate with PAMPS
to induce full maturation. As it is possible that other cytokines may be involved in the
effect of TNFR1- or TNFR2-stimulated DC on T cell function more experiments are
needed to analyse a wider range of cytokines and to determine the potential cytokine
profile. Also, DC can produce a range of chemokines which may also differ depending
on TNFR1- or TNFR2-signalling. It would also be interesting to analyse the effect of DC
on T cells in the presence of T cell polarising cytokines such as IL-12 or IL-4 which may
differentiate the T cell response.
My data also show that TNFR1- but not TNFR2-mediated signalling induces moDC
maturation and sTNF/CysTNFwt induces a T cell stimulatory capacity. The failure of
TNFR2 to induce maturation in moDC could be caused by the failure of this receptor to
induce detectable activation of the classical p65 NFB pathway whereas TNFR1 was
capable of activating the classical NFB pathway via p65. Importantly, TNFR2-
selective stimulation does not appear to suppress TNFR1-mediated DC maturation as
CysTNFwt, mimicking mTNF action and thereby triggering both TNFR, potently induced
DC maturation to a similar extent as the TNFR1-stimulating ligands, sTNF and
CysTNFR1. These data indicate that DC maturation is independent of TNFR crosstalk
indicating different functions for the two TNFR as described previously (Apostolaki &
Victoratos 2010; Blüml et al. 2012).
Interestingly, the up-regulation of CD83, the activation of the p65 NFB pathway and
the induction of T cell proliferation following stimulation with the TNFR1-selective ligand
is less prominent than that of sTNF or CysTNFwt. The reason for this remains unclear
as all three ligands have similar bioactivities and have comparable effects on CD86
and HLA-DR expression therefore it seems unlikely to be due to the ligand
concentration used. It is possible that the effect of CysTNFR1 may be slower to initiate
the phosphorylation of p65 than sTNF or CysTNFwt rather than the signal being weaker
although the PhosFlow time course in Figure 13 suggests that this is also not the case.
Furthermore, in the p52 NFB oligonucleotide binding assay the activation by sTNF is
again greater than that of CysTNFR1. It is possible that these differences are due to the
effects of the point mutations which give the ligand its receptor-selectivity.
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3.5.4. Conclusion
In conclusion, the classical and alternative NFB signalling pathways are differentially
activated by TNFR1 and TNFR2. TNFR1 activates the classical NFB pathway and
has the capacity to induce phenotypical maturation in moDC. TNFR2-mediated
stimulation did not produce any detectable activation of the classical NFB pathway,
however both TNFR can activate the alternative NFB pathway. As TNFR2-mediated
signalling results in p52 activation, but not in maturation, the function of the alternative
NFB pathway is unclear but may play a role in other pathways such as DC survival.
The activation of TNFR-mediated signalling pathways may involve differences in
signalling kinetics; TNFR1-induced classical NFB activation can occur in minutes and
be transient whereas TNFR2 may take hours to promote NFB activation but signalling
may remain active for longer. Since NFB signalling is not only involved in maturation
but also plays a key role in cell survival, I explored the effect of TNFR-signalling on DC
survival which will be discussed in my next chapter.
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4. TNF induced protection of moDC from cytokine
deprivation-induced cell death
4.1. Introduction
Maintaining the balance between immunity and tolerance is an important function of
DC and is controlled not only by their maturation state (as discussed in the previous
chapter), but also by their longevity. Prolonging the lifespan of DC has been shown to
break tolerance and result in autoimmunity (Wang et al. 1999; Chen et al. 2006),
whereas a decrease in DC survival reduces immune protection from pathogens as well
as inhibiting autoimmunity (Jung et al. 2002; Whartenby et al. 2005).
Previous research suggests that DC have a relatively short lifespan and undergo
apoptosis shortly after maturation in order to prevent excessive T cell activation and
subsequent autoimmunity (McLellan et al. 2000). Although TNF is known to promote
DC survival (Ludewig et al. 1995; Lehner et al. 2012), the contribution of the two TNF
receptors to the lifespan of DC is poorly understood. TNFR1, but not TNFR2, contains
an intracellular death domain, suggesting that they may play different roles in cell
survival. It has been shown that bone marrow-derived DC from TNFR1-/- deficient mice
have increased resistance to Fas-mediated apoptosis whereas TNFR2-/- deficient mice
do not (Funk et al. 2000). It has also been shown that during TNF-mediated signalling,
p65 NFB plays a crucial role in protection from apoptosis (Beg et al. 1995). As I have
previously shown TNFR1 and TNFR2 differentially activate this pathway (chapter 3.4;
Figure 12 and Figure 15), it is possible that TNFR1 and TNFR2 also differentially
regulate DC survival.
4.2. Specific aims
1) Investigate the individual roles of TNFR1 and TNFR2 in moDC survival.
2) Identify the pathways involved in TNFR1- and TNFR2-mediated regulation of
moDC lifespan.
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4.3. Experimental Approach
To address the question of whether TNF-induced enhancement of moDC survival is
mediated through one or both TNFR, monocytes were differentiated into immature
moDC and extensively washed to remove cytokines (i.e. IL-4 and GM-CSF) from the
culture medium. I took this approach as ‘cytokine deprivation’ leads to cell death in
moDC (Baldwin et al. 2010) and I also treated the cells with sTNF, CysTNFwt or the
TNFR-selective ligands as described previously. A number of methods were chosen for
cell death analysis. The detection of intracellular active caspase-3 was chosen as
caspase-3 is central to the execution phase of apoptosis and is activated by both the
extrinsic (death ligand) and intrinsic (mitochondrial) pathways. The enzymatic activity of
caspase-3 was also studied to confirm that caspase-3 was not only processed but was
also active. Additionally, Annexin V and ViaProbe were analysed as they can be used
to detect early and late stages of cell death, respectively. Annexin V detects the
externalization of phosphatidylserine (PS) which is located on the cytoplasmic surface
of normal viable cells, but is translocated to the outer leaflet of the membrane early in
apoptosis where it can be detected (and is therefore present before and after the cell
membrane becomes compromised). ViaProbe (7-AAD) recognises and binds to double
stranded DNA and cannot cross the cell membrane therefore indicating membrane
compromised (i.e. ‘dead’) cells and emits a fluorescent signal which can be detected by
flow cytometry.
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4.4. Results
4.4.1. Selective stimulation of TNFR1 or TNFR2 reduces cytokine deprivation-
induced cell death in moDC
It has previously been shown that a high proportion of moDC die after 48 hours of
culture without the addition of exogenous cytokines (e.g. IL-4 and GM-CSF which are
known survival factors) and that LPS-induced autocrine TNF can protect immature
moDC from cell death (Baldwin et al. 2010). I could confirm these published data by
detecting increasing levels of active caspase-3 (i.e. an increase in cell death) over time
in response to the removal of IL-4 and GM-CSF (Figure 28 (A)). Figure 28 (B) shows
that exogenously given sTNF prevents cytokine deprivation-induced cell death in a
concentration dependant manner. Unstained cells were classed as caspase-3 negative
and used for the gating of caspase-3 positive cells. The addition of an isotype control
showed no deviation from the unstained cells (Figure 28 (C)). As the observed effect of
sTNF on DC survival is most likely to be mediated via TNFR1, TNFR1 may have the
ability to rescue moDC from cytokine withdrawal-induced cell death. However, the
effect of TNFR2 has not been addressed thus far, therefore TNFR-selective ligands are
required to assess how this effect is mediated.
To further study the regulation of moDC survival by TNF, moDC induced to undergo
cell death via cytokine-deprivation, were treated with the TNFR-selective ligands. Cell
death was determined by measuring intracellular active caspase-3 levels by flow
cytometry (Figure 29 (A, B)), and a colorimetric assay to measure caspase-3 enzymatic
activity via cleavage of a p-nitroaniline-coupled DEVD substrate (Figure 29 (C)).
Results in Figure 29 show that sTNF (which acts primarily through TNFR1) and
CysTNFwt (which acts through both TNFR) significantly rescued moDC from cell death
after cytokine withdrawal (from 61.3 ± 6.8% caspase-3 positive in unstimulated moDC,
to 19.3 ± 4.4%; p=0.0002 with sTNF and 17.5 ± 5.1%; p=0.0008 with CysTNFwt). Data
also show that both TNFR1- and TNFR2-selective ligands significantly reduced moDC
cell death although this was to a slightly lesser degree than sTNF and CysTNFwt (from
61.3 ± 6.8% caspase-3 positive in unstimulated moDC, to 29.8 ± 5.2%; p=0.0034 with
CysTNFR1 and 31.77 ± 4.15%; p=0.0029 with CysTNFR2 + 80M2). As expected,
CysTNFR2 alone or MAb 80M2 alone had no effect on moDC survival (Figure 29).
Similar results showing that TNFR1- and TNFR2-mediated signalling enhances moDC
survival were also shown using Annexin V/ViaProbe detection by flow cytometry
(Figure 30).
To obtain a better understanding of the type of cell death moDC undergo after cytokine
withdrawal, I used a number of inhibitors for pathways associated with cell death. The
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inhibitors were added immediately after cytokine withdrawal and the degree of cell
death was determined after 48 h using Annexin V and ViaProbe (as previously).
Necrostatin-1 (Nec-1), an inhibitor of necroptosis, did not inhibit cell death whereas
zVADfmk, an irreversible pan caspase inhibitor which is cell-permeable, did partially
inhibit cell death as shown by an increase in live cells from 21% to 44% (Figure 31 (A,
B)), suggesting that DC were undergoing, at least in part, apoptosis. In addition, a
caspase-8 specific inhibitor (zIETDfmk) also reduced apoptosis as shown by an increase
in live cells corresponding to an increase in the inhibitor (from 21% to 50% at 30 M
zIETDfmk), suggesting that moDC cell death after cytokine withdrawal involves the
extrinsic (death receptor-mediated) pathway (Figure 31 (A)). Previous research has
suggested that inhibiting caspase-8 may induce necroptosis (O’Donnell et al. 2011)
therefore I also used a combination of both zVADfmk and Nec-1. This increased moDC
survival from 25 ± 2.4% (unstimulated cells) to 51 ± 1.3%; p=0.004 (zVADfmk and Nec-
1) compared to 39 ± 2.9%; p=0.023 (zVADfmk alone) (Figure 10 (B)) suggesting that
necroptosis does occur following caspase inhibition but not following cytokine
deprivation alone.
Notably, none of the inhibitors fully prevented cell death indicating that the timing of the
addition of inhibitors or the type of inhibitors used was not optimal. It is possible that
without an activation signal (i.e. TLR ligation) DC may undergo cell death via multiple
mechanisms and the inhibition of one may enhance others. As inhibitors were
dissolved in DMSO which can be toxic to cells, the same DMSO concentration used in
the inhibition experiments (0.01%) was used as a control and showed no difference in
the amount of cell death when compared to unstimulated moDC, thereby excluding an
effect on survival mediated by the solvent (Figure 31 (A)).
The TNF superfamily also includes TNF-related apoptosis-inducing ligand (TRAIL)
which binds to the death receptors TRAIL R1 (DR4) and TRAIL R2 (DR5) and induces
the caspase-8-dependent extrinsic pathway of apoptosis. TRAIL can also bind TRAIL
R3 (DcR1) and TRAIL R4 (DcR2) which function as decoy receptors and protect cells
from apoptosis by neutralizing TRAIL. Mature DC have previously been shown to be
resistant to TRAIL-mediated apoptosis whereas immature DC were partially sensitive
(Leverkus et al. 2000). In line with this TRAIL R1-4 are expressed by immature moDC
and their expression is reduced as moDC mature (Figure 32) thereby they could
potentially mediate the extrinsic pathway of apoptosis in DC.
Results therefore show that both TNFR1 and TNFR2 can enhance moDC survival and
that the mechanism involved in moDC cell death after cytokine withdrawal is, at least in
part, the extrinsic (death receptor-mediated) pathway of apoptosis.
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4.4.2. Antagonisitc TNFR-specific antibodies block TNFR1- and TNFR2-mediated
protection from cell death in moDC
In order to investigate the possibility that enhanced moDC survival mediated by
TNFR1- and TNFR2-selective ligands may be induced by co-operation between the
two receptors or by the indirect activation of TNFR1 via TNFR2-mediatied production of
sTNF (Grell et al. 1999), I used TNFR-specific antagonistic antibodies which were
added directly after washing the moDC, i.e. after cytokine withdrawal, but 30 min prior
to TNFR-stimulation. I confirmed that neither of the TNFR antagonists had any effect
on moDC survival when used alone as compared to unstimulated cells. The
antagonistic TNFR1-specific antibody completely blocked the CysTNFR1-mediated
survival of moDC but did not affect the response to CysTNFR2 plus 80M2 suggesting
that TNFR2 acts in a TNFR1-independent manner (Figure 33). In addition, the anti-
TNFR2 antibody inhibited the response to CysTNFR2 plus 80M2 but had no effect on
the TNFR1-mediated response (Figure 33). This suggests that both TNFR1 and
TNFR2 can independently contribute to the survival of moDC. As different numbers of
donors were used for each condition, Appendix A shows Figure 33 divided into
corresponding donors.
In line with previous results (chapter 3.4.2; Figure 8) and other research (Grell et al.
1995; Richter et al. 2012; Krippner-Heidenreich et al. 2002), sTNF acts primarily
through TNFR1. Figure 33 shows the pro-survival effect of sTNF (from 66 ± 3.4%
caspase-3 positive in unstimulated moDC, to 18 ± 2.4%; p<0.0001 with sTNF) was
blocked by anti-TNFR1 (from 18 ± 2.4% caspase-3+ cells to 51 ± 0.9%; p<0.0001), but
was not affected by anti-TNFR2 indicating that the sTNF-mediated rescue from cell
death in moDC is mediated through TNFR1, but not TNFR2. Furthermore, the pro-
survival effect of CysTNFwt (from 66 ± 3.4% caspase-3 positive cells in unstimulated
moDC, to 16 ± 1.7%; p<0.0001 with CysTNFwt) was only partially blocked by
antagonising either TNFR1 (from 16 ± 1.7% to 35 ± 3.9%; p=0.0004) or TNFR2 (from
16 ± 1.7% to 20 ± 2.1%; p=0.14) alone, which may be due to the strong avidity of the
pre-oligomerised ligand or its ability to signal through both TNFR. Moreover, the effect
of CysTNFwt could be fully blocked by antagonising both TNFR (from 16 ± 1.7%
caspase-3 positive cells with CysTNFwt to 64 ± 5.8%; p<0.0001 with both TNFR
antagonists) (Figure 33), indicating that mTNF enhances moDC survival through both
TNFR1- and TNFR2-mediated signalling.
Additionally, human IgG was used to block Fc receptors which confirmed that the effect
of the antagonistic antibodies was not due to Fc receptor mediated signalling (Figure
34). These data indicate an important role for TNFR2 in DC survival and demonstrate
that TNFR1 and TNFR2 independently mediate the rescue of moDC from cell death.
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Data also show that as expected, sTNF cannot act through TNFR2 whereas mTNF
activates both TNFR1 and TNFR2 in moDC.
4.4.3. Optimisation of TNFR knock down in moDC using siRNA
To further investigate the individual effects of TNFR1 and TNFR2 on moDC maturation
and survival and to exclude any potential cross-reaction between the receptors I
attempted to knock-down TNFR expression by RNA interference. Figure 35 (A) shows
that TNFR1-specific siRNA reduced TNFR1 expression by 30%, whereas TNFR1
expression was not affected by TNFR2-specific siRNA. Alternatively, Figure 35 (A) also
shows that TNFR2-specific siRNA reduced TNFR2 expression by 47% which was not
affected by TNFR1-specific siRNA. Data indicate that both TNFR can be partially
knocked-down by the use of TNFR-specific siRNA and that there is no cross reactivity
of the siRNA between the two receptors. However, the non-sense siRNA also showed
a reduction in expression of both TNFR1 and TNFR2 (expression was reduced by 19%
and 35%, respectively). Furthermore, the expression of surface maturation markers
CD83, CD86 and HLA-DR were increased by the addition of non-sense siRNA and to a
lesser extent by the TNFR-specific siRNA (Figure 35 (B)). As I have shown previously
(chapter 3.4.3, Figure 9 (B)), that the maturation of moDC reduced the expression of
TNFR1 and TNFR2, this may be the cause of the reduction in TNFR expression in
response to non-sense siRNA. I also cannot exclude that the TNFR expression in
response to TNFR-specific siRNA may be affected by the increase in maturation.
In order to reduce the effect of maturation on the expression of TNFR1 and TNFR2 I
titrated both the DF4 reagent (used for siRNA transfection) and the siRNA
concentration. Figure 36 shows that 0.5 l DF4 has almost no effect on moDC
maturation regardless of the concentration of siRNA. However 2.5 l and 5 l DF4
showed an increase in all the maturation markers (CD83, CD86 and HLA-DR). Figure
37 shows the expression of TNFR1 and TNFR2 in response to TNFR-specific siRNA;
Figure 37 (A) showed a reduction in TNFR1 expression of 43% by 50 nM TNFR1-
specific siRNA whereas TNFR1 expression was not affected by the same
concentration of TNFR2-specific siRNA (Figure 37 (B)). Similarly, Figure 37 (D)
showed a reduction in TNFR2 expression of 43% by 50 nM TNFR2-specific siRNA
whereas TNFR2 expression was not reduced by the same concentration of TNFR1-
specific siRNA (Figure 37 (B)). Lower concentrations (25 nM) of TNFR1- or TNFR2-
specific siRNA had no effect on either receptor indicating that no less than 50 nM
siRNA should be used in future experiments. Although the expression of both TNFR1
and TNFR2 is decreased more by 2.5 l and 5 l DF4 Figure 37 (A-D), this may be due
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to increased moDC maturation (as shown in Figure 36) and, therefore, these volumes
cannot be used.
Together, I found conditions (50 nM siRNA and 0.5 l DF4) that would allow a
significant knockdown of TNFR1 and TNFR2, however, the effects of siRNA itself on
moDC maturation are not desirable. Overall, the use of siRNA was less effective than
the antagonistic TNFR-specific antibodies, therefore, this line of research was not
continued.
4.4.4. The Bcl-2/Bcl-xL pathway mediates pro-survival effects of both TNFR1
and TNFR2 whereas p65 NFB signaling is involved in TNFR1- but not
TNFR2-mediated moDC survival
In order to further study the pathways downstream of TNFR1 and TNFR2 and to
dissect their involvement in regulating the lifespan of moDC, I used a number of
commonly used small molecule inhibitors to target different signalling pathways; the
classical NFB pathway, the PI3K pathway, the MAPK/ERK pathway and the Bcl-2/Bcl-
xL mitochondrial apoptosis pathway. All inhibitors were added to DC cultures for 30 min
prior to the addition of sTNF, CysTNFwt or the TNFR-selective ligands. Both the p65
NFB pathway and the Bcl-2/Bcl-xL pathway have previously been shown to be
essential for DC survival (Lehner et al. 2012; Kimberley & Screaton 2004; Kim & Joo
2009; Mattioli et al. 2009; Sánchez-Sánchez et al. 2004). I have shown that the
classical p65 NFB pathway is activated by TNFR1 but not TNFR2 (chapter 3.4.4;
Figure 12 and Figure 15), therefore, I hypothesised that inhibition of this pathway would
only affect TNFR1-mediated survival. In accordance with this, the BAY-11-7082
compound, which inhibits phosphorylation of IB and prevents its degradation
(Richter et al. 2001), therefore blocking the classical NFB pathway, impaired the
enhancement of moDC survival mediated by TNFR1 (Figure 38 (A)) but not TNFR2
(Figure 38 (B)). With the addition of Bay-11-7082 alone, there appeared to be a slight
reduction in Caspase-3+ cells to 62 ± 4.6% compared to 74 ± 4.6% in unstimulated
cells, which was not statistically significant. CysTNFR1 reduced the percentage of active
caspase-3 from 74 ± 4.6% to 40 ± 4.6% indicating enhanced survival. This was then
blocked by the addition of Bay-11-7082 as shown by an increase in caspase-3 from 40
± 4.6% (CysTNFR1) to 67 ± 6.1%; p=0.017 (Figure 38 (A)). This confirms a pro-survival
role for the classical NFB pathway in moDC which is activated by TNFR1- but not
TNFR2-selective stimulation.
Alternatively, the BH3 mimetic ABT-737 leads to the induction of apoptosis via the
mitochondrial pathway (described in chapter 1.4.2.1). Briefly, ABT-737 inhibits the
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heterodimerisation of Bcl-xL and Bcl-2 with members of the pro-apoptotic machinery
such as Bax and Bak, thereby reducing the activity of pro-survival proteins (Bcl-xL and
Bcl-2) and allowing Bax and/or Bak to form pores in the mitochondrial membrane,
releasing cytochrome c and initiating to apoptosis. ABT-737 did not significantly affect
the percentage of caspase-3 compared to that of unstimulated cells (75 ± 5.6% and 71
± 7.5%, respectively) (Figure 38 (C)). However, ABT-737 significantly blocked the
TNFR1-mediated pro-survival effect as the level of caspase-3 is increased from 43 ±
5.7% with CysTNFR1 to 67 ± 5.6%; p=0.0082 with CysTNFR1 plus ABT-737 (Figure 38
(C)). The effect of TNFR2-stimulation on moDC survival is also significantly inhibited by
ABT-737 (from 47 ± 15.5% with CysTNFR2 + 80M2 to 68 ± 8.1% with CysTNFR2 +
80M2 plus ABT-737 (Figure 38 (D)). This suggests that both TNFR act via the Bcl-
2/Bcl-xL pathway. In accordance, stimulation of either TNFR1 or TNFR2 results in
upregulation of Bcl-xL expression in moDC at the protein level (Figure 38 (E)). GAPDH
(Glyceraldehyde 3-phosphate dehydrogenase) is an enzyme involved in the breakdown
of glucose which is expressed at relatively constant levels in all cells and is required for
the maintenance of basic cellular function. The level of GAPDH is consistent between
all treatment groups indicating that the amount of protein loaded from each sample was
equal (Figure 38 (E)).
LY294002 is an inhibitor of the phosphatidylinositol 3-kinase (PI3K) pathway and
prevents subsequent Akt phosphorylation. This pathway is hyperactive in many
cancers where downstream signaling can reduce apoptosis and allow cell proliferation
(Workman et al. 2010), demonstrating the importance of the PI3K pathway in the
regulation of cell survival. LY294002 did not significantly affect the active caspase-3
levels compared to that of unstimulated cells (83 ± 5.1% and 79 ± 5.9%, respectively)
(Figure 39 (A)). However, LY294002 significantly blocked the TNFR1-mediated pro-
survival effect as the level of caspase-3 is increased from 42 ± 4.0% with CysTNFR1 to
63 ± 5.2%; p=0.0093 with CysTNFR1 plus LY294002 (Figure 39 (A)). The TNFR2-
mediated pro-survival effect was also significantly blocked as the level of caspase-3
increased from 39 ± 9.8% with TNFR2-stimulation to 61 ± 6.6%; p=0.0313 with TNFR2-
stimulation plus LY294002 (Figure 39 (B)). Inhibition of the PI3K pathway, therefore,
significantly prevents both TNFR1- and TNFR2-mediated enhancement of moDC
survival (Figure 39 (A and B)) suggesting that the PI3K pathway is used by both
receptors to support moDC survival.
The MAPK/ERK pathway is also known to be involved in a range of human cancers
and participates in cross-talk with the PI3K pathway (Britten 2013). U0126 is an
inhibitor of MEK1 and MEK2 kinase activity that blocks activation of the MAPK/ERK
pathway by preventing the transcriptional activity of AP-1. U0126 did not significantly
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affect the percentage of caspase-3+ cells compared to that of unstimulated cells (74 ±
7.1% and 74 ± 7.0%, respectively) (Figure 39 (C)). However, inhibition of MEK1/2
significantly blocked the TNFR1-mediated pro-survival effect of CysTNFR1-mediated
signalling as the level of caspase-3 is increased from 35 ± 5.3% with CysTNFR1 to 61 ±
4.2%; p=0.0359 with CysTNFR1 plus U0126 (Figure 39 (C)). The effect of TNFR2-
stimulation on moDC survival was not significantly inhibited by U0126 even though the
mean percentage of caspase-3 increases from 35 ± 11.0% with CysTNFR2 + 80M2 to
60 ± 8.0% with CysTNFR2 + 80M2 plus U0126 (Figure 39 (D)). Thus, my data suggest
that TNFR1-mediated enhancement of survival may involve the MAPK/ERK pathway
as well as the PI3K pathway (summarised in Figure 41 (A)).
Data from this chapter and the previous chapter are summarised in Figure 41 (B);
TNFR1-signalling activates both the p65 and the p52 NFB pathway resulting in moDC
maturation and survival via the Bcl-2/Bcl-xL pathway. Alternatively TNFR2-signalling
activates the p52 but not the p65 NFB pathway and does not result in moDC
maturation but does lead to moDC survival via the Bcl-2/Bcl-xL pathway.
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Figure 28: sTNF protects moDC from cytokine deprivation-induced cell death.
Immature moDC were left untreated for 0, 24 or 48 h (A) or were treated as indicated
with varying concentrations of sTNF (1-100 ng/ml) for 48 h (B). Cell viability was
assessed by the presence of intracellular active caspase-3 determined by flow
cytometry (A, B). The percentages of cells gated positive for active caspase-3 are
indicated. Data represents two individual experiments with different donors. (C) Isotype
control (black line) compared to unstained moDC (grey shaded). Data represents at
least 3 independent experiments.
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Figure 30: TNFR1- and TNFR2-mediated signalling protects moDC from
apoptosis following cytokine deprivation. Immature moDC were left untreated or
were treated as indicated with sTNF, CysTNFwt or the TNFR-selective ligands (50
ng/ml) +/- MAb 80M2 for 48 h. Cell viability was assessed by ViaProbe and/or Annexin
V detection by flow cytometry. Results represent three independent experiments.
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Figure 32: Cell surface expression of TRAIL receptors by moDC. The cell surface
expression of TRAILR1, TRAILR2, TRAILR3 and TRAILR4 (black line) compared to
unstainted moDC (grey shaded) on immature and mature moDC was analysed by flow
cytometry. Results represent two independent experiments with different donors.
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Figure 34: Blocking Fc receptors with human IgG does not affect caspase-3
processing upon TNFR stimulation. Immature moDC were left untreated or were
treated with 10 g/ml human IgG, TNFR1- or TNFR2-specific antagonistic antibodies
for 30 min prior to stimulation with sTNF or CysTNFwt (50 ng/ml) for 48 h. Cell viability
was assessed by the presence of intracellular active caspase-3 determined by flow
cytometry. The percentages of cells gated positive for active caspase-3 are indicated.
Results represent 2 independent experiments with different donors.
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Figure 36: Titration of siRNA and transfection reagent DF4 and the effect on
moDC maturation marker expression. Immature moDC were cultured in antibiotic
free media and treated with increasing amounts of the transfection reagent DF4 (O.5 to
5 l) and 25 nM or 50 nM anti-TNFR1 siRNA or anti-TNFR2 siRNA for 24 h. Cell
surface expression of CD83, CD86 or HLA-DR was determined by flow cytometry. The
median fluorescence intensity (MFI) is shown and results represent 2 independent
experiments.
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4.5. Discussion
The main aims of this chapter were to investigate the individual roles of TNFR1 and
TNFR2 in moDC survival and to identify the signalling pathways involved. In the
previous chapter (3.4) I showed that TNFR1- but not TNFR2-mediated signalling
activated the classical NFB pathway whereas both TNFR activated the alternative
NFB pathway suggesting that the two receptors may mediate different but overlapping
functions. I also discussed data showing that TNFR1- but not TNFR2-signalling
induced phenotypical maturation of moDC. In contrast, in this chapter, I show data
demonstrating that moDC survival can be enhanced independently by both TNFR1-
and TNFR2-mediated signalling, indicating that some innate signals may promote DC
survival even in the absence of maturation. I have also shown that moDC survival can
be enhanced by both TNFR1- and TNFR2-mediated signalling and that both TNFR are
dependent on the Bcl-2/Bcl-xL pathway. Only the TNFR1-, but not TNFR2-mediated
protection depends on the activation of the p65 NFB pathway. These data may, at
least in part, underline the differences in the functional effects mediated by the two
receptors demonstrating their distinct roles in regulating DC maturation and survival.
4.5.1. TNFR-mediated moDC survival and TNFR antagonsim
The survival of DC is a key factor in the regulation of adaptive immune responses.
Similarly to my data using cytokine withdrawal, other research has shown that
withdrawing plasma from the culture medium of mature human moDC reduced their
survival and that this effect was prevented by the addition of TNF (Um et al. 2004),
thereby confirming that TNF is important in moDC survival.
More specifically, my data show that both TNFR1- and TNFR2-selective stimulation
enhance moDC survival. Both CysTNFR1 and CysTNFR2 + 80M2 were less effective at
enhancing moDC survival than sTNF or CysTNFwt. As discussed in the previous
chapter (3.5.3), the reason for this remains unclear. One option may involve the
introduction of point mutations which give the ligands receptor selectivity, however, all
four ligands have similar bioactivities (when CysTNFR2 is used in combination with
80M2) suggesting that this is not the case. Furthermore, the blocking effect of the
TNFR1-specific antagonistic antibody H398 was only complete for CysTNFR1, but not
for sTNF or CysTNFwt, whereas the TNFR2-specific antagonistic antibody 22221 fully
blocked CysTNFR2 + 80M2 but showed almost no effect on CysTNFwt. This may be due
to sub-optimal conditions as H398 and 22221 were not titrated, or sTNF and CysTNFwt
may have bound to the TNFR before the antagonistic antibody had bound to all the
TNFR molecules, although these reasons are unlikely as cells were incubated with the
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antagonistic antibodies for 30 min prior to the addition of TNF and high concentrations
were used (10 g/ml). Also, the pro-survival effect of CysTNFwt was only partially
blocked by antagonising either TNFR1 or TNFR2 alone, which may be due to the
strong avidity of the pre-oligomerised ligand or its ability to signal through both TNFR
as the effect of CysTNFwt could be fully blocked by antagonising both TNFR.
In addition, my results show that there is high variability between donors (Figure 33),
firstly in the amount of cell death following cytokine withdrawal; for example, in
unstimulated cells the percentage of caspase-3+ cells ranges from 49% to 85%, and
secondly in the degree to which TNFR-selective stimulation protect the cells; for
CysTNFR1 the lowest reduction in active caspase-3 compared to unstimulated cells
from the same donor was 17% and the highest was 60%, whereas for CysTNFR2 +
80M2 the lowest was 11% and the highest was 57%. The reason for this may be the
high variability in TNFR1 and TNFR2 expression between donors as I discussed in the
previous chapter (chapter 3.4.3; Figure 9).
The use of siRNA to knockdown TNFR in moDC proved difficult due to off target effects
such as the induction of moDC maturation. The use of siRNA has been shown to result
in activation of the dsRNA recognition protein PKR (protein kinase R) in mammalian
cell lines which resulted in IFN-mediated activation of the Janus kinase/signal
transducer and activator of transcription (JAK/STAT) pathway and global upregulation
of IFN-stimulated genes (Sledz et al. 2003; Sledz & Williams 2004). PKR can also
activate NFB signalling via the phosphorylation of IKB in vitro (Kumar et al. 1994)
which may then regulate processes such as cell proliferation. It is therefore extremely
difficult to prevent siRNA from mediating effects on moDC survival and maturation
beyond the silencing of specific target genes (i.e. TNFR) rendering this method
unsuitable for use in any further experiments.
4.5.2. Overlapping signalling mechanisms involved in TNF-mediated DC survival
Activation of p65 and p52 NFB has been shown to confer resistance to both the
intrinsic and extrinsic apoptosis pathways in lymphoma cell lines (Bernal-Mizrachi et al.
2006). I have shown that TNFR1-mediated signalling can activate both NFB pathways
and enhance moDC survival whereas TNFR2-mediated signalling also enhances
moDC survival, but only activates the alternative NFB pathway. My data also show
that cytokine withdrawal induces moDC death, at least in part, via the external pathway
of apoptosis and that this is reduced by TNFR1- or TNFR2-mediated signalling. TNFR2
enhanced moDC survival potentially via activation of the alternative NFB pathway,
whereas the TNFR1-mediated enhancement of survival may be due to activation of the
classical and/or alternative NFB pathway (as summarised in Figure 41 (B)).
111
Different mechanisms of cell death are described by (Galluzzi et al. 2012). Intrinsic
apoptosis can be caspase-dependent (involving caspase-9 and -3) or caspase-
independent, involving mitochondrial outer membrane permeabilisation (MOMP) and is
triggered by intracellular stress such as DNA damage or oxidative stress. Alternatively,
extrinsic apoptosis refers to a caspase-dependent apoptotic cell death induced by
extracellular signals. It can be initiated by the binding of ligands to their death domain-
containing receptors i.e. TNF and TNFR1, FasL (CD95L) and Fas (CD95), TRAIL and
TRAILR1 or TRAILR2, although activation of a death receptor does not always lead to
cell death as shown by my data regarding TNFR1 and discussed by (Schütze et al.
2008). My data show that TNFR1, TRAILR1 and TRAILR2 are all expressed on the
surface of moDC and therefore may interact during the induction of cell death. For
example, TNFR1 stimulation in human multiple myeloma cell lines increased cell death
induced by FasL, but reduced TRAIL-mediated cell death (Rauert et al. 2011).
My results show that upon cytokine withdrawal, moDC undergo cell death, at least in
part, via apoptosis and not necroptosis as cell death can be inhibited by a caspase-
inhibitor (zVADfmk) but not a necroptosis inhibitor (Nec-1). Necroptosis (programmed
necrosis) can also be triggered by the ligation of death receptors under certain
circumstances for example, inhibition of caspases prevents degradation of RIP1 and/or
RIP3 which suppresses apoptotic signalling leading to necroptosis (Cho et al. 2010; He
et al. 2009). My data support this finding as the combinational use of both zVADfmk and
Nec-1 further increased moDC survival. However, the rescue from cell death was not
complete and even when blocking caspase-mediated apoptosis and necroptosis,
moDC still showed 49% dead cells after 48 h. The underlying mechanism for this
remains unknown. It is possible that cell death has already been initiated in some cells
i.e. during the harvesting and washing of the moDC, or that the inhibitors were not fully
optimised, or that another pathway is also involved (for example caspase-independent
intracellular apoptosis).
4.5.2.1. The NFB signalling pathway and DC survival
Both the classical and alternative NFB pathways are known to enhance APC survival.
Contrary to the results presented in this thesis, previous research indicates that TNF
activates the classical but not the alternative NFB pathway (Derudder et al. 2003). My
data has shown that only TNFR1- but not TNFR2-mediated signalling activates the
classical NFB pathway but that both TNFR1 and TNFR2 activate the alternative NFB
pathway. Generally, TNFR1-mediated activation of the alternative NFB pathway is
suppressed by the adapter kinase RIP1 through the inhibition of TNF-mediated TRAF2
and cIAP1 degradation (Kim et al. 2011; Gentle et al. 2011). As my results show that
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TNFR1-selective stimulation activates both the classical and alternative NFB
pathways, it is possible that RIP is absent in my system and that its absence may allow
activation of the alternative NFB pathway. However, preliminary results suggest that
this is not the case as RIP is expressed in moDC and its expression is not reduced or
absent during stimulation with sTNF (Figure 18), therefore, it remains unclear under
which physiological or pathological conditions TNFR1 can mediate the induction of the
alternative NFB pathway.
It has been previously reported that TNF fails to activate p100 processing and therefore
alternative NFB pathway (Coope et al. 2002). More recent data has demonstrated that
in a number of cell lines and also in primary T cells that TNFR2 but not TNFR1
activated the alternative NFB pathway (Rauert et al. 2010). Also, in the same study,
sTNF trimers failed to activate the alternative NFB pathway showing that the
alternative NFB pathway involves not only TNFR2, but also mTNF (Rauert et al.
2010), therefore the lack of TNF-mediated alternative NFB pathway activity in
previous studies may be due to the use of sTNF which does not activate TNFR2.
However, both of these studies are inconsistent with my data which shows that both
TNFR1 and TNFR2 activate the alternative NFB pathway in moDC suggesting that
the alternative NFB pathway can be differentially activated by TNF depending on the
cell type.
The alternative NFB pathway involves the release of NIK from its constitutive
degradation allowing NIK to accumulate before it can facilitate the phosphorylation and
activation of IKK, which in turn targets p100 for phosphorylation and partial
degradation releasing p52. The p52 molecule can then form a complex with RelB and
translocate to the nucleus (Figure 40 (B)). Previous data shows that NIK was required
for TNF-mediated activation of the alternative but not the classical NFB pathway in
lymphoblastoid cells, whereas NIK was required for CD40-mediated activation of both
NFB pathways (Ramakrishnan et al. 2004). Other data confirm that de novo synthesis
of NIK is required for the activation of alternative NFB signalling mediated by CD40
(Qing et al. 2005). Authors suggest that this may account for the delay in alternative
NFB pathway activation (compared to the classical NFB pathway) and may explain
why TNF fails to induce p100 processing. My data however, shows that both TNFR1-
and TNFR2-mediated signalling in moDC activated the alternative NFB pathway
(albeit to a lower extent than CD40-stimulation). Defects in the regulation of NIK can
result in the uncontrolled growth of immune cells, for example constitutive activation of
p100 processing mediated through the over-expression of NIK has been shown to
result in B cell hyperplasia and autoimmunity (Sasaki et al. 2008). NIK over-expression
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also resulted in increased levels of Bcl-xL but not Bcl-2 (Sasaki et al. 2008), although it
remains unclear if RelB/p52 dimers are directly responsible for the activation of Bcl-xL.
4.5.2.2. The PI3K/Akt and MAPK/ERK pathways
A number of other pathways are also implicated in DC survival. The PI3K pathway
(summarised in (Cantley 2002)) is important in the inhibition of apoptosis and is linked
to a number of cancers (Workman et al. 2010) as well as inflammatory and
autoimmune diseases. Therefore, proteins within the PI3K pathway provide potential
therapeutic targets (Foster et al. 2012) in a range of diseases. PI3K activation leads to
the activation and phosphorylation of Akt (a serine/threonine protein kinase), which can
activate proteins involved in protein synthesis, cell proliferation, cell cycle entry and
apoptosis. For example, Akt can inhibit pro-apoptotic Bax thereby preventing pore
formation in the mitochondrial outer membrane and inhibiting apoptosis (Yamaguchi &
Wang 2001), as well as being able to activate the MAPK pathway. My data show that
inhibition of the PI3K pathway significantly prevents both TNFR1- and TNFR2-
mediated enhancement of moDC survival (Figure 39 (B)) suggesting that the PI3K
pathway is used by both receptors to support moDC survival. In line with this, previous
studies have shown human CD34-derived myeloid DC required PI3K-Akt-mTOR
signalling for proliferation and survival during differentiation, but not for the surface
expression of co-stimulatory molecules (van de Laar et al. 2010). In addition, BM-
derived DC from TNF-/- mice have defects in maturation in response to adenovirus
infection which has been shown to be dependent on the autocrine production of TNF
via the PI3K pathway (Philpott et al. 2004).
The MAPK/ERK pathway is involved in cross-talk with the PI3K pathway and is also
known to be involved in a range of human cancers (Britten 2013). Both the PI3K and
MAPK/ERK pathways have been shown to be differentially involved in the regulation of
DC IL-12, IL-23 and IL-27 cytokine production (Jackson et al. 2010). My data suggest
that both TNFR1- and TNFR2-mediated enhancement of survival may involve the PI3K
pathway (Figure 39 (A, B)), however, only TNFR1-mediated survival significantly
involved the MAPK/ERK pathway (Figure 39 (C)). The results for TNFR2 (Figure 39
(D)) were not significant, possibly due to the high donor-to-donor variation (which may
involve differences in TNFR expression between donors). Additionally, it has been
shown that moDC from elderly donors are phenotypically comparable but functionally
different (including reduced Akt phosphorylation and therefore reduced PI3K pathway
activation) when compared to those from young donors (Agrawal et al. 2014). As the
age of donors in my experiments is unknown, this may also contribute to donor
variability.
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4.5.3. Regulation of moDC survival by Bcl-2 family members
Bcl-2 family proteins play a major role in both positively and negatively regulating
mitochondria-dependent apoptosis. In addition to the differential activation of classical
and alternative NFB signalling by TNFR1 and TNFR2, I have also shown that both
TNFR induced the upregulation of anti-apoptotic Bcl-xL (Figure 38 (E)). In support of
this, it has been shown that both p65 and p52 are capable of binding to the Bcl-xL
promoter and may play a role in the regulation of its expression (Tamatani 1999;
Marinari et al. 2004).
The ratio of pro- and anti-apoptotic members of the Bcl-2 family is important in
regulating the lifespan of DC and may be responsible for the longevity of different DC
populations. It has been shown that shorter lived myeloid DC have a lower ratio of anti-
apoptotic Bcl-2/Bcl-xL to pro-apoptotic Bax/Bak compared to longer lived plasmacytoid
DC (Chen et al. 2007). Also, autocrine TNF is essential for moDC survival and induces
different members of the Bcl-2 family involved in protection from both the intrinsic and
extrinsic apoptosis pathways (Lehner et al. 2012). In vivo transgenic mouse studies
have shown that the overexpression of the anti-apoptotic protein Bcl-2 specifically in
DC prolonged mouse survival and increased immunogenicity (Nopora & Brocker 2002).
In addition, up-regulation of anti-apoptotic Bcl-xL is associated with the reduction of
Fas-mediated apoptosis in human LPS-matured DC (Lundqvist et al. 2002). This
suggests that the independent functions of TNFR1 and TNFR2 in DC may converge at
the level of Bcl-2/Bcl-xL which is already known to play a central role in DC survival
and function (Hou & Van Parijs 2004; Lehner et al. 2012).
4.5.4. Conclusion
In conclusion, both TNFR1 and TNFR2 are able to independently enhance moDC
survival. As TNFR2 had no effect on the maturation of moDC (chapter 3.4.6) but
significantly enhanced moDC survival this indicates that TNFR2 can promote DC
survival even in the absence of maturation. In addition my data show that in order to
enhance moDC survival, both TNFR are dependent on the Bcl-2/Bcl-xL pathway
whereas only TNFR1, but not TNFR2 depends on the activation of the p65 NFB
pathway. Therefore my data suggest a possible mechanism for the differences in the
functional effects mediated by the two receptors.
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5. Ex vivo analysis of myeloid DC
5.1. Introduction
As discussed in the previous two chapters, the capacity of DC to regulate adaptive
immunity is controlled by both their maturation state and their life span. DC are
heterogeneous and the phenotype of different DC subsets plays an important role in T
cell activation, polarisation and the induction of tolerance (Collin et al. 2013). DC can
be divided into subsets based on location and surface phenotype (chapter 1.1.1; Figure
1). In humans two of the major subsets are myeloid DC (CD11c+CD1c+ or
CD11c+CD141+) and plasmacytoid (p)DC (CD123+BDCA-2+BDCA-4+), which exert
different functions within the immune system. For example unlike the majority of DC,
pDC are less efficient at antigen presentation, have lower MHC II expression and are
B220/CD45R+ (CD45R (including the B220 isoform) is the receptor for CD45, a
lymphocyte common antigen, expressed on all leukocytes and is essential for T cell
activation via the TCR). In addition, the lifespan of different DC populations varies
along with their expression of apoptosis signalling molecules, with myeloid DC having a
shorter lifespan than pDC (Kamath et al. 2002; Chen et al. 2007).
MoDC are regarded as a model for inflammatory DC i.e. DC derived from monocytes
under inflammatory conditions (as reviewed in mice (Shortman & Naik 2007) and
humans (Segura & Amigorena 2013)). Inflammatory DC are not normally found in
healthy tissue but thought to be derived from monocytes during cases of chronic
inflammation such as RA. Therefore, moDC do not necessarily represent DC from a
healthy, steady-state environment but may reflect inflammatory conditions.
CD11c+/CD1c+ myeloid DC isolated directly from peripheral blood (hereafter referred to
as blood myeloid DC), have been used in this study in order to examine whether the
TNF-mediated response of steady state DC differs to that of inflammatory/moDC. As
previous research suggests that in vivo monocyte-derived DC pay little contribution to
steady state DC I investigated blood myeloid DC isolated from healthy donors. In
addition, I obtained 2 synovial fluid (SF) samples from RA patients in order to
determine whether DC from a chronic inflammatory environment would have a
phenotype comparable to the moDC inflammatory model or the steady state blood
myeloid DC.
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5.1.1. Specific aims
1) Determine the involvement of TNFR-mediated signalling in the maturation of
blood myeloid DC.
2) Investigate the individual roles of TNFR1- and TNFR2-mediated signalling in
blood myeloid DC survival.
3) Determine the effect of TNFR1 and TNFR2 on the maturation and survival of
myeloid DC isolated from synovial fluid.
5.1.2. Experimental Approach
In order to further dissect the role of the two TNFR in regulating the function of human
DC, freshly isolated steady-state blood myeloid DC were used. Blood myeloid DC were
separated from PBMC by immuno-magnetic negative selection. Immediately after
purification, blood myeloid DC were treated with sTNF, CysTNFwt or the TNFR-
selective variants CysTNFR1 and CysTNFR2 plus MAb 80M2 (as done previously with
moDC). As blood myeloid DC are present at extremely low concentrations in peripheral
blood (0.6-1.8% of PBMC), flow cytometry was used to analyse the expression of
surface markers characteristic of DC maturation and intracellular active caspase-3,
which indicates cell death. The purity of the blood myeloid DC was routinely analysed
(blood myeloid DC were defined as CD11c+/CD1c+) and populations with a purity of ≤ 
70% were not used in future experiments. Whole PBMC were analysed by flow
cytometry and pDC were defined as DAPI-/CD45+/CD19-/CD20-/CD3-/CD56- and HLA-
DR+/CD1c-/CD123+.
Synovial fluid samples were obtained from patients with chronic arthritis and myeloid
DC were again enriched using negative selection. SF myeloid DC were used as they
are DC from a chronic inflammatory environment and therefore may be similar to
‘inflammatory’ moDC and behave in a different manner to ‘steady-state’ blood myeloid
DC.
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5.2. Results
5.2.1. Purity and characterisation of blood myeloid DC
PBMC were analysed for the surface expression of lineage markers and were
comprised of; 13% CD14+ for monocytes (as used in moDC experiments), 62% CD3+
for T cells, 9% CD19+ for B cells, 3% CD1c+ indicates myeloid DC but is also
expressed on subpopulations of B cells, 22% CD11c+ for all myeloid cells (including DC
and monocytes) and 2% CD1c+/CD11c+ for myeloid DC (Figure 42). The percentages
of each cell type are within the expected range for PBMC except T cells which are
slightly lower than expected in this donor; 10-30% monocytes, 70-80% CD3+ T cells, 5-
20% B cells, 5-20% NK cells and 1-2% DC. My results show that PBMC contain clear
populations of each of these cell types some of which can also be identified by size
(using FSC) and granularity (using SSC) (Figure 42). Blood myeloid DC
(CD1c+/CD11c+) were enriched by negative selection (Figure 43) resulting generally in
a population of 75-90% purity. On average 245 x 106 PBMC were used resulting in an
average of 1.05 x 106 blood myeloid DC (0.4% yield). As PBMC are generally
comprised of only 0.6-2% DC this shows around a 66-fold enrichment.
As the blood myeloid DC were generally 75-85% pure, the expression of T and B cell
lineage surface markers was also analysed which shows ~3% T cell and ~1% B cell
contamination (Figure 44). This is important to take into account as for example, the
maturation of human DC can also be negatively regulated by CD19+ B cells (Morva et
al. 2012). Although other contaminating cells were not analysed they may include
monocytes and NK cells. For all future experiments these contaminating cells were
gated out during analysis, however their effect on the survival and maturation of blood
myeloid DC during culture could not be evaluated at this stage.
I previously confirmed that both TNFR1 and TNFR2 are expressed on moDC (chapter
3.4.3, Figure 9). Flow cytometry was used to detect TNFR expression on the surface of
peripheral blood myeloid cells (Figure 45). Both TNFR1 and TNFR2 are expressed on
blood myeloid DC (CD1c+/CD11c+) following their enrichment from PBMC as described
previously (Figure 45 (A)). Whole PBMC were also analysed for by flow cytometry and
pDC were defined by surface marker expression (defined within PBMC as DAPI-/CD19-
/CD20-/CD3-/CD56-/CD1c- and CD45+/HLA-DR+/CD123+) Figure 45 (B). Briefly, dead
cells were excluded by DAPI positivity (a viability dye) and live leukocytes were
identified as CD45+ cells (lymphocyte common antigen). B cells (CD19+ or CD20+), T
cells (CD3+) and NK (CD56+) cells were also excluded. Following this gating strategy,
pDC were identified as HLA-DR+/CD1c-/CD123+, and showed expression of both
TNFR1 and TNFR2 (Figure 45 (B)). TNFR1 and TNFR2 were detected using H398 and
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22221 (both IgG2A antibodies) respectively, and the same biotin and streptavidin
conjugated antibodies. As different primary antibodies are used to detect each receptor
it is difficult to accurately compare their relative amounts, however as both primary
antibodies are IgG2A and saturating antibody concentrations were added the relative
amounts of TNFR1 and TNFR2 can be generally compared. Results therefore show
similar levels of TNFR1 and TNFR2 expression in blood myeloid DC, but higher levels
of TNFR2 than TNFR1 expression in pDC. The number of donors and the MFI of
TNFR1 and TNFR2 expression on each subset of DC is shown in Table 3.
Immature moDC Blood myeloid DC pDC
TNFR1 2735 ± 610.9 n=3 3167 ± 1137 n=5 411.5 ± 316 n=5
TNFR2 8115 ± 1867 n=3 660 ± 651.5 n=5 2899 ± 1620 n=5
Table 3: TNFR expression on moDC, CD1c+ blood myeloid DC and CD123+ pDC.
5.2.2. TNFR1 and TNFR2 enhance the maturation of blood myeloid DC
As shown in chapter 3.4.6 the maturation of DC can be characterised by an increase in
the expression of surface molecules such as the co-stimulatory molecule CD86.
Myeloid DC are CD1c positive therefore any CD1c negative cells were excluded,
although there may still be a low amount of CD1c+ B cell contamination (probably
around 1%). The maturation markers CD83 and CD86 within the CD1c
positive/caspase-3 negative populations were analysed (thereby excluding most of the
dead or dying cells). Results show that within 24 hours of stimulation both TNFR1- or
TNFR2-mediated signalling induced the expression of HLA-DR, CD83 and CD86
(Figure 46 (A)). Additionally, the expression of PD-L1 and ICAM-1 was increased by
CysTNFwt which can activate both TNFR1 and TNFR2 (Figure 46 (B)). Time course
analysis at 24 h and 48 h revealed that the enhanced expression of CD83 and CD86
following TNFR1- or TNFR2-mediated signalling is significant after 24 h (Figure 47 (A
and B), respectively). Although sTNF, CysTNFwt, CysTNFR1 and CysTNFR2 plus 80M2
still induce significant effects after 48 h, CD83 expression is much weaker (according to
the MFI) than at 24 h and CysTNFR2 plus 80M2 no longer has a significant effect on
CD86 (Figure 47 (C and D)). Data in Figure 47 is summarised in Table 4. The
difference between sTNF/CysTNFwt and the TNFR-selective ligands may be due to
differences in the half life of the ligand/TNFR complexes and/or in their capability to
induce TNFR internalisation, which might be affected by ligand oligomerisation (all TNF
ligands except sTNF contain a free Cystein residue at their N-terminus) and point
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mutations (CysTNFR1 and CysTNFR2, but not sTNF and CysTNFwt contain two point
mutations per TNF monomer) in the ligands, whereas the difference between 24 h and
48 h may be due to an increase in the amount of dying cells. Figure 48 (A-D) shows
that CysTNFR2 alone and 80M2 alone have no effect on CD83 (A and C) or CD86 (B
and D) expression at 24 h (A and B) or 48 h (B and D). In addition, LPS has a similar
effect on CD83 as CysTNFwt, and a greater effect on CD86 than any of the ligands.
CD83 24 h n=6 CD83 48 h n=7 CD86 24 h n=4 CD86 48 h n=4
Unstimulated 86.7 ± 12.8 198.3 ± 18.8 175.1 ± 13.1 235 ± 25.6
sTNF 2485 ± 450.7 1324 ± 311.9 673.4 ± 54.2 776.3 ± 171.7
CysTNFwt 3200 ± 396 2251 ± 423.3 823.4 ± 48.4 1879 ± 305.7
CysTNFR1 1045 ± 322 404 ± 19.5 534.7 ± 47.9 299.3 ± 28.4
CysTNFR2 + 80M2 509.7 ± 159.6 318.5 ± 23.9 413 ± 40.8 344.3 ± 49.6
Table 4: CD83 and CD86 expression on blood myeloid DC following TNFR stimulation.
To investigate whether the increase in maturation marker expression is mediated
through TNFR1, TNFR2 or through co-operation between the two receptors (e.g. the
production of mTNF via TNFR1-signalling may activate TNFR2 or TNFR2-mediated
sTNF production may activate TNFR1), I used TNFR-specific antagonistic antibodies
(as also used in chapter 4.4.2). Freshly isolated blood myeloid DC were treated with
antagonistic TNFR1- or TNFR2-specific antibodies (10 g/ml H398 or 22221,
respectively) for 30 min prior to TNFR-stimulation. Firstly, I confirmed that neither of the
TNFR antagonists had any effect on blood myeloid DC survival when used alone as
compared to unstimulated cells (Figure 49). The anti-TNFR1 antibody completely
blocked the CysTNFR1-mediated survival of blood myeloid DC but did not affect the
response to CysTNFR2 + 80M2, indicating that TNFR2 acts in a TNFR1-independent
manner (Figure 49). Alternatively, the anti-TNFR2 antibody inhibited the response to
CysTNFR2 plus MAb 80M2 but had no effect on the TNFR1-mediated response (Figure
49). It also confirmed that sTNF acts through TNFR1 as the pro-maturation effect of
sTNF was blocked by anti-TNFR1 but not anti-TNFR2, whereas the effect of CysTNFwt
was only partially blocked by antagonising either TNFR1 or TNFR2, indicating that
mTNF enhances blood myeloid DC survival through both TNFR1- and TNFR2-
mediated signalling. Results shown in Figure 49 are divided into corresponding donors
and shown in Appendix B.
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I also determined cytokine production as an indicator of DC maturation, as done
previously with moDC (chapter 3.4.6). Supernatants from cell cultures were analysed
for production of IL-6 and IL-1(Figure 50), which are both known mediators of
inflammation. None of the TNF ligands resulted in the production of either IL-6 or IL-1
within 24 h of blood myeloid DC stimulation. Alternatively, LPS-matured blood myeloid
produced IL-6 but not IL-1. Therefore, there is no positive control for DC production of
IL-1, but as the standard for IL-1 was easily detected, I can exclude a technical
problem with the ELISA. It is possible that an ELISA is not sensitive enough to detect
low levels of cytokine production by the blood myeloid DC.
Results therefore show that in blood myeloid DC both TNFR1 and TNFR2 can enhance
the expression of maturation markers but did induce a cytokine response. In line with
these results, TNF-stimulation of moDC was also not sufficient to induce a cytokine
response (chapter 3.4.6; Figure 25).
5.2.3. TNFR2- but not TNFR1-mediated signalling protects blood myeloid DC
from cell death
I have shown in the previous chapter (4.4.1) that moDC undergo cell death within 48
hours of culture after removal of IL-4 and GM-CSF from the moDC cultures, and that
the addition of TNF can protect the moDC from cell death. To investigate whether
blood myeloid DC die after cytokine withdrawal within a similar time period to moDC,
blood myeloid DC were left unstimulated or were treated with sTNF, CysTNFwt,
CysTNFR1 or CysTNFR2 plus 80M2 for 24 h and 48 h. As previously, the processed
form of caspase-3 was used to assess cell death by flow cytometry and was measured
within the CD1c positive population. Figure 51 shows that culture without the addition
of cytokines results in the death of 36% of blood myeloid DC within 24 h, which is
slightly increased to 38% at 48 h. Furthermore, this cell death can be reduced by the
addition of CysTNFwt to 13% at 24 h and 19% at 48 h, and to a lesser extent by sTNF
to 28% at 24 h and 33% at 48 h (Figure 51). Cell death can also be reduced by the
addition of CysTNFR2 plus 80M2 to 24% at 24 h and 25% at 48 h, however, cell death
was not reduced by CysTNFR1 (38% at 24 h and 39% at 48 h) (Figure 51). As the
reduction in blood myeloid cell death was more pronounced at 24 h and the effect was
no longer significant art 48 h, the 24 h time point was used in all future experiments.
To study the regulation of blood myeloid DC survival by the individual TNFR, blood
myeloid DC were treated with sTNF, CysTNFwt, CysTNFR1 or CysTNFR2 plus 80M2,
both with and without TNFR-specific antagonistic antibodies. Stimulation with sTNF
and CysTNFwt significantly protected blood myeloid DC from cell death (from 38%
active caspase-3+ unstimulated cells to 27% with sTNF or 15% with CysTNFwt, (Figure
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52 (black circles) and Appendix C1). When compared to that of moDC, the CysTNFwt
response is similar but the sTNF response is reduced (from 60% active caspase-3+ in
unstimulated moDC to 16% with sTNF or 14% with CysTNFwt, chapter 4.4.1 Figure 29).
Interestingly, CysTNFR2 plus 80M2 significantly protected blood myeloid DC from
cytokine deprivation-induced cell death (as shown by the reduction in active caspase-3
from 38% in unstimulated cells to 26% with CysTNFR2 plus 80M2), whereas CysTNFR1
did not have any effect (Figure 52 (black circles) and Appendix C1). This is in contrast
to moDC as both TNFR1- and TNFR2-selective stimulation enhanced survival of moDC
(from 60% active caspase-3+ in unstimulated moDC to 35% with CysTNFR1 or 44% with
CysTNFR2 + 80M2, chapter 4.4.1; Figure 29). This suggests that TNFR1 may play a
role in DC survival under inflammatory conditions but not in steady state conditions,
whereas TNFR2 promotes a similar response on DC survival under both conditions but
is more pronounced in steady state conditions.
To identify whether the enhancement of blood myeloid DC survival occurred directly
through TNFR2 or whether TNFR1 was also necessary I used TNFR-specific
antagonistic antibodies. As in previous experiments I confirmed that neither of the
TNFR antagonists alone had any effect on blood myeloid DC survival (Figure 52)
indicating that endogenously expressed TNF does not affect the survival of these cells.
The pro-survival effect of sTNF was blocked by anti-TNFR1 but not anti-TNFR2
indicating that sTNF acts primarily through TNFR1 in blood myeloid DC. Alternatively
the pro-survival effect of CysTNFwt was only partially blocked by either TNFR1 or
TNFR2 antagonism indicating that mTNF enhances blood myeloid DC survival through
both TNFR1- and TNFR2-mediated signalling (Figure 52). The anti-TNFR2 antibody
completely blocked survival mediated by CysTNFR2 plus MAb 80M2 whereas the anti-
TNFR1 antibody had no effect indicating that TNFR2 acts in a TNFR1-independent
manner (Figure 52). Results therefore show that TNFR2- but not TNFR1-selective
signalling resulted in enhanced survival in blood myeloid DC. Results in Figure 52 are
divided according to corresponding donors in Appendix C2 and C3.
5.2.4. Myeloid DC isolation from synovial fluid
As described previously, moDC are thought to represent an inflammatory cell type,
whereas blood myeloid DC represent steady state conditions. In order to investigate
this further, I compared these cell types with myeloid DC present during chronic
inflammation to identify whether these behave more like moDC. To do this, synovial
fluid samples were obtained from two RA patients. PBMC were separated and myeloid
DC were enriched as described previously in this chapter. The purity of SF myeloid DC
was determined by CD1c and CD11c expression as determined by flow cytometry and
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both of the RA patient samples show ~43% purity (Figure 53). Any potential effect of
contaminating cells on the maturation and/or survival of myeloid DC cannot be
excluded at this time.
The maturation markers CD83, CD86 and HLA-DR within the CD1c positive and
caspase-3 negative cell populations were analysed after 24 h in culture with TNF or the
TNF ligands. Results in Figure 54 (A) show that sTNF has no effect on maturation
whereas there is a slight increase in CD83 and CD86 expression with the addition of
CysTNFwt. Selective stimulation of TNFR1 or TNFR2 has no effect on maturation of
myeloid DC in either of the samples (Figure 54 (A and B)). However the high
expression of CD83 and CD86 in unstimulated cells suggests that these cells have, to
some extent, already matured. All of the cells are HLA-DR positive which is to be
expected as all myeloid DC express HLA-DR. As they originate from the synovial fluid
of RA patients it is not unexpected that they will already be mature prior to TNF
treatment due to the chronic inflammatory environment in the RA joint. This is
confirmed by other groups who showed that synovial DC are more mature (in terms of
activation markers and cytokine production) than DC from peripheral blood (Page et al.
2002; Radstake et al. 2004). An ELISA was also conducted on supernatants from the
TNF-treated myeloid DC used in (Figure 54(A)) but no IL-6 or IL-1 was detected (data
not shown). This may indicate that the SF myeloid DC are not fully mature however, it
is also possible that the DC are exhausted/paralysed which has previously been
described in relation to IL-12 and LPS in human moDC (Langenkamp et al. 2000) and
murine DC (Reis e Sousa et al. 1999).
Myeloid DC isolated from the synovial fluid of the two RA patients used in Figure 54
were also analysed for the expression of intracellular active caspase-3 to indicate the
level of cell death (Figure 55). After 24 h unstimulated cells show 49% and 26% (donor
A and donor B, respectively) active caspase-3 positive cells (Figure 55). This is
reduced by CysTNFwt (49% active caspase-3+ cells to 23% in donor A) and to a lesser
degree by sTNF (49% active caspase-3+ cells to 31% in donor A). Additionally,
CysTNFR1 had no effect in cells from either donor whereas CysTNFR2 + 80M2
enhanced myeloid DC survival from 49% active caspase-3+ cells to 29% in donor A
and 26% to 19% in donor B (Figure 55 (A-C)). These data are in contrast to results in
moDC where both TNFR1- and TNFR2-mediated signalling resulted in enhanced
survival (chapter 4.4.1; Figure 29), but support results in blood myeloid DC where
TNFR2- but not TNFR1-mediated signalling enhanced survival (Figure 52).
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Figure 42: Analysis of size/granularity of distinct cell populations within human
PBMC. PBMC were isolated from peripheral whole blood and analysed by flow
cytometry. Cells positive for the cell surface markers indicated were back-gated using
FlowJo analysis software resulting in the visualisation of monocytes (CD14, green), T
cells (CD3, orange), B cells (CD19, blue), myeloid DC and some B cells (CD1c,
purple), myeloid cells (CD11c, red) and myeloid DC (CD1c/CD11c, pink) within the
PBMC population (grey). Results show side scatter (y axis, representing granularity)
versus forward scatter (x axis, indicating size) and represent at least three independent
experiments with different donors.
Figure 43: E
were isolate
negative sel
column sho
myeloid DC
cells analyse
with differen
A126
nrichment and purity of freshly isolated blood myeloid DC. PBMC (A)
d from peripheral whole blood or blood myeloid DC (B) were separated by
ection (EasySep human myeloid DC enrichment kit; StemCell). The left
ws size/granularity, whereas the right column shows the purity of blood
as determined by CD1c and CD11c expression after the exclusion of dead
d by flow cytometry. Results represent at least 6 independent experiments
t donors.
B
Figure 44: Identification
PBMC were isolated from
by negative selection (E
Columns A and B show
indicating size), column B
analysed within the PBMC
histogram (D) show the pe
(D) three independent exp
D127
of cells contaminating the blood myeloid DC fraction.
peripheral whole blood and blood myeloid DC were enriched
asySep human myeloid DC enrichment kit; StemCell).
SSC (y axis, representing granularity) versus FSC (x axis,
indicates T cells (CD3, blue) and B cells (CD19, green)
or blood myeloid DC populations (red). Column (C) and
rcentage of B and T cells. Results represent (A-C) one and
eriments with different donors.
T c
ell
s
B
ce
lls
T c
ell
s
B
ce
lls
0
20
40
60
80
PBMC
myeloid DC
%
po
si
tiv
e
ce
lls
Figur
Surfac
(A) Fr
enrich
/CD19
cytom
protoc
antibo
shadeA128
e 45: Expression of TNFR1 and TNFR2 on the cell surface of myeloid cells.
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eshly isolated CD1c+/CD11c+ blood myeloid DC (EasySep human myeloid DC
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-/CD20-/CD3-/CD56-/CD1c- and CD45+/HLA-DR+/CD123+) were analysed by flow
etry. TNFR were detected using a biotin/streptavidin-based amplification
ol. TNFR1-specific antibodies (H398; left, black line) or TNFR2-specific
dies (22221; right, black line) are compared with an IgG2A isotype control (grey
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Figure 46: TNFR1- and TNFR2-mediated signalling results in enhanced
expression of maturation markers in blood myeloid DC. Freshly isolated blood
myeloid DC were treated for 24 h as indicated with (A) sTNF, CysTNFwt or TNFR-
selective ligands (50 ng/ml each) +/- MAb 80M2 (2 g/ml) or (B) CysTNFwt (50 ng/ml).
The expression of (A) CD83, CD86, HLA-DR and (B) PD-L1 and ICAM-1 was
determined by flow cytometry. Unstimulated cells (grey shaded) were compared to
TNF-stimulated cells (black line). Results represent (A) from 3 to 7 independent donors
or (B) one donor.
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Figure 49: TNFR-antagonism blocks TNFR-mediated enhancement of maturation
marker expression induced by the corresponding TNFR but does not affect
signalling via the other receptor. Blood myeloid DC were left untreated or were
treated with antagonistic TNFR1- or TNFR2-specific antibodies for 30 min prior to
stimulation with 50 ng/ml sTNF, CysTNFwt, CysTNFR1 or CysTNFR2 + MAb 80M2 for 24
h. The expression of CD83 (top) and CD86 (bottom) was determined by flow cytometry.
The mean and SEM of the MFI (median fluorescence intensity) are shown. Data from
Figure 47 (A, B) is included. Statistical differences were determined in relation to
unstimulated blood myeloid DC using a student’s t test; *P≤0.05 **P≤0.01 ***P≤0.001. 
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Figure 50: Blood myeloid DC do not produce IL-6 or IL1 in response to TNF.
Blood myeloid DC were treated as indicated with LPS (100 ng/ml), sTNF, CysTNFwt or
TNFR-selective ligands (50 ng/ml) +/- MAb 80M2 (2 g/ml) for 24 h. Supernatants were
harvested and cytokine concentrations (IL-6 and IL-1) were determined by sandwich
ELISA. Results represent 7 independent donors except LPS which shows one donor
only.
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Figure 51: Both sTNF and CysTNFwt protect blood myeloid DC from cytokine
deprivation-induced cell death. Blood myeloid DC were cultured in the presence or
absence of sTNF or CysTNFwt (50 ng/ml) for 24 or 48 h. The induction of cell death was
assessed by the presence of intracellular active caspase-3 determined by flow
cytometry. The percentages of cells gated positive for active caspase-3 are indicated.
Results represent 3 or 4 independent experiments using different donors.
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Figure 52: TNFR2- but not TNFR1-mediated signalling protects blood myeloid DC from cytokine deprivation-induced cell death.
Blood myeloid DC were cultured in the presence or absence of 10 g/ml antagonistic TNFR1- or TNFR2-specific antibodies (H398 or
22221 respectively) for 30 min prior to stimulation with 50 ng/ml sTNF, CysTNFR1 or CysTNFR2 + MAb 80M2 for 24 h. Cell viability was
assessed by the presence of intracellular active caspase-3 determined by flow cytometry. The percentages of cells gated positive for
caspase-3 are indicated. The mean and SEM are shown for a minimum of 3 independent experiments with different donors. Statistical
differences were determined using a student’s t test; *P≤0.05 **P≤0.01 ***P≤0.001. 
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hown in Figure 53 and Figure 54) were isolated and enriched for myeloid DC.
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5.3. Discussion
The aims of this chapter were to investigate the expression of TNFR1 and TNFR2 on
human blood myeloid DC and to explore the effect of TNFR signalling on their
maturation and survival. I have shown that blood myeloid DC do express TNFR1 and
TNFR2 and that the downstream effects of each receptor are similar in blood myeloid
DC and moDC. However, blood myeloid DC appear more sensitised to TNFR-mediated
maturation when compared to moDC. My data show that TNFR1- and to a lesser
extent TNFR2-mediated signalling results in blood myeloid DC phenotypical maturation
as defined by enhanced expression of maturation markers CD83 and CD86. However,
TNF-induced signalling alone (when compared to the TLR ligand LPS) is not sufficient
to induce full maturation as shown by a lack of IL-6 production by blood myeloid DC. I
also show data demonstrating that blood myeloid DC show enhanced by TNFR2- but
suppressed TNFR1-mediated survival when compared to moDC, thereby indicating
that blood myeloid DC respond differently (or show a shift in sensitivity) to TNFR-
mediated signalling in comparison to moDC (Table 5).
DC Maturation DC Survival
sTNF CysTNFwt CysTNFR1
CysTNFR2
+ 80M2 sTNF CysTNFwt CysTNFR1
CysTNFR2
+ 80M2
moDC ++ ++ + - ++++ ++++ ++ +
Blood
Myeloid
DC
+++ ++++ ++ + ++ +++ - ++
Table 5: TNFR-mediated maturation and survival of moDC and blood myeloid DC.
In addition, I analysed myeloid DC from the synovial fluid of RA patients to represent
chronic inflammatory conditions and allow comparison with ‘inflammatory’ moDC and
steady state blood myeloid DC. Only the use of CysTNFwt resulted in an increase in the
expression of surface maturation markers in SF myeloid DC, although unstimulated
cells showed high expression of CD83 and CD86, suggesting that the inflammatory
environment of the RA joint had already resulted in some degree of maturation prior to
SF myeloid DC isolation. Furthermore, the survival of SF myeloid DC was enhanced
via TNFR2- mediated signalling. These data may, at least in part, underline the
differences in the functional effects mediated by the two receptors demonstrating their
distinct roles in regulating DC maturation and survival during both inflammatory and
steady state environments.
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5.3.1. Analysis of blood myeloid DC populations
Following enrichment by negative selection, the population of blood myeloid DC
(CD1c+/CD11c+) was 75-90% pure and also contained ~3% T cell and ~1% B cell
contamination plus other unknown cells (potentially including monocytes and NK cells).
These cells may exert effects on the blood myeloid DC independently to the
exogenously added TNF, for example, TNF-producing cells may be present. Also, the
maturation of human DC can be negatively regulated by CD19+ B cells (Morva et al.
2012), although my data show an increase in maturation making B cell-mediated
suppression unlikely. The effect of contaminating cells on the blood myeloid DC during
24 h culture could not be evaluated at this stage, but might have affected the
interpretation of this study. To prevent any effects of contamination with other cell
populations, in future experiments DC subsets could be sorted using multi-colour flow
sorting prior to TNFR-stimulation and analysis.
I have shown that both TNFR1 and TNFR2 are expressed on freshly isolated human
blood myeloid DC and plasmacytoid DC. As with moDC, TNFR expression levels
varied between each donor, a difference which may account for donor to donor
variability in other assays. However, as the TNFR expression was not analysed for
each donor in parallel to the maturation and survival assays, it is not possible to
correlate TNFR expression with the TNF response.
5.3.2. TNF-mediated maturation of blood myeloid DC
As discussed in the previous chapter (3.5.3), DC maturation in mouse models has
been shown to require TNFR1-mediated signalling in response to infection (Ding et al.
2011; Sundquist & Wick 2005), whereas TNFR2 was not required (Ding et al. 2011) or
was not investigated (Sundquist & Wick 2005). My data show that in blood myeloid DC
TNFR1- and to a lesser extent TNFR2-mediated signalling significantly increased the
expression of surface markers involved in the co-stimulation and activation of T cells.
The enhanced phenotypical maturation induced by CysTNFR1 and CysTNFR2 + 80M2
was weak compared to that of sTNF or CysTNFwt, and was diminished by 48 h,
potentially due to higher levels of cell death. As to be expected in steady state
conditions, the unstimulated blood myeloid DC had consistently low CD83 and CD86
suggesting that they were in an immature state within the blood prior to isolation.
Both CysTNFR1 and CysTNFR2 + 80M2 were less effective at enhancing the
phenotypical maturation of blood myeloid DC than sTNF or CysTNFwt. Again, as
discussed in the previous chapter (3.5.3), the reason for this remains unclear, although
it is interesting that in this case CysTNFwt has a greater effect than sTNF which
suggests that CysTNFwt is simultaneously acting through a combination of both TNFR1
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and TNFR2 potentially leading to an additive effect. As with moDC (chapter 3.5.3), the
phenotypical maturation induced by TNFR-stimulation was not sufficient to induce full
blood myeloid DC maturation shown by the lack of cytokine production and again is
consistent with previous work showing that full maturation of DC requires activation
through a pathogen recognition receptor (PRR) (Spörri & Reis E Sousa 2005; Roelofs
et al. 2005).
Furthermore, the blocking effect of the TNFR1-specific antagonistic antibody H398 was
complete for CysTNFR1, almost complete for sTNF but was not complete for CysTNFwt,
suggesting that CysTNFwt does in fact act via both TNFR1 and TNFR2. However, the
combination of both TNFR1- and TNFR2-specific antagonistic antibodies also did not
fully inhibit CysTNFwt, this may be due to strong avidity of the pre-oligomerised ligand
or due to the lack of donors for this condition. The TNFR2-specific antagonistic
antibody 22221 fully blocked the CysTNFR2 + 80M2 mediated enhancement of CD86
expression and appeared to fully block enhancement of CD83 expression although
CD83 expression was so low that this result turned out not to be significant. Further
analysis of blood myeloid DC maturation would include investigation of their functional
ability to activate naïve T cells using an MLR as was done with moDC, although the
small numbers of blood myeloid DC would make this more challenging and require
further optimisation.
5.3.3. TNFR-mediated blood myeloid DC survival
My results show that stimulation with CysTNFwt, CysTNFR2 + 80M2 and to a lesser
extent sTNF, protected blood myeloid DC from cell death. This is similar to the
response of moDC except that the moDC response to sTNF was comparable to
CysTNFwt. Interestingly, CysTNFR1 did not have any effect on blood myeloid DC
survival even though there was an effect with sTNF which is known to acts primarily
through TNFR1 (Grell et al. 1995; Richter et al. 2012; Krippner-Heidenreich et al.
2002). In order to determine if the effect of sTNF was indeed mediated via TNFR1 I
used TNFR-specific antagonistic antibodies. In line with my previous results using
moDC, the effect of sTNF on myeloid blood DC was fully blocked by antagonising
TNFR1 but not TNFR2 demonstrating that the effects of sTNF are mediated via TNFR1
alone. As discussed previously (chapter 3.5.3), the reason for this difference between
the effects of sTNF and CysTNFR1 remains unclear but may be due to the effects of the
point mutations in CysTNFR1 which give the ligand its receptor-selectivity. In addition,
the use of a TNFR2-specific antagonist (22221) fully inhibited the effect of CysTNFR2 +
80M2 whereas the TNFR1-specific antagonist (H398) had no effect thereby confirming
that TNFR2 enhances blood myeloid DC survival independently of TNFR1. As seen
with moDC, the pro-survival effect of CysTNFwt was not fully blocked when
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antagonising either TNFR which may be due to the strong avidity effect of the pre-
oligomerised ligand, which is difficult to antagonise using anti-TNFR antibodies.
5.3.4. Myeloid DC freshly isolated from synovial fluid
I also obtained two synovial fluid (SF) samples from RA patients in order to determine
whether DC from a chronic inflammatory environment would have a phenotype
comparable to the moDC inflammatory model or the steady state blood myeloid DC.
Myeloid DC obtained from SF were around 43% pure (i.e. CD1c+/CD11c+) which is
much lower than blood myeloid DC. This may be due to the enrichment kit used
(EasySep human myeloid DC enrichment kit; StemCell) which is not optimized for use
on SF. As the purity of myeloid DC populations from SF was low and the sample size
was small I cannot draw accurate conclusions from the TNFR-mediated signalling data
as the contaminating cells may act on the myeloid DC during the 24 h culture and there
are not enough samples to determine significance. It is unknown what cell types
represent the other ~57% of the samples but it potentially includes T cells, B cells, NK
cells, monocytes and macrophages. In a proteoglycan induced arthritis (PGIA) mouse
model SF was shown to contain myeloid-derived suppressor cells which may suppress
DC maturation (Egelston et al. 2012). To further investigate this line of research DC
would be analysed following multi-colour flow sorting prior to analysis, however this is
beyond the scope of this project.
Selective stimulation of TNFR1 or TNFR2 did not have any effect on the maturation of
myeloid DC in either of the RA SF samples (Figure 54). Other research has shown that
myeloid DC from rheumatoid SF display a semi-mature phenotype which resembles
that of moDC that have been generated in vitro (Thomas et al. 1999). RA SF myeloid
DC also show higher expression of CD40, CD80, CD83 and CD86 compared to those
from peripheral blood but no significant differences in cytokine secretion were detected
(Jongbloed et al. 2006; Moret et al. 2013), also suggesting a semi-mature phenotype.
This is in agreement with my results showing that surface maturation marker
expression is high in freshly isolated SF myeloid DC and that no cytokine secretion
could be detected in blood myeloid DC or SF myeloid DC following TNFR stimulation.
As the baseline CD83 and CD86 expression was high, the lack of response to TNF
may be because the myeloid DC had already matured within the inflammatory
environment of the RA joint. Additionally, TNF may be produced by contaminating
monocytes/macrophages which could enhance maturation and affect my results. In
order to determine if this is the case and that maturation marker expression is already
at its maximum, LPS should be used as a positive control. In addition, the expression
of TNFR1 and TNFR2 could be investigated prior to TNFR-stimulation as receptor
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downregulation in response to maturation may partially explain the lack of response to
TNF.
My results also show that the survival of myeloid DC isolated from the synovial fluid of
the two RA patients was enhanced by stimulation with sTNF, CysTNFwt and CysTNFR2
+ 80M2, whereas CysTNFR1 did not have any effect. This is in line with my data in
blood myeloid DC and in contrast to moDC (chapter 4.4.1; Figure 29), where both
TNFR1 and TNFR2 enhanced survival. Segura et al. describe human inflammatory DC
as a distinct population identified in SF samples from RA joints which shares gene
signatures with in vitro moDC and inflammatory macrophages, suggesting they are
derived from monocytes and are the in vivo equivalents of moDC (Segura, Touzot, et
al. 2013). Inflammatory DC also displayed features from both conventional DC and
inflammatory macrophages and were involved in induction and maintenance of Th17
responses (Segura, Touzot, et al. 2013). This is partially in contrast to my data as the
survival of SF myeloid DC in response to TNFR-selective stimulation was similar to that
of blood myeloid DC, but differed to that of moDC. This suggests that with regard to
TNFR-responsivity, inflammatory DC isolated from the SF of RA patients represent
blood DC more than inflammatory moDC. However, more patients would be needed to
accurately draw such conclusions as statistical significance could not be determined at
this time due to a lack of SF donors.
5.3.5. Conclusion
My results show that the phenotypical maturation of human DC is most potently
regulated by TNFR1-mediated signalling as in moDC TNFR2-mediated signalling has
no effect and in myeloid blood DC activation of TNFR2 is much less effective in
enhancing the expression of surface maturation markers when compared to TNFR1.
Alternatively, human DC survival can be significantly enhanced by either TNFR in
moDC but mainly via TNFR2 in myeloid blood DC and SF myeloid DC. Therefore, my
data show that moDC and blood myeloid DC exert different sensitivities
towards TNFR1- and TNFR2-mediated DC maturation and survival. Whereas in blood
myeloid DC maturation is generally enhanced by TNFR1- or TNFR2-signalling, their
survival seems to be promoted by TNFR2-, but not TNFR1-signalling when compared
to moDC/inflammatory DC.
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6. General discussion
The individual roles of TNFR1- and TNFR2-mediated signalling in human DC have
never been studied in detail. This study is the first to make use of TNFR-selective
ligands to investigate and dissect the roles of TNFR1 and TNFR2 in regulating the
maturation and survival of human DC while comparing ‘inflammatory’ moDC, SF-
derived myeloid DC and steady-state blood myeloid DC. My research was driven by
the aims to;
1. Determine the expression of TNFR1 and TNFR2 on human DC subsets
2. Determine the competency of each TNFR for the activation of NFB
3. Determine the involvement of TNFR1 and TNFR2 in DC maturation and survival
4. Identify signalling molecules/pathways involved in TNFR1- and TNFR2-
mediated regulation of DC survival
5. Compare the responses of moDC, blood myeloid DC and myeloid DC isolated
from RA patient synovial fluid
The major findings of this study are briefly summarised in Figure 56 and more detailed
results from moDC are summarised in chapter 4.4.4; Figure 41 (B). In moDC, TNFR1-
selective, but not TNFR2-selective stimulation resulted in activation of the classical
NFB pathway, increased expression of DC maturation markers CD83 and CD86 and
enhanced T cell stimulatory capacity, whereas both TNFR1 and TNFR2 activated the
alternative p100/p52 NFB pathway and enhanced moDC survival. This demonstrates
that innate signals can promote DC survival in the absence of DC maturation.
Accordingly, the p65 NFB pathway was involved in the pro-survival effect of TNFR1
whereas the Bcl-2/Bcl-xL pathway was essential to survival mediated by both TNFR1
and TNFR2 thus identifying both differences and overlap in TNFR-mediated signalling.
In contrast, in myeloid blood DC, phenotypical maturation was most potently regulated
by TNFR1, whereas TNFR2 was superior in protecting DC from cell death. Selective
stimulation of TNFR1 or TNFR2 did not have any effect on the maturation of myeloid
DC isolated from the SF of RA patients as cells already displayed a mature phenotype,
however TNFR2-mediated signalling enhanced SF-derived myeloid DC survival,
whereas TNFR1-mediated signalling only enhanced survival via sTNF (but not
CysTNFR1). Therefore my data shows that TNF promotes DC maturation and survival
through distinct signalling pathways and that moDC and myeloid DC have different
sensitivities towards TNFR1- and TNFR2-mediated signalling.
Although my data show differences between the responses of moDC and myeloid DC
to TNFR1- and TNFR2-selective stimulation, these differences may not be as clear in
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an in vivo setting. The concentration of TNF in vivo is difficult to assess as local
concentrations can become high in small intercellular spaces although they may not
reach the saturating concentration of 50 ng/ml used in these experiments. The effects
mediated by each TNFR in different cell types may ultimately involve differences in
sensitivity which could alter the balance between maturation, survival and apoptosis.
Moreover, the ratio of TNFR1 and TNFR2 co-expression may be important in shifting
the balance between cellular survival and apoptosis. Therefore, it remains unknown if
steady state DC and inflammatory DC would respond differently to TNF in vivo.
Figure 56: Summary of TNFR-mediated maturation and survival in DC subtypes.
TNFR1 enhanced moDC maturation and survival whereas TNFR2 only enhanced
survival. TNFR1 and to a lesser extent TNFR2 enhanced blood myeloid DC maturation
but only TNFR2 enhanced survival. Myeloid DC isolated from synovial fluid already
showed enhanced maturation but survival was mainly enhanced by TNFR2.
6.1. A comparison of DC subtypes
It has been known for a number of years that monocytes can differentiate into DC in
vitro (Sallusto & Lanzavecchia 1994). In this thesis moDC were used as a model for
inflammatory DC which are not normally found in healthy tissue but are thought to
differentiate from monocytes during cases of chronic inflammation such as RA (as
reviewed in (Shortman & Naik 2007; Segura, Durand, et al. 2013)). Previously, murine
models have demonstrated that monocytes develop into moDC in vivo during infections
with Leishmania major (León et al. 2007) or Listeria monocytogenes (Serbina et al.
2003) and in models of inflammatory disease such as RA (Campbell et al. 2011). Also,
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monocytes from the Ly6C+ inflammatory mouse model do not produce DC in lymphoid
organs when transferred into a non-irradiated mouse, but do produce DC when
transferred into mice subjected to GM-CSF-dependent inflammation (Naik et al. 2006).
MoDC which develop in mice have also been analysed in detail and were shown to be
DC in terms of motility, location (proximity to T cell areas), phenotype and function (T
cell stimulatory capacity) (Cheong et al. 2010).
Inflammatory DC have been identified in humans using transcriptomic analysis as a
distinct subset which differs from other DC and from inflammatory macrophages
(Segura, Touzot, et al. 2013). These human inflammatory DC are proposed to be
monocyte-derived, are present in inflammatory environments including synovial fluid
from RA patients and are involved in the Th17 response (Segura, Touzot, et al. 2013).
As previous research suggests that monocyte-derived DC pay little contribution to
steady state DC I also investigated blood myeloid DC isolated from healthy donors. I
also obtained two SF samples from RA patients in order to determine whether DC from
a chronic inflammatory environment would have a phenotype comparable to the moDC
inflammatory model or the steady state blood myeloid DC.
Other research shows that myeloid DC from rheumatoid SF display a semi-mature
phenotype which resembles that of moDC which have been generated in vitro (Thomas
et al. 1999) and show with higher expression of CD40, CD80, CD83 and CD86
compared to those from RA peripheral blood (Jongbloed et al. 2006). This is in
agreement with my initial results showing that surface maturation marker expression is
high in unstimulated DC. As the myeloid DC populations from SF were only ~43% pure
and the sample size was low I cannot draw accurate conclusions from this data. It is
unknown what cell types represent the other ~57% of the samples, for example in a
proteoglycan induced arthritis (PGIA) mouse model SF was shown to contain myeloid-
derived suppressor cells which may suppress DC maturation (Egelston et al. 2012).
For future analysis DC subsets would be sorted using multi-colour flow sorting however
this is beyond the scope of this project.
DC precursors in peripheral blood can differentiate after entry to rheumatoid synovial
tissue (Pettit et al. 2000) and SF from both RA and PsA patients have been shown to
contain both myeloid DC and pDC (Jongbloed et al. 2006). It has been suggested that
myeloid DC contribute to RA disease activity (Richez et al. 2009). Data has shown that
DC progenitors and growth factors are present in RA but not OA synovial fluid therefore
potentially play a role in RA disease progression and also that cell-free RA SF can
induce DC maturation (Santiago-schwarz et al. 2001). In addition, it has also been
proposed that TNF may negatively regulate CD14-derived DC differentiation in vivo as
enhanced numbers of CD14-derived DC correlates with enhanced levels of soluble
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TNFR1 which acts as a TNF antagonist, thus suggesting that TNF inhibits the
development of CD14-derived DC (Santiago-schwarz et al. 2001). This is in contrast to
my data which shows that TNF-mediated signalling enhanced CD14-derived moDC
and myeloid DC survival, thereby reiterating the point that more work is needed to
differentiate between effects mediated by TNFR1 and TNFR2 in RA.
6.2. TNFR-mediated activation of the NFB pathway in DC
Regulation of the classical and alternative NFB pathways is a crucial factor in the
balance between inflammation and tolerance. NFB signalling is widely implicated in
inflammatory diseases, both in pro- and anti-inflammatory processes (Bonizzi & Karin
2004). My data showed that TNFR1- but not TNFR2-mediated signalling activated the
classical NFB pathway whereas both TNFR1 and TNFR2 activated the alternative
NFB pathway in moDC. My findings that the classical and alternative NFB signalling
pathways in moDC are differentially activated by TNFR1 and TNFR2 may partially
explain the opposing functions of TNF in disease as these pathways can mediate a
wide range of effects. The lack of activation of p65 via TNFR2 seen in my data may be
cell-type specific as other research has shown that the classical NFB pathway is
activated by TNFR2, for example in mouse neurones which lack TNFR1 (Marchetti et
al. 2004). Overlapping mechanisms of NFB pathway activation by different molecules
within the pathway are shown in Figure 57 and described in the following paragraphs.
Receptor interacting protein (RIP) kinases are crucial regulators of cell survival which
are capable of activating NFB and are expressed in moDC both with and without
TNFR1-stimulation (Figure 18). Generally, TNFR1-mediated signalling recruits RIP1
(also known as RIPK1) and TRAF2 leading to classical NFB pathway activation and
increased expression of anti-apoptotic genes, resulting in cell survival. However,
opposing data suggests that RIP1 is not essential for the activation of classical NFB
signalling by TNFR1 as TNFR1 stimulation in RIP1-/- MEF results in classical NFB
activation (including p65 translocation) and enhanced survival suggesting a death-
inducing role for RIP1 in these cells (Wong et al. 2010). Alternatively, TNFR1-mediated
activation of the alternative NFB pathway is suppressed by the adapter kinase RIP1
through the inhibition of TNF-mediated TRAF2 and cIAP1 degradation (Kim et al. 2011;
Gentle et al. 2011). In addition, when classical NFB signalling is low, TNFR1 can
mediate a pro-apoptotic signal via activation of the caspase cascade where caspase-8
may mediate the cleavage of RIP1 blocking further anti-apoptotic signals (Festjens et
al. 2007). One reason for the apparent lack of TNF-mediated alternative NFB
activation in some cell types may be due to its negative regulation by RIP1 which
stabilises TRAF2, decreasing its degradation and therefore preventing NIK stabilisation
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(Kim et al. 2011; Gentle et al. 2011). In accordance, TNF can induce the alternative
NFB pathway in cells deficient of RIP1 (Kim et al. 2011; Gentle et al. 2011). However,
in contrast my results show that in immature moDC RIP1 is present and the alternative
NFB pathway is active thus RIP1 does not suppress the alternative pathway in moDC.
The alternative NFB pathway is activated by several TNFR family members including
LT receptor (Dejardin et al. 2002) and CD40 (Coope et al. 2002). Activation of the
alternative NFB pathway is usually triggered by non-inflammatory stimuli, and
resulting signals inhibit pro-inflammatory cytokines and play a role in T cell tolerance
(Zhu & Fu 2010). This could potentially result in a negative feedback mechanism where
the pro-inflammatory effect of sTNF is diminished. However, the alternative pathway
can also mediate a pro-inflammatory response depending on the original stimuli. For
example, CD40-mediated activation of the alternative NFB pathway induced pro-
inflammatory IL-12 cytokine production in LPS-matured murine myeloid DC (Yanagawa
& Onoé 2006). Furthermore, defects in the alternative NFB pathway have been shown
to result in defects in immune development (Caamaño et al. 1998; Franzoso et al.
1998) and lead to autoimmunity (Cheema et al. 2001). Anti-inflammatory IDO
production has been shown to require alternative NFB signalling in DC and selective
activation of alternative NFB signalling resulted in non-inflammatory DC that suppress
T cell activity and promote T cells with regulatory properties (Tas et al. 2007). These
studies and my data suggest that TNFR2-stimulated DC may produce anti-
inflammatory signals via the alternative NFB pathway. This could be further
investigated by identifying the expression/secretion of anti-inflammatory molecules
(e.g. soluble TNFR).
NIK is another signalling molecule involved in the activation of the alternative NFB
pathway. After receptor activation NIK is released from its constitutive degradation and
accumulates before phosphorylating IKK molecules, leading to the partial degradation
of p100 and release of p52. The p52 molecule can then form a complex with RelB and
translocate to the nucleus. The longer time frame taken to activate the alternative
NFB pathway compared to the classical NFB pathway may involve the cleavage of
p100 which is a slower process than that of p65-phosphorylation (Naude et al. 2011)
and also the time taken for NIK to accumulate.
The alternative NFB pathway is important in DC maturation and function as the
deletion of NIK (which controls RelB) specifically in mouse DC results in deficient Th1
and Th17 responses (Hofmann et al. 2011). In addition, a mouse model of
inflammatory arthritis showed that mice lacking functional NIK were resistant to antigen
induced arthritis (Aya et al. 2005). Furthermore, the Aly (alymphoplasia) mouse model
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contains a spontaneous point mutation in the NIK gene which prevents its interaction
with IKK complexes. This Aly model has been used to show that a defect in NIK
prevents activation of the alternative NFB pathway in DC in response to CD40 and
impairs the ability of the DC to cross-prime CD8+ T cells (Lind et al. 2008). It has also
been used to show that a defect in NIK decreased DC-mediated T cell differentiation
into regulatory T cells (Tamura et al. 2006). With regard to the classical NFB pathway,
in the Aly mouse model NIK is required for classical NFB signalling downstream of
CD40 in B cells but not in DC (Garceau et al. 2000) and in NIK-/- mice, NIK is not
required for TNF-mediated activation of the classical NFB pathway (Yin et al. 2001).
This indicates differences in the activation of classical NFB signalling in different cell
types.
It has been shown that CD40 ligation activated the alternative NFB pathway and
induced IL-12 cytokine production in LPS-matured murine myeloid DC and alternative
NFB pathway activation was abolished in NIK-mutated mature DC (Yanagawa &
Onoé 2006). This shows that CD40 ligation is a potent enough signal to induce DC-
mediated cytokine production (unlike TNF), and also that NIK is important in the
activation of the alternative NFB pathway. In mouse B cell lines, CD40 and TNFR2
activate NFB signalling during B cell activation via different mechanisms (Munroe &
Bishop 2004). The CD40-mediated response was shown to activate NFB-mediated
transcription 3 times greater than the TNFR2-mediated response, although the CD40-
mediated response was reduced by 30% by blocking TNFR2 suggesting an
overlapping mechanism. CD40 was shown to activate the classical NFB pathway and
to a lesser extent than the alternative NFB pathway. Alternatively, and in line with my
data, TNFR2 was shown to exclusively activate the alternative NFB pathway (Munroe
& Bishop 2004).
The Rel homology domain of p100 is most commonly associated with RelB. During
alternative NFB signalling RelB forms complexes with p52 and translocates to the
nucleus and induces the transcription of a range of different genes. RelB deficient mice
have defects in DC cross-priming (Castiglioni et al. 2002) indicating its importance in
the immune response. RelB entering the nucleus in response to TNF cannot bind to
DNA in MEF as TNF promotes its association with p65 (Jacque et al. 2005). TNF-
induced phosphorylation of p65 at serine-276 is required for p65/RelB complex
formation and in the absence of ser-276 phosphorylation, TNF stimulation leads to a
strong increase in RelB controlled genes such as Bcl-xL (Jacque et al. 2005).
Therefore, p65 plays a role in reducing RelB activity in response to TNF and shows
one mechanism of cross-talk between the two NFB pathways (Figure 57). In addition
to TNFR1, other receptors show similar cross-talk between NFB pathways. For
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example, Dectin-1, an innate receptor involved in antifungal immunity on human DC
can activate both the classical p65 and alternative RelB NFB subunits (Gringhuis et
al. 2009). The suppression of the alternative NFB pathway by heterodimerisation of
RelB with p65 has been shown to induce cytokines involved in T cell differentiation
such as IL-12p40 (Gringhuis et al. 2009). Therefore mechanisms which sequester RelB
into inactive p65-RelB dimers may prevent anti-inflammatory signals and increase pro-
inflammatory T cell responses.
Differences in expression of sTNF and mTNF may also play a role in the activation of
NFB as sTNF only strongly activates TNFR1 but mTNF has the capacity to activate
both TNFR. For example, it has been demonstrated in cell lines and in primary T cells
that only mTNF not sTNF stimulates alternative NFB signalling via TNFR2 whereas
sTNF and TNFR1 were not able to induce p52 activation (Rauert et al. 2010). This is
partially in contrast to my data as in moDC both TNFR1 and TNFR2 activated the
alternative NFB pathway. Data therefore suggest that the effects of TNFR1 and
TNFR2 differ between DC and T cell populations. Also, the differences between
signalling induced by mTNF and sTNF can affect the induction of immune responses.
For example, it has been shown that mTNF and its interaction with TNFR2 is essential
for the induction of antigen-specific Treg cells by tolerogenic (vitamin D3-modulated) DC
(Kleijwegt et al. 2010). In addition, transgenic mice which express non-cleavable mTNF
in endothelial cells were protected from immune-mediated Concanavalin A-induced
acute hepatitis (Willuweit et al. 2001) which may suggest a role for TNFR2 in these
protective effects.
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Figure 57: RIP, NIK and RelB control NFB activation in response to TNF-
mediated signalling: a summary of previous studies. RIP can mediate the
activation of the classical NFB pathway, although it may not be essential for TNFR1-
mediated signalling. RIP activation can inhibit TRAF2 degradation and thereby inhibit
the alternative NFB pathway. NIK is essential for activation of the alternative but not
the classical NFB pathway in DC. The RelB dimerisation partner may determine
whether the classical or alternative NFB pathway is activated. Adapted from (Kim et
al. 2011; Gentle et al. 2011; Wong et al. 2010; Hofmann et al. 2011; Lind et al. 2008;
Garceau et al. 2000; Jacque et al. 2005).
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6.3. DC survival mediated by TNF and other members of the TNF superfamily
The survival of DC is a critical parameter in the regulation of adaptive immune
responses and is regulated by several TNF superfamily members. The TNF
superfamily contains 19 members, which signal through 29 receptors (Aggarwal 2003),
several of which can cross-react and therefore contribute to the regulation of a vast
range of cellular effects. For example, in DC the binding of CD40L to its cognate
receptor can lead to an upregulation of TNF (Caux et al. 1994) which subsequently
may lead to the activation of TNFR1. Also, murine BM-derived DC overexpressing
CD40L, RANKL or 4-1BB were shown to have significantly enhanced survival
compared to control DC (Yurkovetsky et al. 2006).
Receptor activator of NFB ligand (RANKL) is expressed on activated T cells and has
two receptors; RANK and osteoprotegerin (OPG) both of which are expressed by DC.
OPG expression is upregulated in human moDC maturation induced by TNF, RANKL
or LPS (Schoppet et al. 2007). Knock out of OPG in BM-derived murine DC resulted in
enhanced survival and production of TNF, IL-12p40 and IL-23 in response to LPS
(Chino et al. 2009). Therefore the RANKL-RANK interaction promotes DC survival and
the interaction is limited by OPG. As well as enhancing DC survival, RANKL can also
induce functional (but not total) maturation of human moDC (Schiano de Colella et al.
2008).
TNF-related activation-induced cytokine (TRANCE) is expressed by activated T cells
and is a DC survival factor which upregulates the expression of the anti-apoptotic
molecule Bcl-xL in murine BM-derived DC and inhibits apoptosis in both murine BM-
derived DC and human moDC (Wong et al. 1997). This suggests a possible
overlapping mechanism of survival with TNF as my data show that both TNFR1- and
TNFR2-mediated signalling enhanced the expression of Bcl-xL in human moDC.
Similarly to CD40L, TRANCE can enhance DC survival and induce the expression of
proinflammatory cytokines such as IL-6 (Josien et al. 1999). Although unlike CD40L,
the TRANCE receptor is mainly expressed on mature DC (and not immature DC),
therefore does not appear to be important in DC maturation (Wong et al. 1997).
Furthermore, TRANCE can co-operate with TNF or CD40L to enhance splenic and BM-
derived DC survival to a greater extent than either ligand alone (Josien et al. 1999)
thereby increasing T cell-mediated immune responses. TRANCE can also be
expressed on osteoblasts and induces osteoclast activation leading to bone resorption.
TRANCE activity can be inhibited by OPG (Fuller et al. 1998) which in turn can be
neutralised by TRAIL (Emery et al. 1998) illustrating multiple mechanisms involved in
the regulation of biological processes such as cell activation or apoptosis.
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4-1BB (CD137) is a costimulatory molecule expressed on T cells but it is also
expressed on DC along with its ligand 4-1BBL. Knock out mice have indicated that 4-
1BB is induced during DC maturation (but is not necessary for maturation itself) and
functions as a DC survival factor both in vitro and in vivo (Choi et al. 2010). In murine
BM-derived DC, 4-1BB activation increased the expression of DC maturation markers
CD80 and CD86, increased the secretion of IL-6 and IL-12 and increased DC survival
due to increased levels of Bcl-2 and Bcl-xL (Kuang et al. 2012). Alternatively, using
knock out mice, a lack of 4-1BB resulted in reduced expression of antiapoptotic
molecules Bcl-2 and Bcl-xL (Choi et al. 2010). This is similar to enhanced Bcl-xL
expression in DC mediated by TRANCE (Wong et al. 1997), and TNFR1 and TNFR2
(my data). The cross-linking of 4-1BBL on human moDC has been shown to induce
maturation by means of autocrine signalling via the release of TNF as the neutralisation
of TNF inhibited the increase in CD83 expression (Lippert et al. 2008). Furthermore,
neutralisation of autocrine TNF during DC maturation can impair the survival of DC and
enhance co-stimulatory molecule expression and T cell stimulatory capacity (Baldwin et
al. 2010; van Lieshout et al. 2005; Lehner et al. 2012).
Data from the literature and my own studies therefore show that the role of TNF and
other TNF superfamily members in mediating DC survival is complex and overlapping
with the potential for multiple survival inducing signals to interact with each other.
6.4. The therapeutic potential of TNFR2-specific activation
The regulation of DC survival is important in determining DC function. My data
demonstrate that TNFR1 and TNFR2 promote DC maturation and survival through
distinct and independent signalling pathways, as signals enhancing survival do not
necessarily result in enhanced maturation. In particular, results showing that TNFR2
enhances moDC survival without inducing maturation represent a novel finding in the
regulation of DC lifespan. This result is of interest as specific activation of TNFR2 has
recently been suggested as a new immunotherapeutic strategy to selectively destroy
autoreactive T cells (Faustman & Davis 2013) and to stimulate the expansion of
regulatory T cells in inflammatory and autoimmune diseases due to the restricted
expression of TNFR2 compared to TNFR1.
TNFR2, as opposed to TNFR1, has been shown to play a protective role in several
diseases including autoimmune disorders (Ban et al. 2008), neurodegenerative
disorders (Fontaine et al. 2002) and heart disease (Monden et al. 2007). Furthermore,
polymorphisms in the TNFR2 gene have been associated with susceptibility to RA
(Hussein et al. 2011) and although the functional effect is unknown it has been shown
that the polymorphism in TNFR2 results in a significantly lower ability to induce TNFR2-
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mediated NFB signalling. The effect of TNFR2-mediated signalling was first shown
using a mouse model with homozygous deficiencies in either TNFR1 or TNFR2, and
revealed that TNFR2-stimulation can induce cell death in mature T cells (Zheng et al.
1995). More recently, the specific activation of TNFR2 has been proposed as a novel
approach to kill autoreactive CD8+ T cells in autoimmune diseases (Kodama et al.
2005; Faustman & Davis 2010). It has been shown that a TNFR2 agonist selectively
killed autoreactive T cells but not healthy T cells in isolated human blood from type I
diabetes patients (Ban et al. 2008). Also, a proof-of-concept randomized, controlled
clinical trial has shown that BCG (the mycobacterium bovis bacillus Calmette-Guerin)
induced TNF and killed insulin-specific autoreactive T cells in the circulation of type I
diabetes patients (Faustman et al. 2012), which showed low toxicity although it is not
specific to TNFR2.
As my data indicates that TNFR2-signalling enhances the lifespan of DC, it is vital that
this is taken into account when designing therapeutic strategies involving agonistic
TNFR2 ligands. For example, the unwanted side-effect of specifically activating TNFR2
and prolonging the lifespan of DC could be beneficial and support tolerance, although it
could also be counterproductive and lead to a break in self-tolerance giving rise to
autoimmunity (Wang et al. 1999; Chen et al. 2006). In line with this, the upregulation of
TNFR2 has been associated with enhancement of autoimmune diseases such as
Crohn’s disease (Holtmann et al. 2002) and it has been shown in a transgenic mouse
model that high levels of TNFR expression results in severe inflammatory diseases and
systemic toxicity regardless of TNF levels (Douni & Kollias 1998). However,
development of a therapeutic TNFR2 agonist may prove useful in the ex vivo
generation of tolerogenic DC-based immunotherapies which would benefit from
prolonged survival without the induction of maturation. In contrast there are also data
suggesting that TNFR2 can mediate protective effects in arthritis, for example, using
knock out mice the absence of TNFR1 has been shown to suppress induced arthritis
whereas the absence of TNFR2 increased arthritis development (Blüml et al. 2010).
This suggests that TNFR2 may be protective or detrimental depending on the cell type
it is expressed on, thus demonstrating the importance of investigating TNFR function
on specific cell types.
The role of TNFR2-mediated enhancement of DC survival in the absence of maturation
is presently uncertain. Previous work has demonstrated that the regulation of DC
survival in itself is important in determining DC function. For example, in mice,
defective DC apoptosis leads to autoimmunity (Chen et al. 2006) and in humans,
mutations in caspase-10 have been shown to underlie defects in death receptor-
induced DC apoptosis in autoimmune lymphoproliferative syndrome (APLS) type I
(Wang et al. 1999). Fms-like tyrosine kinase 3 (FLT3) is a cytokine receptor involved in
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cell survival, proliferation and differentiation. Inhibition of FLT signalling can induce
apoptosis in mouse and human DC and thereby downregulate autoimmune responses.
In addition, targeted FLT3 inhibition improved disease in models for MS and EAE
therefore showing potential for development into therapies for autoimmune diseases
(Whartenby et al. 2005). Thus, the prevention of DC apoptosis favours autoimmunity.
As TNFR2-selective stimulation enhanced DC survival, data therefore support a
possible role of TNFR2 in assisting immune and/or inflammatory responses with the
potential to also enhance autoimmune responses.
Impaired apoptosis is not only associated with autoimmunity but is critical in cancer
development and forms a barrier to effective treatment. BH3-only proteins are Bcl-2
family members and are essential initiators of programmed cell death. BH3-only
mimetics have the potential for development of novel anti-cancer drugs (Plötz & Eberle
2014; Karst & Li 2007; Vaillant et al. 2013; Adams & Cory 2007). It has been shown in
vivo with regards to cancer therapy, that a TNFR2 agonist in non-human primates was
non-toxic in a dose-dependent manner, unlike TNF which showed systemic toxicity
(Welborn et al. 1996). DC have also been studied in relation to cancer immunotherapy
and the development of DC-based vaccines (Palucka et al. 2007; Palucka et al. 2011).
The effectiveness of these vaccines would also depend on the survival potential of the
DC.
6.5. Conclusions
In conclusion my data show that DC maturation and survival are differentially and
independently regulated through TNFR1 and TNFR2. This study is novel as the
individual roles of TNFR1- and TNFR2-mediated signalling in human DC have never
been investigated. As my study is the first to make use of TNFR-selective ligands to
investigate and dissect the roles of TNFR1 and TNFR2, my data represent an
important step forward in the TNF-mediated regulation of human DC maturation and
survival. Previous studies have been performed using knock-out mice however, as my
data shows, the TNFR1- and TNFR2-mediated signalling pathways overlap, which may
easily result in misinterpretations of TNFR knock out models. In particular, my data
comparing ‘inflammatory’ moDC, steady-state blood myeloid DC and SF-derived
myeloid DC suggests that differences between TNFR-mediated signalling pathways
are not black and white and may be due to differences in receptor expression and
sensitivity which can then alter the balance between receptor activation, cell maturation
and apoptosis.
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6.6. Strengths and weaknesses
The strengths of this study include the use of TNFR-selective ligands to dissect the
roles of TNFR1 and TNFR2 which has not previously been done in DC. Also the use of
DC from different conditions (i.e. inflammatory versus steady state) allows data to be
analysed in the context of human disease. The main weakness of this study is that
moDC may not represent the majority of DC in vivo while the blood myeloid DC
populations were not 100% pure. Also there is a lack of data regarding RA SF myeloid
DC as only two samples were available. Methods to overcome these weaknesses are
discussed in the following section (6.7). The use of moDC is of benefit to this project as
large numbers of cells can be generated from each donor, however, there are still a
number of difficulties associated with their use. For example, when LRS cones are
collected from the blood donor centre the cells are at a very high density which may
cause a stress response in some cells. It is therefore important that the cells were
donated on the day of collection (i.e. not left from a donation given the previous day)
and that the cone was processed as soon as possible. Also, factors during culture such
as slamming the incubator door may cause activation of the moDC thus affecting
results. The use of cell lines to such as MUTZ-3 as an in vitro model also has
weaknesses as MUTZ-3 DC also require differentiation via the addition of cytokines as
with moDC (Masterson et al. 2002), are heterogeneous (cells include a proliferating
pool, an intermediate stage and non-proliferating DC precursor pool), and DC bypass
the immature stage (Santegoets et al. 2008) making them unsuitable for this study.
MUTZ-3 DC have also been shown to more closely resemble moDC than ex vivo
primary DC (Lundberg et al. 2013).
When blocking the individual TNFR (i.e. the use of antagonistic antibodies) or using
small molecule inhibitors, the blocking was not necessarily complete and there was
high donor variability. I have postulated that the difference in the response to TNF
between donors may be due to an initial difference in TNFR expression. Data would
therefore benefit from the analysis of TNFR expression alongside the DC survival
assays. In addition, experiments could be repeated in triplicate using parallel wells from
the same donor to determine inter-experiment variability.
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6.7. Future work
For future work DC subsets (including pDC) would need to be isolated using multi-
colour fluorescence activated cell sorting in order to give pure populations, although
this process may also result in problems with enhanced DC activation through potential
contamination of the cell sorter with endotoxins. Also, more donors are needed in order
to accurately analyse DC from the SF of RA patients and to determine the statistical
significance. In my results, the blocking effect of TNFR1 and TNFR2 antagonistic
antibodies was superior to siRNA as they did not affect moDC maturation; however the
blocking effect was still not complete in some cases presumably due to the weak
agonistic activity of the antibodies. Alternatively, a Fab fragment could be used to
specifically block the individual TNFR which compared to the bivalent H398 or Fab2
fragment has no agonistic activity, however due to its monovalence high amounts
would be required to obtain full blocking. In addition, the analysis of TNFR-specific
downstream signalling the NFB pathway analysis could be expanded along with the
investigation of other TNF-activated pathways such as JNK. One potential reason for
the high variation between donors may be due to the differences in TNFR expression
therefore further studies would benefit from the analysis on TNFR expression in parallel
to functional assays. Additionally, it would be interesting to investigate whether TNFR1
and/or TNFR2 have any synergistic effects with other DC survival signals including
other members of the TNFR superfamily (as discussed in chapter 6.3). Furthermore, it
would be interesting to exploring the effects of survival, maturation and T-cell activating
potential following TNFR1 and/or TNFR2 stimulation in freshly isolated DC subsets
(pDC and myeloid DC) from tissues (ex vivo) as well as DC from RA patients.
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8. Appendices
Appendix A: Additional figures pertaining to chapter 4.4.2.
Data from Figure 33 “TNFR1-antagonism blocks TNFR1-mediated but not TNFR2-
mediated protection from cell death and vice versa” (in moDC) divided into comparable
donors.Un
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Appendix B: Additional figures pertaining to chapter 5.2.2.
Data from Figure 49 “TNFR-antagonism blocks TNFR-mediated enhancement of
maturation marker expression induced by the corresponding TNFR but does not affect
signalling via the other receptor” (in blood myeloid DC) divided into comparable donors.193
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Figure B: TNFR-antagonism blocks TNFR-mediated enhancement of maturation
marker expression induced by the corresponding TNFR but does not affect
signalling via the other receptor. Blood myeloid DC were left untreated or were
treated with antagonistic TNFR1- (B1-3) or TNFR2-specific (B2-3) antibodies for 30 min
prior to stimulation with 50 ng/ml sTNF, CysTNFwt, CysTNFR1 or CysTNFR2 + MAb
80M2 for 24 h. The expression of CD83 (top) and CD86 (bottom) was determined by
flow cytometry. The mean and SEM of the MFI (median fluorescence intensity) from 5
(B1), 3 (B2) or 2 (B3) independent donors are shown. Statistical differences were
determined in relation to unstimulated blood myeloid DC using a student’s t test;
*P≤0.05 **P≤0.01 ***P≤0.001.  
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Appendix C: Additional figures pertaining to chapter 5.2.3.
Data from Figure 52 “TNFR2- but not TNFR1-mediated signalling protects blood
myeloid DC from cytokine deprivation-induced cell death” divided into comparable
donors.
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Appendix D: HLA-DR positive cells enriched from the SF of a juvenile idiopathic
arthritis (JIA) patient.
In addition to myeloid cells from two RA patients, one JIA SF sample was obtained.
PBMC were separated and enriched for myeloid DC as previously, however, during the
sample purity check no cells were CD1c+ suggesting that there were no myeloid DC
present (although it is also possible that CD1c was absent an error as there was no
positive control). Data presented below shows HLA-DR+ cells which therefore could
not be compared to the RA samples discussed in this thesis. The maturation markers
CD83 and CD86 within the HLA-DR positive and caspase-3 negative cell populations
were analysed after 24 h in culture with CysTNFR1 or CysTNFR2 plus 80M2. Results
show that stimulation of TNFR2 but not TNFR1 results in an increase in the expression
of CD83 and CD86. The same cells were simultaneously analysed for the expression
of intracellular active caspase-3 to indicate the level of cell death. After 24 h 41% of the
unstimulated cells were caspase-3 positive, this is reduced by CysTNFR2 plus 80M2 to
23% but remains at 42% when stimulated by CysTNFR1.
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Appendix E: Published data pertaining to this thesis.
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